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ABSTRCT
Primary chick embryo liver cells were used to explore the reguation
of o-aminolevulinic acid synthase and heme oxygenase , the enzymes that
catalyze the rate-limiting reactions of heme anabolism and catabolism
respectively. The general focus of the work was the exploration of the novel
observation in which glutethimide and iron synergistically induced both
o-aminolevulinic acid synthase and heme oxygenase , a phenomenon that
would not be predicted a priori. The course of events appeared to be: first
that heme synthesis was increased after addition of the glutethimide and
that iron potentiated heme synthesis; second, the heme induced heme
oxygenase five to ten fold; and third, that heme oxygenase degraded the
heme permitting an uncontrolled induction of o-aminolevulinic acid
synthase. This induction of o-aminolevulinic acid synthase could be
prevented by the addition of a metalloporphyrin inhibitor of heme
oxygenase. Induced o-aminolevulinic acid synthase activity could be
dramatically reduced by the addition of nanomolar concentrations of a
metalloporphyrn, inhbitory for heme oxygenase , and heme.
Specific observations related to the synergistic induction of heme
oxygenase by glutethimide and iron was that the induction of heme
oxygenase activity by glutethimide and iron occurred rapidly, with
maximal increases occurrng four to six hours after original treatment.
Induction of heme oxygenase by glutethimide and iron was shown to be
dependent on de novo heme synthesis since 4 dioxoheptanoic acid, a
potent and specific inhbitor of heme biosynthesis, prevented the activity of
VIll
heme oxygenase from increasing in the presence of glutethimide and iron.
Induction of activity was associated with increases in heme oxygenase
mRNA and protein; and when induction was prevented by
dioxoheptanoic acid, no increase in either mRNA or immunoreactive
protein was observed.
Aminolevulinic acid synthase activity was also synergistically
increased by glutethimide and iron; this increase occurred 4-6 hours after
maximal heme oxygenase activity had been attained. The temporal
relationship between the induction of o-aminolevulinic acid synthase and
heme oxygenase suggested that the oxygenase depleted a regulatory heme
pool that would normally prevent uncontrolled induction of the synthase.
When cultures were exposed to tin-mesoporphyrin, a potent inhibitor of
heme oxygenase, induction of o-aminolevulinic acid synthase, normally
produced by glutethimide and iron was prevented. Addition of tin-
mesoporphyrn after o-aminolevulinic acid synthase induction had already
been established promptly halted any further induction. When heme or a
combination of heme and tin-mesoporphyrn was added after induction of
o-aminolevulinic acid synthase was established , activity of the synthase
was rapidly reduced.
Finally, experiments in primary chick embryo liver cells with tin-
zinc- and copper- chelated porphyrns were done to assess their effects 
activities of o-aminolevulinic acid synthase, induced by prior treatment of
cells with glutethimide and iron. Nanomolar concentrations of zinc- or tin-
porphyrns reduced o-aminolevulinic acid synthase activities, while copper-
chelated porphyrns did not. When nanomolar concentrations of heme
were added with zinc- or tin-porphyrns , o-aminolevulinic acid synthase
activity was further reduced. Effects of the non-heme metalloporphyrns on
o-aminolevulinic acid synthase were closely correlated with their abilities to
inhibit heme oxygenase (r=0.78). The largest decrease of o-aminolevulinic
acid synthase (67%) was obtained with zinc-mesoporphyrin and heme.
There was a rapid appearance of the cytosolic, precursor form of
o-aminolevuinic acid synthase in the presence of both 10 M heme or 50
nM zinc-mesoporphyrn and 200 nM heme. Reduction of the half-life of the
mRNA from 5.2 hours to 2. 5 hours was observed in the presence of both
10 M heme or 50 nM zinc-mesoporphyrn and 200 nM heme.
In summary, the chick embryo liver cell culture model treated with
glutethimide and iron may serve as one experimental model for patients
suffering from acute porphyrias, in whom uncontrolled induction of
hepatic o-aminolevuinic acid synthase plays a key role in pathogenesis of
disease. The synergistic induction of o-amnolevulinic acid synthase in the
presence of glutethimide and iron may serve as an experimental paradigm
for this disease. The reduction of o-aminolevulinic acid synthase by low
doses of zinc-mesoporphyrn and heme may help form the experimental
foundation for eventual studies in patients sufering from acute porphyras.
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INODUCTION
Hirica backgun an porphyr biostles
Porphyrins. the foundation of life Porphyrins are a class of
biological compounds essential to the sustenance of every kind of life.
Metalloporphyrns are the catalytic molecules supplying all the energy
needs for all living organisms, because they function as the chemical
catalysts converting sunlight into biochemically stored energy. Eukaryotic
aerobes satisfy their high energy needs through oxidative respiration
which is catalytically supported by the various mitochondrial cytochromes
all of which contain iron-protoporphyrin IX* (Figure 1.1 (lJ ) as the
catalytic species. Iron-protoporphyrin IX also serves as the functional
prosthetic group in oxygen transporting proteins, and as the catalytc group
in cytochrome P-450 dependent mono-oxygenase system. These central
roles of pyrrole-derived compounds underscore their importance, and
suggest the importance of understanding the regulatory features of pyrrole
synthesis and degradation (for reviews see 1-
* Iron-protoporphyrin IX and heme wil be used interchangeably and are not meant to
imply any particular oxidation state of the iron. Although , traditionally, heme implies
ferrous-protoporphyrin IX and hemin implies ferric-protoporphyrin IX with a chloride
counter ion , this convention will not be followed , since most of the discussion of heme will
be independent of. oxidation state. When the oxidation state of the protoporphyrin IX-
chelated iron is important to the discussion, this wil be clearly described.
The bracketed numbers , i.e. (1) , refer to compound structures while references are
referred to with superscripted numbers.
Figure 1.1: Structure of ferrc protoporphyrn IX (heme) (1). Heme is a
cyclic tetrapyrrole chelating an iron in either a low-spin octahedral
coordination, in which the iron lies essentially within the place of the
porphyrn ring, or a high-spin square pyramidal coordination, in which
the iron lies as much as 8 A out of the porphyrn ring. The valence of the
iron modulates between divalent and trivalent states and permits some
marvelous redox chemistry to occur. The numbering system shown is the
offcial numbering system of the International Union of Pure and Applied
Chemistry and the International Union of Biochemistry.
CH2
CH3
O=C
CH2
C=O
(1)
CH2
Chemical Isolations and Characterizations of Porphyrins
Porphyrin research originated in the 1840's with the isolation of
Eisenfreies hiimatin (iron-free hematin) from dried and powdered blood
(for a review of the history of porphyrn research see 10). Later efforts
showed that the main constituent of Eisenfreies hiimatin was
hiimatoporphyrin Independently, uroporphyrn was isolated from the
urine of a patient who , in retrospect, suffered from congenital porphyria.
Studies of different compounds led to the discovery of the strong
spectrophotometric absorbance of this class of compounds by Soret (see 11).
Due to the complexity of the heme biosynthetic pathway, many different
compounds were isolated from porphyrc patients, and many erroneous
theories were presented. Although the delineation of the biosynthetic
pathway would wait until the advent of isotopic labelling, the correct
chemical structure of heme was proposed in 1912. The chemical
separations of the three non-metallated cyclic tetrapyrroles were
accomplished during this time: Stokvis12 and Fischer were two of several
who chemically isolated uroporphyrn (2), Saillet and Fischer isolated
coproporphyrn (3), an, otoporphyrn (4) was , unkowingly, prepared by
Laidlaw (r" ..re 1.2). Perhaps one of the reasons that Fischer was able to
isolate two of these compounds was the successful recrutment of Matthias
Petry as a laboratory aide. Mr. Petry suffered from congenital
erythropoietic protoporphyra, and he not only worked in the laboratory, but
provided a constant source of porphyrns , until his death in 1925. He then
became the subject of an autopsy that described the porphyrn deposits in
Figure 1.2: Structures of three naturally occurrng porphyrins (2-
and porphobilinogen (5). The isomers shown are the ones that were first
chemically isolated, as these are the normally occurring porphyrin
isomers , and the porphyrns are listed in the order of metabolic synthesis.
NH2
(2-4) (5)
Porphyrn (n)
Uroporphyrin III
Coproporphyrin III
Protoporphyrin IX
= Acetate
= Methyl
= Propionate
= Vinyl
developing erythropoietic cells, bones, and organs. Although the
porphyrins were isolated from the excrement of porphyria patients, the
porphyrins are not substrates for the heme biosynthetic enzymes , except for
ferrochelatase. Rather, the porphyrinogens are the substrates 13 but are
easily oxidized to porphyrins upon exposure to air.
The heme bios nthetic athwa . The discovery of the monopyrole
porphobilinogen (5), occured in the 1930' 10 and represented the last of the
pyroles in the pathway to be described. This characterization was also the
last major breakthrough in biological porphyrn synthesis independent of
the biochemical delineation of the heme biosynthetic pathway. Further
description of the pathway came via the use of radiolabelled precursors
either C-acetate or 15N-glycine and accurately described glycine and
succinyl-CoA as the precursors of o-aminolevuIinate, which subsequently
formed the monopyrrole porphobilinogen, and ultimately the
tetrapyrroles. 14-17 David Shemin even used himself as an experimental
subject to show the utilization of 15N-glycine in the formation of heme. 18
The tetrapyrole uroporphyrinogen III is the intermediate that is common
among all tetrapyrole molecules. 20 This molecule can be either oxidized
to form coproporphyrnogen III or methylated to eventually form cobyrinic
acid (6), a precursor of vitamin B12 (7) (Figue 1.3).21 Coproporphyrnogen
III is oxidatively de carboxylated to protoporphyrnogen IX, which is then
oxidized to protoporphyrn IX, the first and only non-metallated porphyrn
that is biologically active in the metabolic pathway. 13 Protoporphyrn IX is
the metabolic branch-point of chlorophyll and heme. Chlorophyll contains
Figue 3: Structures of cobyrnic acid (6) and vitamin B12 (7). These
compounds are derived from the heme precursor, uroporphyrinogen.
These compounds serve to demonstrate the multifarious functions of
tetrapyroles.
CH3
CH3
A = Acetate
Pr = Propionate
AJ = Acetamide
P A = Propionamide
(6)
-c '
0 OH(XX
(7)
magnesium, heme contains iron 7 and the post-chelation modifications
are quite different.
Amin linic ac d. tne fir mmi tted ate
Aminolevulinic acid (8) is the first committed intermediate in the
biosynthesis of tetrapyroles. The formation of ALA * can occur either via
the glycine pathway or the C5 pathway. The glycine pathway, also referred
to as the Shemin pathway, produces ALA from glycine and succinyl-CoA
using pyrdoxal phosphate as a cofactor. ALA may also be formed from
glutamate via the C5 or 4,5 dioxovaleric acid (DOVA) pathway, which forms
ALA from glutamic acid via a glutamyl-tRNA intermediate, and requires
the action of an NADPH-dependent dehydrogenase, and glutamate-
semialdehyde 2, amnotransferase. 23 These reaction schemes show the
complexity of the formation of ALA, and suggest many possibilities for
reguation of ALA formation.
react The mechanism of the
condensation of glycine and succinyl-CoA includes the formation of the
glycine-pyridoxal phosphate Schiff base, which is preceded by the
deprotonation of the amine (Figure 1.4, reaction 1).24- 26 The pro-
hydrogen is exclusively removed and the pro- hydrogen of the glycine
becomes the pro- hydrogen of the aminolevulinic acid. This reaction
mechanism requires that the enzyme perform both the condensation and
the decarboxylation steps and that the 2-amino- ketoadipic acid
intermediate remain as the pyrdoxal phosphate complex.28 The energy
See pages xvi-xvi for abbreviations
Figure 1.4:
aminolevulinic acid.
Naturally occurnng reactions synthesizing 
Reaction 1 shows the formation of ALA (8) from
glycine and succinyl-CoA, the pathway occurrng in all anmals , and some
plants. This reaction shows the role of pyrdoxal phosphate (PLP).
Reaction 2 shows the C5 pathway that is used by almost all prokaryotes and
in many plants.
demonstrated.
The mechanism whereby tRNAgl is utilized is
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required for the complete synthesis of heme is provided by the succinyl-CoA
substrate.
Mechanism of the lutamate reaction. The formation of ALA via the
C5 pathway utilizes a mechanism that was discovered in plants in 1974
after years of research that showed plants poorly incorporated glycine and
succinyl-CoA into tetrapyroles.29 The first step in the C5 pathway is the
glutamyl-tRNA synthetase which charges the tRNA. This reaction
requires ATP and Mg+2 and the tRNA substrate appears to be the same
tRNA used for both ALA and protein formation (Figure 1.4, reaction 2).30,
The tRNA-bound glutamate is reduced in a pyrdine nucleotide dependent
reaction to form a glutamate- 1-semialdehyde type of product. The exact
nature of the intermediate has yet to be delineated but it could be glutamate-
1-semialdehyde 32-34 or its hydrated hemiaceta1.35 Study of the synthetic
glutamate- 1-semialdehyde synthesized by Kannangara and co-workers
appears to show that the compound is the cyclic ester between the 
"(-
carboxyl and the hydrated aldehyde group, hydroxy-
aminotetrahydroxypyran-1-one (HAT) (9J. HAT is much more stable to heat
and in aqueous solution since this compound contains no free aldehyde or
carboxyl groups36 and HAT does form AL.37 The next compound could be
dioxovaleric acid (10J,38 but if this compound is an intermediate 39,40 it
appears to remain enzyme bound. 43 Transamnation is the final step 
ALA and appears to be an intermolecular transfer 44 suggesting that 4
dioxovaleric acid could indeed be an intermediate.
or e pathw ? The formation of ALA via two
different pathways indicates that either one, the other, or Hoth may be
involved in formation of heme in animals. The glycine pathway was
discovered in animals first, and the C5 pathway discovered in plants
suggesting that the two pathways are segregated between the plant and
animal kingdoms. However ALA synthase has been shown to 
functional in Rhodobacter spheroides 45 and Rhodopseudomonas
palustris 
47 with no evidence of the C5 pathway. The green
photosynthetic phytoflagellate Euglena gracilis appears to contain both
synthetic pathways, with the C5 pathway supplying ALA exclusively for the
formation of plastid pyroles , while the Shemin pathway supplies ALA for
all of the other pyroles.48-50 Despite the existence of ALA synthase in 
spheroides and R. palustris it appears that ALA synthase does not
significantly contribute to ALA formation in the higher photosynthetic
plants , although certain plant cells do contain ALA synthase.51-60 A
surey of photosynthetic bacteria showed that the C5 pathway is distributed
among all the bacterial groups and may be the more primitive pathway,
while the glycine pathway is only found in the purle nonsulfur bacteria
spheroides, R. palustris and Rhodospirillum rubrum. 61 The widespread
existence of dual pathways in higher plants has yet to be unequivocally
demonstrated.
The formation of ALA in animals is obviously supported by the
glycine pathway, since animals were used to discover the steps in
porphyrn biosynthesis. However, since the formation of ALA can be
accomplished using two different mechanisms utilizing common
substrates, the possibility exists that the glutamate pathway could also
support porphyrn biosynthesis in animals. The enzyme L alanine:4
dioxovaleric acid (DOVA) aminotransferase (E.C. 2. 1.43) does exist in the
mitochondrial matrix of mammalian cells , except for humans , where it is
localized to the peroxisome.62 DOV A aminotransferase can convert 4
dioxovaleric acid to ALA in vitro.63- 66 DOV A aminotransferase , in vitro
forms ALA at a much higher rate than produced by basal ALA synthase 
vitro, 24 nmole ALA formed/r/mg protein for DOV A aminotransferase
and 0.64 nmole ALA formed/hr/mg protein for ALA synthase.
However it is not clear that the required substrate , 4 dioxovaleric acid, is
present in the mitochondrial matrix, or peroxisome, and there is no
increase in DOV A aminotransferase in the presence of porphyrinogenic
compounds 67 as seen with ALA synthase. There is only one
unconfirmed report describing the utilization of glutamate for the
formation of ALA in animals. Despite the high activity for DOV A
aminotransferase in vitro there is no evidence to support the hypothesis
that DOV A aminotransferase functions to provide ALA for animals. The
lack of induction of DOV A aminotransferase in the presence of
porphyrnogenic compounds , and the induction of ALA synthase, argues
against the function of DOV A aminotransferase as a supplier of
endogenous ALA. The primary activity of this enzyme appears to be an L-
alanine:glyoxylate aminotransferase (E.C. 2. 1.44).43 In humans , type 1
hyperoxalura is caused by the incorrect localization of this protein into the
mitochondra instead of the peroxisome.69 The glycine pathway appears to
be the only physiologic pathway for AL formation in mammals.
Formati on of hobilin n. Porphobilinogen (5) (PBG) is formed
from the condensation of two molecules of ALA by ALA dehyc:atase , a zinc
containing cytosolic enzyme.70-72 The ALA dehydratase is a homo-octamer
that condenses two molecules of ALA in a Knorr type reaction with the
ellision of two molecules of water. The mechanism of reaction has been
investigated for mammalian enzymes as well as bacterial enzymes , and is
identical for all dehydratases investigated. 73-75 Zinc appears to playa role
as a structural element, not a catalytic center76 and is required for the
enzyme binding a second molecule of ALA. 7 
Formation of h drox meth lbilane. Porphobilinogen deaminase
(hydroxymethylbilane synthase) (E.C. 4. 1.8) catalyzes the head to tail
polymerization of four molecules of porphobilinogen to form 
hydroxylmethylbilane, a linear tetrapyrole, and the last intermediate of
the heme biosynthetic pathway to be discovered. The mechanism of the
reaction is complex and created many postulated, but erroneous reaction
products such as the headless dipyrole 78 the N-alkylporphyrnogen 79 and
the aminomethylbilane.80-82 The latter is the closest to reality and was only
eliminated after transient NMR experiments on enzymatically formed
products. 84 The proposed product, 1-hydroxymethylbilane (HMB), was
synthesized and found to be the substrate for uroporphyrinogen III
synthase.85 This intermediate is quite unstable with a half-life of 4.
minutes at 37 C84 and rapidly undergoes uncatalyzed cyclization to
uroporphyrnogen I. The I isomer of uroporphyrnogen is not the natural
substrate for uroporphyrinogen decarboxylase, although it will be
decarboxylated to form coproporphyrnogen I; however the I isomers will
not lead to the formation of heme. The naturally occurring III isomers will
be preferentially formed in acid solutions of porphobilinogen, with the
Figure 1.5: Formation of porphobilinogen from o-aminolevulinic acid.
Even though ALA dehydratase contains zinc, this metal does not appear to
be directly involved in the catalysis, and the mechanism shown reflects the
absence of the zinc at a catalytic center. The enzyme is involved in the
formation of a Schiff base with the first substrate. The lysine that functions
as the catalytic site has been identified. 
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molar ratio of isomers; III:IV:II:I::4:2:1:1 86 which indicates that the
thermodynamically favored uroporphyrnogen is the III isomer. The
syntheses of heme , chlorophyll and cobyrinic acid depend solely on the
enzymatic steps leading to the formation of uroporphyrinogen III. One
interesting aspect of this reaction is the utilization of a dipyrromethane
cofactor (11) to provide an anchor on which to build the tetrapyrrole
hydroxymethylbilane. The dipyrromethane is assembled from two
molecules of PBG, remains enzyme bound once formed, and catalyzes the
formation of numerous molecules of hydroxymethylbilane (Figure 1.6).
Formation of uro rino en III. Uroporphyrinogen III
synthase (E.C. 4. 1.75) must not only cyclize the hydroxymethylbilane
substrate but rearrange the orientation of the D-ring of the
uroporphyrnogen I (13) to form the III isomer (15) (Figure 1.7). A spirane
rearrangement has been postulated as the mechanism89 and synthetic
studies have supported this hypothesis.90 Studies of the enzyme suggest
that the cyclization of the 1-hydroxymethylbilane (12) and the
rearrangement occurs at the same site on the enzyme (Figue 1.8).
Formation of vi amin B12. Uroporphyrnogen III is a universal
intermediate for the formation of tetrapyroles , and in animals , but not in
humans, uroporphyrinogen is a precursor of cobyrinic acid (6), the
macro cycle of vitamin B12 (7) The natural synthesis of this compound
although not completely delineated, is quite complex and is reviewed
elsewhere.
Formation rino The formation ofIII.
coproporphyrnogen III (22) is accomplished by the decarboxylation of the
Figure 1.6: Formation of the dipyrromethane cofactor and
hydroxymethylbilane from porphobilinogen. This reaction scheme shows
the utilization of porphobilinogen to form the dipyrromethane cofactor (C)
(11) and then the head to tail condensation to form an enzyme-bound
hexapyrrole. Each step requires the deamination of one molecule of
porphobilinogen, and once the hexapyrrole is formed the product is
hydrolyzed to leave the dipyromethane cofactor enzyme-bound , yielding
hydroxymethylbilane (12).
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Figure 7: Structures of various porphyrnogens. The tetrapyrole
derivedmacrocycle depicts a general porphyrnogen. The different isomers
and compounds are generated by changing either the positioning or
substitutions at any of the eight bridging monopyrrole derived carbons. The
table will be used here and throughout and the numbers referrng to the
compounds in the text are listed in order through the table , and not
necessarily in order through the text, in order that identification of
individual porphyrnogens is facilitated.
(13-30)
Porphyrinogen
(n)
Uroporphyrnogen I
Uroporphyrnogen II
Uroporphyrinogen III
Uroporphyrinogen IV
Carboxyl porphyrinogen III
Carboxyl porphyrinogen III
Carboxyl porphyriogen III
Coproporphyrnogen I
Coproporphyrnogen II
Coproporphyrnogen III
Coproporphyrnogen IV
Harderoporphyrinogen
Isoharderoporphyrinogen
Protoporphyrinogen IX
Protoporphyrnogen XIII
Mesoporphyrnogen IX
2- Vinyl- hydroxyethyl deuteroporphyrnogen
4- Vinyl- hydroxyethyl deuteroporphyrnogen
Acetate
Ethyl
He = -CHOH-CH3
= Methyl
Propionate
= Vinyl
Figue 1.8: Reaction mechanism for uroporphyrnogen In synthase.
The mechanism demonstrates the proposed spuanereaction
rearrangement of the D-ring leading to the III isomers for
uroporphyrnogen and coproporphyrinogen. The chemical cyclization of 
hydroxymethylbilane would lead to the I isomers for uroporphyrnogen and
coproporphyrinogen , neither of which is a substrate for the heme
biosynthetic pathway.

acetate side chains of uroporphyrinogen III by uroporphyrinogen III
decarboxylase (UROD) (E.C. 4. 1.1.37). UROD catalyzes the decarboxylation
of each of the acetic acid side chains to methyl groups. The natural
substrate is the III isomer of uroporphyrnogen, but the I (13) isomer
functions as a substrate, albeit at a lower rate. The synthetic II (14) and IV
(16) isomers can also function as substrates.92 The substrate binding site of
UROD must accommodate not only the 8-carboxyl porphyrnogen (15), but
the 7- (17), 6- (18), and 5- (19) carboxyl porphyrnogen substrates , each of
which is increasingly more hydrophobic. In order to catalyze each
successive decarboxylation the product of the previous reaction must be
completely released, and rebound in a different configuration. The
impairment of the rebinding step may lead to accumulation of specific
porphyrns under certain conditions, and will be discussed later. The
reaction catalyzed by UROD was thought to be specific with the first
decarboxylation occurring on the acetate of the D-ring, next the A-ring,
then the B-ring and finally the C-ring acetate is decarboxylated.
However recent data indicating that decarboxylation of the porphyrnogen
occurs randomly have challenged this theory. 95-97 The issue remains
unresolved.98 In the proposed mechanism, the protonated pyrrole ring
functions as an electron withdrawing group, analogous to the pyrdine ring
of pyrdoxal phosphate, and facilitates removal of the acetic carboxyl group
as carbon dioxide (Figure 1.9). This mechanism would explain why the
porphyrnogens, not the porphyrns, are substrates of this enzyme. lOO
rmation roto en IX. The oxidative decarboxylation
of coproporphyrinogen III is the antepenultimate step in heme
biosynthesis. Coproporphyrinogen oxidase (E.C. 1.3. 3) catalyzes the
stepwise decarboxylation of the A- and B- ring propionate side chains to give
harderoporphyrinogen (24), and subsequently protoporphyrinogen IX
(26).101- 104 In eukaryotes , this enzyme is located in the inter-membrane
, space of the mitochondria. 105 106 The catalytic characterization
demonstrated that only harderoporphyrinogen was formed, and not
isoharderoporphyrnogen (25), with this intermediate remaining enzyme
bound. Two postulated mechanisms can account for the enzymatic
reaction , one involving a hydroxypropionate intermediate 107 108 and one
involving an intermediate imine and a hydride ion (Figure 1.10).1
distribution of the two different mechanisms between anaerobic and aerobic
conditions has been proposed 108 110 since the hydroxypropionate
intermediate only be formed under aerobic conditions.can
Coproporphyrinogen oxidase substrate specifici ty precl udes
coproporphyrinogens I (20) and II (21) as substrates 101 104 but
coproporphyrnogen IV (23) can be converted to protoporphyrinogen
XIII (27).104 111 112 The lack of a requirement for a metal ion or cofactor
suggests that a hydroxylation mechanism does not exist for
coproporphyrnogen oxidase, and it is possible that the hydride ion pathway
functions as the sole pathway for the oxidative decarboxylation of
coproporphyrnogen. 109
Forma ion pOI:p n IX. Protoporphyrnogen IX is oxidized
an oxygen-dependent six electron oxidation catalyzed by the
mitochondral enzyme, protoporphyrnogen oxidase (E.C. 1.3.3.4). 113 114
Although protoporphyrinogen IX is rapidly oxidized in vitro chemical
Figure 1.9: The reaction mechanism for uroporphyrinogen
decarboxylase. The mechanism is displayed for only one ring, although
each decarboxylation occurs via the same mechanistic pathway. The use of
the pyrrole nitrogen as an electron donor precludes uroporphyrin as a
substrate since the pyrrole carbon electrons can not function as an electron
acceptor due to the extensive 7t-7t bonding in the conjugated porphyrn
macrocycle.
l r!
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oxidation in vivo is not a step in the heme biosynthetic pathway, 115 although
accumulation of protoporphyrin occurs under certain conditions. 116- 121
The sensitive nature of the substrate has made characterization of this
enzyme quite diffcult. Other substrates for protoporphyrnogen oxidase are
mesoporphyrinogen IX (28), protoporphyrinogen XIII (27), and
2(4)vinyl-4(2)hydroxy-ethyl deuteroporphyrnogen (29 (30)).101 113 Cobalt
protoporphyrn, bilirubin, and the ditaurine conjugate of bilirubin have all
been reported to be inhbitors of protoporphyrogen oxidase activity.1 124
Formati of heme. Ferrochelatase (E.C. 4. 99. 1.1), properly
protoheme ferrolyase, catalyzes the insertion of ferrous iron into the
protoporphyrin IX macrocycle. Although the reaction can occur non-
enzymatically, 125 there is no doubt of the physiological importance of
ferrochelatase.1 128 The Km and Vmax for the porphyrn increase in the
order protoporphyrin IX""hematoporphyrin IXc:mesoporphyrin
IXc:deuteroporphyrin and the metals the order
Co+ ""Ni+2c:Fe+2c:Zn+2 129-134 Other metals, metalloporphyrns (including
heme), and N-methylated porphyrins are inhibitory. 133 135- 137 Lead is
particularly interesting since exposure of animals to lead leads to increased
production of zinc-protoporphyrn. 138- 141 Ferrochelatase has an absolute
requirement for ferrous iron, and it seems that the ferrochelatase is
associated with the mitochondral electron transport complex I , which has
an NADH-dependent ferrc iron reduction system 142 143 although the
reduction of iron may occur elsewhere as well. 144- 146
Form ion hlor lls. The first step in chlorophyll synthesis is
the insertion of magnesium into protoporphyrin IX by magnesium
Figure 1.10: Mechanism of the reaction catalyzed by
coproporphyrnogen oxidase to form .protoporphyrnogen. The mechanism
depicted theshows
hydroxypropionate intermediate that has also been proposed.
hydride and not themechanismIon
(j-O
(j-O
=: 
(j-O
chelatase to form magnesium protoporphyrn. 147 Since magnesium is
naturally divalent, no reduction step is necessary; however, A TP 
required for this activity. 148 Zinc protoporphyrin is a product of this
enzymatic activity as well.148 The formation of chlorophyll and other
tetrapyrole-derived photosynthetic pigments are completely dependent on
the biosynthesis of protoporphyrn IX by the enzymes discussed previously.
Reviews of chlorophyll metabolism may be found elsewhere. 6 , 7 ,
f h e de vat ves Heme derivatives are used in several
cytochromes, such as cytochrome oxidase and cytochrome c. The
biosynthetic steps required to form heme a, contained in cytochrome
oxidase, are unknown but it appears to require an intermediate derived
from mevalonate, probably farnesyl phosphate, to form heme 149
Cytchrome c contains covalently bound heme attached via a thioether bond
between protein cysteines and the vinyl groups of the A and B rings of the
porphyrn. 150
ary o JIe e b osynt . The complexity and diversity of the
formation of tetrapyrroles are a marvel of nature, and present many
interesting problems, from discovering the stereochemistry of substrates
and products, to understanding the features involved in reguating the
synthesis of tetrapyroles. Understanding of the features of the heme
biosynthetic pathway is important in understanding possible sites of
reguation, and ultimately, in formulating methods to control the diseases
associated with disorders of normal heme biosynthesis. The features of the
regulatory mechanisms will be discussed, along with features of the
porphyras , the regulation of heme degradation, and the selected properties
of some of the compounds studied in this work.
Regution of heme biostlesis
Introduction. The regulation of heme biosynthesis in higher
animals will be the focus of this discussion, although regulation of heme in
bacteria and lower eukaryotes is also of great importance 151-153 especially
relating to the field of herbicides. 154 The regulation of heme in anmals is
divided into two different classifications , erythroid and non-erythroid
regulation. 155 The requirements for heme in these cells types is drastically
different since erythroid cells need large amounts of heme to supply heme
for hemoglobin 156 which accounts for ==80% of total body heme. 157 The liver
is a unique situation of a non-eryhroid cell type , due to the large demand
for heme by cytochrome P-450s. 158
lation of he atic heme bios thesis. Regulation of hepatic heme
biosynthesis is accomplished through modulation of ALA synthase
activity, 159- 161 since this activity is rate-limiting under normal
conditions. 161 The activity of PBG deaminase in human liver, under
normal conditions , is about 2-fold greater than that of ALA synthase.1
The short half-life of ALA synthase protein, between 30 and 180
minutes 163- 165 unquely suits the rapidly changing needs for heme in the
hepatocyte 158 166 since the average half-life of mitochondral proteins is 5
days. 167
The major metabolite known to modulate ALA synthase activity is
heme 159-161 the end product of the biosynthetic pathway. Many different
mechanisms for this regulation have been proposed, inclqding: direct
inhbition by heme, repression of translation, increased degradation of the
mRNA, repression of transcription, and inhibition of mitochondrial
translocation.
Inhibition of ALA s nthase activit heme. Heme at high, non-
physiologic concentrations , was reported to inhbit ALA synthase in chick
embryo liver cell cultures 168-170 and in a partially purified rat liver enzyme
preparation. 171, 172 It had been proposed that the mitochondral localization
of both ALA synthase and ferrochelatase would allow locally high
concentrations of heme 173- 175 and that inhibition of the synthase might
therefore be a regulatory mechanism. The three terminal enzymes in
heme biosynthesis appear to form a metabolic channeling complex
although there are no data to support the involvement of ALA synthase or
heme-mediated inhbition of the synthase in such a complex. 123, 176 Other
data have shown that increases in heme generation do not decrease ALA
synthase activity177 and studies on the purified enzyme show that heme is
not an inhibitor.1 The consensus opinion by investigators in the field is
that direct inhibition of ALA synthase by heme is not physiologically
important. 178-180
ession of ALA synt ase ran lation. Some investigators
had reported that heme affected the translation of ALA synthase
mRNA 169 181-183 and that in heterogeneous cell-free translation systems 20
~M heme inhibited elongation of ALA synthase protein.184 However, in
post-mitochondral supernatants from chick embryo liver 10 ~M heme did
not inhibit polysome elongation185 and in other heterogeneous elongation
systems 100 heme did not inhbit polysome elongation.159 There are no
data to show that heme, at any concentration prevents, or inhibits
initiation of translation of ALA synthase mRNA, and the sparse
conficting data published , strongly argue against a translational control
mechanism for ALA synthase.
Incr se of ALA s tha mRNA de radation. Reports suggesting
transcriptional control of the ALA synthase gene were based on the
observation that ALA synthase mRNA levels were decreased in the
presence of heme. 18G- 188 Recent data in chick embryo liver cell cultures
show that the half-life of AL synthase mRNA is decreased from 180-220
minutes to 70-90 minutes in the presence of heme (1- 10~M), 189 190 while 
change in AL synthase gene transcription was observed. 89 The existence
of a labile , heme-modulated RNase to mediate this effect was postulated
since addition of cycloheximide prevented the reduction of the half-life of the
ALA synthase mRNA by heme.1 Whether this phenomenon is due to 
specific RNase or a more generalized effect of translation of mRNA stability
remains to be clearly elucidated.1 Results obtained in rats contradict
these results, in that others reported that the half-life of ALA synthase
mRNA in rat liver was not changed in the presence of heme , but rather
that ALA synthase gene transcription was decreased. 92 These differences
could be due to differences in the animal models, or an increase in the
endogenous heme of rat liver due to allylisopropylacetimide (AlA)
treatment. 189 The reported half-life of the rat AL synthase mRNA was 20
minutes192 suggesting that endogenous heme levels were already high and
the half-life of the mRNA was already decreased.
ion l r ess ALA synt ase e-ene. The half-life
of the mRNA of hepatic ALA synthase is reported to be short, from 1-
hours 169, 176 189 190 193 194 and a priori suggests that transcriptional
regulation could be an effective site for the control of ALA synthase activity.
Earlier reports presented indirect data suggesting transcription was a site
of heme-mediated regulation 186- 188 and some later reports presented
nuclear transcription experiments supporting this hypothesis.1 195 196 In
the chick embryo liver cell culture there is no effect of heme on the
transcription of ALA synthase 189 while in the rat systems heme may affect
transcription.1 195 196 The existence of a heme-activated transcription
factor in yeast 7 demonstrate that heme-binding proteins can modulate
transcription in certain systems. The existence of a similar protein in
animals has yet to be demonstrated. The differences between
transcriptional regulation and decreases in mRNA stability required
further investigation.
Decre e of mitochon rial im ort re-ALA s nthase. ALA
synthase is synthesized on cytosolic ribosomes 165 173, 185 198 and must be
imported into the mitochondria in order to be physiologically active. Both
the precursor (cytosolic) and mature (mitochondrial) forms are catalytically
active in vitro 173, 199- 204 but in vivo succinyl CoA is only found in the
mitochondria, not in the cytosol. Heme has been found to inhibit the
translocation and processing of the cytosoIic , precursor form into the
mitochondra 205-210 and this has been proposed as a site for regulation.
Recent data from Lathrop and Timk0211 demonstrated the existence
of a heme reguatory motif (HRM) in the amino terminal of the pre-ALA
synthase protein. Heme inhbited the transport of both the purfied mouse
erythroid ALA synthase and a chimeric protein containing the HRM and
mitochondrial ornithine transcarbamoylase (OTC). The non-chimeric OTC
translocation was not inhibited by heme.211 Site directed mutagenesis of
the conserved cysteine (Cys Ser 10) in ALA synthase produced a protein
whose mitochondrial transport was unaffected by heme. The identified
HRM (amino acid sequence: LCPVL) was inserted into the OTC protein and
this again conferred heme regulation of the protein transport. Site directed
mutagenesis of conserved cysteine (Cys Ser 10) again produced a
chimeric protein whose mitochondral transport was unaffected by heme.
Although the experiments were carried out with the mouse erythroid ALA
synthase, the same sequences exist in hepatic forms of ALA synthase , rat
hemopexin212 and the yeast heme-activated transcription factor.1 213 214
The existence of this motif throughout several heme-activated proteins
suggests that this motif may be a general mechanism for metabolic control.
f r ulator chanism In summary, there is
evidence for heme-dependent regulation synthaseALA
transcription 192 195, 196 enhancement of mRNA degradation 189 190 and
reduction of mitochondrial uptake of the precursor protein.205-208 210 215 216
One researcher studying the effects of heme on the half- life of ALA
synthase states, "Addition of heme to the cultured hepatocytes decreased
the steady-state level of ALA synthase mRNA by approximately 50%
whereas ALA synthase enzyme activity was almost completely
suppressed."189 The most probable reason for these observations is the
existence of two or more physiologically relevant sites of regulation.
Although there is not enough data to form a general model describing the
reguation of hepatic ALA synthase , recent evidence suggests ihat in chick
embryo liver cells the two major sites of reguation are the HRM-dependent
mitochondral import and the decrease in the half-life of the ALA synthase
mRA. 189 206,207 209 215
The regutory heme pol
ression of ALA s nthase activit excess 
. The observed
effects of heme on ALA synthase led to the formulation of a concept referred
to as the free , regulatory, or unassigned heme pool.168 181 Since heme is
rapidly bound by proteins 217-220 the heme pool will not be referred to as
free" heme , although some small fraction of cellular heme must always be
unbound (Figue 1.11). Since the major function of cellular heme that will
be considered is its role in regulation of ALA synthase activity, this heme
will be referred to as regulatory heme. Exogenous heme was found to
rapidly inhbit heme synthesis in cultured chick embryo cells in serum free
medium with Kr=10-7 M 168 221 in media containing bovine seru albumn
=2x10-6 M 222 and with human serum albumin K =2x10-8 M.187 223
Microsomal and mitochondrial cytochromes (P-450 , b5, etc... ) bind heme
with a Kd 10-7 M224 225 whereas heme oxygenase activity is induced by
heme concentrations ::10-6 M.226-230 These data suggest that under normal
circumstances, heme will first supply the demand for cellular
hemoproteins, next heme will modulate the activity of ALA synthase to
prevent excess heme formation, and finally, if excess heme is present
heme oxygenase will be induced.
tion ALA syn ase ac ivity bLheme . A corollary to
the regulatory heme pool model for ALA synthase repression is the
hypothesis that a reduction of intracellular heme will result in the
induction of ALA synthase. Chemicals that destroy heme231 (e.
AIA 232-234 3 , diethoxycarbonyl- 1 , dihydrocollidine (D DC), 23 5 ,236 or
, j
Figure 1.11: Schematic representation of the regulatory heme pool.
Reguation of heme metabolism is thought to be regulated via a regulatory
heme pool. This model proposes that increases in cellular heme
concentration serve to decrease the activity of AL synthase (light blue), the
enzyme that catalyzes the rate limiting step in heme biosynthesis. This
regulation can occur at the site of mitochondrial translocation of pre-ALA
synthase , at the level of mRNA by altering message half-life , and at the
" .
"1 :
level of transcription. If the amount of heme in the cell increases then
heme oxygenase (green) will increase to degrade any excess heme. The
largest factor affecting heme levels in the cell is the amount of apo-
cytochrome P-450 (pink) that requires heme in order to be catalytically
active. This enzyme can be induced by a variety of drgs and heme may act
as a positive regulator of cytochrome P-450 gene expression. The theory of
how metalloporphyrins function to decrease ALA synthase activity
suggests that inhbition of heme oxygenase occurs first, which causes an
increase in the regulatory heme pool. This heme would then exert a
repressive effects on ALA synthase. The schematic also shows the sub-
cellular distribution of the heme metabolic pathway (red).
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griseofulvin236-238), or chemicals that inhibit heme synthesis (e.
dioxoheptanoic acid (DHA),239-241 deferoxamine 242 243 or N-methylated
porphyrns231 244) can produce modest increases in ALA synthase activity.
Inhibitors of heme biosynthesis are often used in conjunction with other
porphyria-producing chemicals an experimental model for
porphyria.236,240 245,246 Experimental results with phenobarbital, and other
porphyrnogenic chemicals demonstrated an increase in apocytochrome
450 and ALA synthase activity,224 225,235 247-250 and induction of apo-
hemoproteins was envisioned to cause an increase in demand of heme
thereby leading to an induction of ALA synthase. One study in chick liver
cell suspensions reported an increase in ALA synthase activity after a
transitory exposure to heme alone.251 These experiments have not been
confrmed, and others have been unable to reproduce the results (E. Cable
unpublished results; P. Sinclair, personal communication). Recently,
other experiments investigating the relationship between induction of
cytochrome P-450 and ALA synthase have shown that mRNAs for P-450 and
ALA synthase were simultaneously increased after treatment with
phenobarbital-like drugs.252 253 Increases in ALA synthase mRNA were
observed after AlA treatment, even in the presence of cycloheximide
indicating that synthesis of new molecules of apocytochrome P-450 is not
required for induction of ALA synthase by AlA.
Recent transient transfection experiments with the rat hepatic ALA
synthase cDNA have identified both positive and negative cis-acting
sequences254 along with a consensus nuclear respiratory factor responsive
element sequence (NRF -1 RE). This consensus sequence idendfied in other
respiratory proteins allows the cell to control the supply of proteins involved
in cellular respiration.
255-257 The existence of NRF-1 RE sequence in the
ALA synthase 5' flanking region suggests the importance of this factor in
controlling the availability of heme for mitochondral cytochromes. This
would indicate that AL synthase is directly controlled via the NRF -1 RE
instead of being elevated only after the mitochondrial apo-hemoproteins
depleted the regulatory heme pool. The biological importance of this
sequence is underscored by the fact that the erythroid ALA synthase gene
lacks NRF -1 RE (see next section).254
Although no "drug- responsive" elements have been identified to date
in the hepatic AL synthase gene , available data show that heme depletion
alone may generate a small (S 2-fold) induction of ALA synthase, but that
heme depletion per se will not give rise to the high activities ( fold) of
ALA synthase observed different experimentalmany
systems.231 232 248 258-260 Heme depletion can lead to synergistic inductions
ALA synthase the porphyrinogenicpresence
compounds.236 240 245 246 Thus, the reguatory heme pool may be viewed as
primarily functioning to decrease ALA synthase activity when replete
while permtting, but not causing, increases of ALA synthase activity when
depleted.
of er thr id h me bio nthesis. Erythroid heme
biosynthesis represents a special case scenario for regulation of heme
synthesis. In developing red blood cells , ALA synthase activities must
remain elevated , compared to non-differentiated cells, even in the presence
of high heme concentrations.261-264 Differential regulat\on of heme
biosynthesis in erythroid versus non-erythroid cells is accomplished
primarily through two separate genes encoding ALA synthase.265-268
Induction of ALA synthase seems to play a key role in erythroid
development.269 Erythropoietin270 271 and iron availability272-274 play key
roles in induction of ALA synthase activity during differentiation of
erythroid cells. Erythroid ALA synthase seems to be primarily under
control of the iron responsive element binding protein (lRE-bp).272 274 This
protein was first described for its ability to bind transferrin receptor
mRNA275-277 and ferritin mRNA. 78-281 In the absence of iron the protein
remains bound to a sequence specific stem-loop mRNA structure and
prevents translation of the ferrtin message. However, in the presence of
iron , the protein binds iron and its affnity for mRNA decreases rapidly.
The identification of an IRE on erythroid specific ALA synthase
mRNA272 274 provided a breakthrough in understanding the induction of
erythroid ALA synthase even in the presence of large concentrations of
heme. Several investigators have described an aconitase activity
(E.C. 4. 1.2.3) associated with the IRE- 282-285 and the nucleotide sequences
from E. coli and bovine aconitase display a remarkable similarity to the
human IRE-bp.286 287 Similarities between aconitase and the IRE-bp exists
for the cytosolic aconitase only, and not the mitochondrial form.286
Switching between the aconitase activity and the IRE-bp function may be
regulated by the change in an iron-sulfur cluster from 4Fe-4S to
3Fe-4S.283 288-290
Both ALA dehydratase267 291 and PBG deaminase292-295 are also
differentially reguated in erythroid cells versus non-erythroid cells, but via
differential mRNA splicing. The differences between hepatic and erythroid
heme biosynthesis are necessary to supply the needs for each specific cell
type. Understanding the differences in function between the different cell
types gives further insight into the problems faced by people with hepatic or
erythropoeitic porphyras , and the possible treatments for each type.
Porpyr
Introduction. The porphyras are a group of inherited or acquired
diseases in which the fundamental defect is in heme biosynthesis. These
diseases present different symptoms, and are classified due to the
enzymatic defect in the heme biosynthetic pathway. The first case of
human porphyra was described just over 100 years ago by Stokvis12 in a
woman who had taken sulfonal. Sulfonal precipitated porphyria in 5- 10%
of female patients, and barbiturates were known to precipitate porphyra as
weu.1 Other patients presenting with port-wine colored urine
abdominal pain, and psychiatric disturbances appeared independent of
precipitating chemical exposure.296 297
Many chemicals were found to precipitate or exacerbate patients
suffering from porphyra and are classified as porphyrinogenic, while
chemicals that did not have a deleterious effects on patients suffering from
porphyra are considered safe. There are other chemicals that have either
given mixed results (e.g. deleterious only in some patients), or for which
experimental data are inconsistent. Animal systems have been used as
models for porphyra and to test chemicals for porphyrnogenic properties.
The most widely-used and reliable model is the chick embryo liver cell
culture system.246-248,298-310 Patients suffering from acute hepatic
porphyras should avoid exposure to porphyrnogenic compounds , because
of the extreme and debilitating symptoms and signs that may occur after
such exposure.
Table List of drugs that have been determined as1.1:
porphyrinogenic, possibly porphyrinogenic and non-porphyrinogenic in
either humans or cell culture models (*). Persons suffering from acute
porphyria, even in the latent phase, should avoid exposure to the
porphyrnogenic chemicals. In cell culture systems however, some of these
drgs can be used to produce perturbations in heme biosynthesis that serve
as a paradigm for human porphyras.
AlcohoI248 311-319
Aminoglutethimide*320
Aminopyri 321
Amitriptyline*322
Amphetamines322
Barbiturate 321 323-325
Benzodiazepines326
Busulfan*322
Carbamazepine*32 7
Carbromal328
Chlorambucil*322
Chloramphenicol299
Chlordiazepoxide320 321
Chlormezanone322
Chloroform 329
Chlorpropamide320
Cimetidine*322
Clomazepam327 330-332
Clonidine*322
Cocai 333
Colisti 322
Cyclophosphamide*334-336
Cycloserine322
Danazol337
Dapsone329
Dichloralphenazone322
Diclofenac322
Diethylpropion322
Dimenhydrinat 322
Diphenyl-
hydantoin323 330 338
Dipyrone322
Ergot preparations321 322
Ethambutol322
Ethchlorvynol339
Ethinamate*322
Ethosuximide322
Ethotoin322
Etomidate*322
Eucalyptol322
Flufenamic acid322
Flunitrazepa 325
Furosemide322
Porphyrnogenic Drugs
Glucocorticoids340
Gluthethimide258 322
Gold preparations*322
Griseofulvin 341-346
Hexachlorobenzene34 7 -355
Hydantoins322
Hyoscine322
Indomethacin 356
Isoniazid322
Isopropyl
meprobamate322 357
Ketoprof 322
Lidocaine*322
Mephenezine322
Meprobamate35 7 ,358
Mercury compound 358
Methoxyfurane322
Methsuximid 359
Methyldopa360
Methyprylon322
Metoclopramide329
Metronidazole*322
Metyrapone*361-363
Nalidixic acid364
Nikethamid 322
Nitrazep 322
Novobiocin 322
Oral contraceptives
365-367
Pancuronium322
Paramethadione322
Pargyline*368
Pentazoci 322
Pentylenetetrazole339
Phenelzi 322
Phenoxybenzamine*368
Phensuximid 322
Pheny Ihydrazi 322
Phenytoi 327
Primidone322
Probenecid *322
Progestero 369-3 7 4
Pyrazinamide322
Pyrazolones322
Ranitidi 322
Spironolactone*322
Succinimid 322
Sulfonamid 322
Sulfonylureas322
Theophyllne375 376
Tolazamide*328
Tolbutamid 322
Tranylcypromine*322
Trimethadione322
Valproic acid330
Xylocai 322
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Possibly Porphyrnogenic Drugs
Chlormethiazole322
Chloroqui 377 -383
Clonazep 327 330 330-332 384
Diazep 322
Enflurane*322
Erythromyci 322
Estrogens366
Halothane322
Hydralazi 322
Imiprami 322
Ketami 322
Mefenamic acid322
Meperidi 322
Nitrofurantoi 322
Oxazep 322
Paraldehyde322
Pethidine322
Phenylbutazone385 386
Pyrimethami 322
Pyridoxi 322
Rifampi 322
Steroid 385,387 -395
Tetracyclines322
Acetaminophen 322
Acetazolamide*322
ACTH322
Adrenali 322
Allopurinol*322
Aminoglycosides322
Aspiri 322
Atropi 322
BAL322
Beta blockers322
Biguanid 322
Bromid 322
Bumetanid 322
Bupivicaine*322
Buprenorphi 322
Cephalexin 322
Cephalosporins322
Chloral Hydrat 322
Chlormethiazole322
Chlorpromazi 322
Chlorthiazid 322
Clofibrate* 195 396 397
Codeine322
Colchici 322
Cyclizi 322
Dexamethasone231 398-404
Diamorphi 322
Diazoxide*322
Dicoumarol
anticoagulant 322
Digitalis compound 322 ,
Dihydrocodei 322
Diphenhydrami 322
Disopyramide*322
Domperidone*322
Droperidol322
EDTA 322
Epinephri 322
Ether (Diethyl)322
Fenoprofen*322
Fentanyl322
Flurbiprof 322
Fusidic acid322
N on- Porphyrinogenic Drugs
Gentamici 322
Guanethidi 405 406
Hepari 322
Ibuprofe 322
Indomethacin 356 407
Insulin322
Labetalol322
Lithi 322
Lorazepam *322
Mandelamine*322
Mecamylamine*322
Meclozi 322
Metformin *322
Methadone322
Methanamine
mandelat 322
Methy Iphenidate*322
Morphi 322
Naproxe 322
N eostigmine322
Nitrous Oxide322
N ortriptyli 322
Paracetamol322
Penicilamine322
Penicili 322
Phenformin *322
Prednisolone322
Prilocai 322
Primaquine408
Procaine322
Prochlorperazine322
Promazi 322
Promethazi 322
Propantheline Bromid 322
Propoxyphene322
Propranolol322
Propylthiouracil322
Prostigmine322
Pyrilami 322
Qui 322
Quini 322
Reserpi 322
Resorcinol322
Salicylat 322
Streptomycin 322
Succinylcholi 322
Sulindac*322
Tetraethy lammoni urn
bromide322
Thiazid 322
Thiouracils322
Thyroxi 322
Triazolam*322
Trifluoperazi 322
Tripelennami 322
Tubocurarine322
Vitamin A409
Vitamin B1322
Vitamin B2322
Vitamin B 12322
Vitamin D322
Vitamin E322
Vitamin K322
Classification of a. The porphyras are generally grouped
into hepatic and eryhropoietic porphyras depending upon the major site of
overproduction of heme precursors , either hepatic or erythropoietic cells.
Another categorizing scheme is based on the occurrence in some patients of
acute symptomatic attacks interspersed by non-symptomatic latent periods.
Thus , the porphyrias are categorized as either acute or non-acute (Table
1.2).
...
Table 1. 2: Enzyme defects , clinical features and inheritance of
human porphyra. Classifications of porphyras, the enzyme defects and
the inheritance are listed in Table 1.2. The table is from "The
porphyrias
" .
161 Note that photosensitivity is a feature of all of the
porphyrias that are associated with porphyrin accumulation, whereas
neurological features occur in those with accumulation of ALA. Unless
otherwise stated, the isomers are the physiologic porphyrn isomers.
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Hepatic porpyr
Acute intermittent a. Acute intermittent porphyria (AlP),
the most common form of the acute hepatic porphyrias 161 is due to 
autosomal dominantly inherited defect in PBG deaminase. Almost all AlP
are heterozygous for this defect, and are asymptomatic prior to puberty and
approximately 90% remain asymptomatic throughout their lifetimes.
Homozygotes 410 however, present in infancy or childhood with severe
symptoms. Clinical manifestations are more common in women, it is
believed due to the porphyrinogenic effects of female sex hormones. Such
hormones are probably the most common class of compounds which induce
attacks in acute porphyrics.411 During the acute phase of AlP, urinary
excretions of ALA and PBG increase 20-200 fold, and excretions of
uroporphyrn and coproporphyrn are also increased.412 Precipitation of
attacks of AlP are strongly dependent on exposure to precipitating factors
and one important treatment of the disease is to remove the patient from
exposure to porphyrnogenic compounds.413 414
The most common clinical features of acute intermittent porphyra
relapse nauseaabdominal pain and vomiting, andare
constipation. 161 415 416 The psychiatric features of this disease, depression
delirium, disorientation, and paralysis , have led to an incorrect diagnosis
of patients presenting with these symptoms. This has led to hospitalization
of AlP patients in mental institutions.417 Treatment of the psychiatric
features of the disease without proper diagnosis have led to admnistration
of drugs that further exacerbated already severe conditions.418
Photosensitivity never occurs in AlP and can be used to distinguish AlP
from the other porphyras.
Hereditar a. Hereditary coproporphyra (HCP) is an
autosomal dominantly inherited of coproporphyrinogendefect
oxidase.419-421 HCP is an acute porphyria exhibiting acute and latent
phases. When symptomatic , HCP is generally more mild than AlP with
similar urnary levels of ALA and PBG, but coproporphyrin excretion can
be dramatically increased during the acute phase. The symptoms and
signs of HCP are clinically indistingushable from AlP except that victims
of HCP can exhbit cutaneous photosensitivity. 367 422 Homozygous HCP is
very rare (fewer than 10 cases reported), but clinical manifestations are
severe and occur early in life.423 424 Another rare variant of HCP is
harderoporphyria 423 named because of the high levels of excreted
harderoporphyrn in the urine and feces.
arie ate ria. Variegate porphyra (VP) is another acute
porphyra, inherited in an autosomal dominant fashion.425-428 . VP is
caused by a 50% decrease in the penultimate enzyme of heme biosynthesis
protoporphyrinogen oxidase.429 430 VP is most commc-- - mong South
Africa whites 426 with evidence that all affected indiv: -1uals are the
offsprig of two Dutch settlers from 1680. 161 Cases ofVP have been reported
worldwide 428 431-435 and probably reflect independently occurring
mutations. Chester porphyra, from a kindred in Chester, UK, is the co-
existence of both variegate and acute intermttent porphyras432 436 and all
the subjects with this disorder can be traced to one couple marred in 1896.
Homozygous cases of VP have presented with more severe clinical
symptoms than presented by heterozygotes.437-440 The clinical features of
VP are similar to those of HCP , and include photosensitivity and excretion
of a high level of fecal and bile protoporphyrn.428 441 442
Severe deficienc of ALA deh dratase. Severe deficiency of ALA
dehydratase (ALAD deficiency) is the rarest porphyra , with only 4 patients
described to date.443-447 One diagnosed individual was an asymptomatic 68
year old male , and another confrmed homozygotic infant. Inheritance 
ALAD deficiency is autosomal recessive. There is no cutaneous
photosensitivity, but there are neurologic symptoms similar to those seen
with AlP.
OI:p a cutanea tarda. Porphyra cutanea tarda (PCT) is the most
common form of porphyra, and is characterized by a decrease in
uroporphyrnogen decarboxylase activity.448-459 Homozygous decreases in
UROD are known as hepatoerythropoietic porphyra (HEP).460-463 PCT
appears in two forms: a sporadic form (type I), and a familial form (type
II). PCT is a hepatic form of porphyra and appears later in life sometimes
in conjunction with exposure to alcohol, other chemicals, like
polychlorinated cyclic hydrocarbons 304 336 448 464-467 and frequently in
conjunction with increases in hepatic iron.468-473 One possible explanation
for the decrease in UROD activity is the impairment of rebinding of the
porphyrnogen substrate.453 454 The name for the disease is derived from
the clinical hallmarks of cutaneous photosensitivity due to the
accumulation of uro- and 7 -carboxy- porphyrns in the skin. Appearance of
PCT in children virtually assures familial inheritance.474 PCT patients do
not suffer the acute attacks seen in the other hepatic porphyras, and
treatment is as simple as avoidance of precipitating factors475 and
phlebotomy.476-480
Erpoietic porpyr
Con enital er thro oietic ria. Congenital erythropoietic
porphyria (CEP) is an homozygotic, autosomal recessive, disorder of
uroporphyrinogen III cosynthase.1 CEP is very rare , less than 300
reported cases , and is characterized by the onset of the disease in infancy,
and pronounced cutaneous photosensitivity.481-483 CEP patients (like
Matthias Petry, p. 4) suffer from deposits of large amounts of cutaneous
uroporphyrin, which is an overflow from the erythroid system where a
predominance of porphyrn deposits can be observed.484 The eryhropoietic
nature of this disease does not produce the latent and acute phases as seen
with the acute hepatic porphyras.
hro oietic roto yra. Eryhropoietic protoporphyra (EPP)
IS a heterozygotic, autosomal dominant, defect of ferrochelatase.485
Ferrochelatase activities half of normal probably allow the clinical
symptoms of EPP to be milder than CEP although onset of EPP is still in
childhood. Patients with EPP excrete protoporphyrn in the feces , although
high protoporphyrn concentrations can be found in eryhrocytes , plasma
and bile.486 In some patients increases in hepatic ALA synthase may
contribute to the high levels of protoporphyrn. 121 487 There are no
precipitating factor associated with EPP and no neurological symptoms
exist.
Addition rias. There exist examples where two different
porphyrias were present in the same patient, such' as Chester
porphyra432 436 and other types of dual porphyras.488-490 Perhaps the most
shocking types of porphyrias that appear are the chemically-induced
porphyrias, such as the outbreak in Turkey due to ingestion of
hexachlorobenzene-treated seed grain 355 491-494 and those that sporadically
occur in workers exposed to various chemicals.495-497 Treatment of these
porphyrias consist of removing the offending compound from the
environment of the patient, however correct diagnosis of porphyra and
correct identification of the offending compound tends to be more
problematic.
Trtment of porphyr
Treatment for the erythroid types of porphyria generally consists of
nothing more than preventative treatments for the symptoms , however
heme therapy, discussed later, has shown some promise.498 499 Since ALA
synthase in erythroid cells is not normally under tight metabolic control
the best treatment seems to be prevention of the damage that can easily
occur due to the deposition of porphyrns in the skin, such as avoidance of
sunlight exposure or treatment with -carotene. 500-510 These diseases
could be a good model for eventually testing the effectiveness of stem cell
gene therapy due to the heterozygous nature of the inheritance of the
diseases.
The nature of the acute porphyras, AlP, HCP, and VP, and the
similarity of the clinical manfestations , first led investigators to postulate a
defect in AL synthase. 162 511 512 Elevated ALA synthase plays a key role in
the recrudescence of the acute phase of porphyra and an overproduction of
heme precursors. Reversion of ALA synthase activities to normal is
associated with an asymptomatic state.
Prior to the introduction of heme as a treatment for the acute
porphyras 513 the only treatment that existed was placing the patient on a
high carbohydrate diet, oral glycerol514 or corn oil 5 or i.v. infusion of
glucose516 or fructose.517 The effects of carbohydrate on reducing ALA
synthase activity were not reproducible in all situations 516 even in models
of experimental porphyra.247 518-520 The use of Lv. hemin as a therapeutic
j,.
'1"
agent has become widespread and is the standard treatment for patients in
the acute phase.513 521-526 PanhematinCI (Abbott Laboratories) is the only
preparation of heme approved by the FDA for use in the United States.1
Unfortunately, aqueous solutions of heme are notoriously unstable.527
Treatment of patients with the standard dose of 4 mg/kg every 12-
hours528 529 leads to thrombophlebitis in 50% of the patients. 529, 530
Coaguopathy,531 532 hemolysis 533 transitory renal failure 534 and transient
circulatory collapse535 are less frequent side effects, but have been reported.
Heme arginate (Normosang , Leiras Oy, Turku Finland), a
stabilized solution of heme, has become another agent available for heme
therapy.536-540 However this treatment is not curently approved for use in
the United States. Heme arginate rarely produces side effects539 and
rapidly improves hepatic oxidative metabolism.537 538,541 This heme
treatment, infused at 3.5 ~M, is a solution of ~-oxo-dimers and high
molecular weight aggregates.542 Heme-albumn can be used to treat acute
porphyraswithout the troubling side effects of aqueous hematin 543 while
utilizing a natural protein, albumn, that binds heme.
Heme infusion as a method to reduce hepatic ALA synthase activities
is the only treatment widely practiced that utilizes the biochemical
knowledge about the reguation of hepatic heme biosynthesis. One of the
problems with Lv. heme treatments, independent of the carrer, is the large
amount of heme reauired in order to control the patient' s heme biosynthetic
pathway. Hem\ .--t these concentrations could readily induce heme
oxygenase, the rate-limiting enzyme of heme degradation, thereby
decreasing the c(\""entration of admnistered heme.1
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Regution of Heme Degrdation
Introduction. Degradation of heme by heme oxygenase (E.C.
1.14.88.3) leads exclusively to the formation of biliverdin IXa.1,226 227 544-546
Mammals, but not birds, amphibians, or fish 227 , 54 7 further reduce
biliverdin IXa to bilirubin IXa. The reaction is catalyzed by the enzyme
biliverdin reductase (BVR) (E.C. 1.3. 1.24) which is in excess so that heme
oxygenase catalyzes the rate-limiting reaction in heme degradation.1,548-551
The importance of the rate of heme degradation on the control of heme
synthesis has been implicated under certain conditions 251 258 552 and
relates to the investigation of metalloporphyrins inhibitory for heme
oxygenase as chemical modulators of AL synthase activity.
Heme oxygenase can be induced by its substrate , heme , metal ions
and oxidative stress.1,258 548 553-557 Induction of heme oxygenase activity
may reflect the importance of heme degradation to prevent oxidative
damage 558 and the importance of bilirubin as an anti-oxidant.559-561 Heme
itself can catalyze oxidative damage of lipids , proteins, and the cellular
cytoskeleton562-564 and, it potentiates damage mediated by granulocytes565
Due to the potentially toxic effects of heme it is thought to be contained
during intracellular and intercellular transport.220 566 Although some
have posited that heme oxygenase exists in excess compared to its substrate
heme 567 it is clear that heme oxygenase activity is rate-limiting in heme
degradation and does not exist in excess as a safety feature.568
The reaction mechanism of heme oxygenase involves a change in the
oxidation state of heme from the thermodynamically favored ferrc form, to
the reduced ferrous form. Mter the iron has been reduced, molecular
oxygen can be accepted as the 6 ligand and this oxygen is used to
hydroxylate carbon 5. 569 570 Reduction of heme oxygenase is accomplished
by electrons donated from NADPH via NADPH-ferrihemoprotein reductase
(E.C. 1.6.2.4).571-575 The one electron reduction of iron and the binding of
oxygen are obligatory for the reaction to occur. Inhibition of heme
oxygenase by some non-heme metalloporphyrins occurs because such
compounds bind to heme oxygenase but do not activate oxygen.576-585
sfunctions in heme radation. Dysfunctions in heme
degradation will not be directly probed in the research, however some of the
results will have relevance to further understanding heme degradation.
There are no known human diseases that result from a mutation of heme
oxygenase. Not even a leaky mutant has been described to date suggesting
an absolute requirement of heme oxygenase for survival. Most
perturbations of heme catabolism result from the inability of the human
body to conjugate and excrete bilirubin. Uridine diphosphoglucuronate p-
glucuronosyltransferase (UDPGT) (E.C. 2.4. 1.17) is responsible for
bilirubin conjugation, and disruptions in UDPGT activity result 
increases in unconjugated bilirubin in affected patients. Neonatal
hyperbilirubinemia is common and is the result of increased bilirubin
production and the delayed maturation of UDPGT.547 Crigler-Najjar
syndrome , type 1 , results from an autosomal recessive absence of UDPGT
while Crigler-Najjar syndrome, type II is the result of a milder defect in
UDPGT, although the inheritance has not been precisely resolved.547 586-589
Gilbert' s syndrome590 causes increases in unconjugated plasma bilirubin
due to a partial UDPGT deficiency.591 Dubin-Johnson syndrome 592 Rotor
syndrome 593 and benign recurrent intrahepatic cholestasis594 are all
related to increases in conjugated bilirubin levels and are reviewed
elsewhere. 54 
Treatments of d sfunctions of heme de adation. Bilirubin disorders
can be treated with metalloporphyrns that inhibit heme oxygenase, similar
to the treatments that have been used in treating porphyra595 596 . Clinical
trials have demonstrated the effectiveness of tin-protoporphyrn on both
neonatal hyperbilirubinemia and Crigler-Najjar syndrome 597-601 since the
metalloporphyrns inhibit heme oxygenase.577 602-605 Any studies involving
inhbitors of heme oxygenase have potential clinical applications for any of
the hyperbilirubinemic diseases.
Interrela tionshi heme metabolism. The use of
metalloporphyrns in treatment for hyperbilirubinemia demonstrates the
effectiveness of these compounds at inhibiting human heme oxygenase.
The use of tin-protoporphyrn to suppress chemically-induced porphyra in
rats596 suggests the use of these compounds in the control of acute hepatic
porphyras. Heme compounds used to treat patients with porphyra are
potent inducers of heme oxygenase, at least in culture 230 and probably in
patients. 161 The use of metalloporphyrns as inhbitors of heme oxygenase
in the treatment of porphyra may be preferable if these compounds would
be more effective than any of the heme preparations , or would enhance the
effectiveness of heme so that much lower doses could be administered, and
perhaps prolong the effectiveness of heme. Metalloporphyrns , if effective
could overcome the side-effects normally seen with i.v. heme
administration. 529 530 534 535 606 However some metalloporphyrns produce
certain side effects , most notably photosensitivity,607-610 although chemical
modifications of the side chains on the pyrrole macrocycle may alleviate
some of the photosensitivity. 611 612 Different metals substituents may also
alleviate the problem of photosensitivity.613 Porphyrns and porphyrin
derivatives have even been used as photosensitizing agents in phototherapy
for tumors.614-625 Although the side effects of these compounds can be
significant, their usefulness as an effective treatment for porphyra has
been suggested.626
Photosensitizin
g p
erties of metallo rins. The ideal
metalloporphyrn for use in humans, for treatment of porphyria , Crigler-
Najjar syndrome , and neonatal jaundice , would be potent and effcacious
and would not be photoreactive. This ideal compound has not yet been
described. The metalloporphyrns most frequently researched are the tin-
zinc- and chromium- metalloporphyrins.582 597 620 627-633 The consensus
opinion in the field is that the mesoporphyrns are a better choice for in vivo
use because of the lower reactivity of the C3 and C8 ethyl groups.550 611
However, there is no agreement on which metal would function best.
Kappas et al. are strong proponents for the use of tin-
metalloporphyrns , 577 ,578 580 585,596 600 604 while others suggest porphyrns
containing zinc- or chromium.582 583 601 607-609 613 634
The systems utilized to determine phototoxicity and photoreactivity
have generally been in vitro 613 629,635- 638 although one study l1as tested the
effects of tin-protoporphyrn on the survval of neonatal rats. 639 The in vitro
experiments have used solutions with metalloporphyrin, with various
organic molecules, such as histidine, trytophan, human serum albumin
medium-chained triglycerides, and NADPH.613, 636 This type of in vitro
system indicated the severe photosensitizing properties of zinc
porphyrins,629 by testing the degradation of trytophan as a measure of
singlet oxygen production.640 The results demonstrate that within several
minutes zinc-mesoporphyrin generated enough singlet oxygen to
photo degrade trytophan at a rate 2.5 times faster than tin-mesoporphyrn.
This research tested for the ability of metalloporphyrns to inhibit heme
oxygenase activity and found that zinc-mesoporphyrn was much less
effective than tin-mesoporphyrn or zinc-deuteroporphyrn- bisglycol,629
a result that conficts with other experimental data.582 634 641 642 Others
have found that zinc meso- and zinc proto- porphyrns are some of the least
photoactive metalloporphyrins along with manganese meso- and
manganese proto- porphyrns, chromium meso- and chromium proto-
porphyrns, and nickel protoporphyrn.613 These results were based on the
generation of carbon monoxide in the presence of NADCP)H636 and the
photo degradation of bilirubin.637 The heme oxygenase inhibition studies
supported previously published data.582 583 634 643 Probably the most
convincing data supporting the use of zinc-mesoporphyrn for human use
was the mortality studies of metalloporphyrns in rats where LD50 for tin-
protoporphyrn was 11. 7 ~mollg body weight.639 Tin-mesoporphyrn
caused 42% mortality at 30 Jlollg body weight, while zinc-mesoporphyrn
caused no mortality at 45 J.mollg body weight.639 while the bolus
administration of metalloporphyrn was much larger than that used in
humans 626 the regimen used in patients requires the infusion of up to 1
mg/kg/ day over the course of several days. 597 - 6 0 1 Since the
pharmacokinetics of metalloporphyrins in humans has not exhaustively
been studied595,644 the less potentially fatal compounds deserve
consideration for use.
. .
CHATER II
RESE OBJCTI
Primar chick embr o liver cells as a model for he atic heme
metabolism. Primary chick embryo liver cell cultures are a simple culture
system primarily consisting of hepatocytes , although other cell types are
included. This relatively inexpensive system does not require an
extracellular matrix , unlike mammalian liver culture systems.645-650
These cultures have been shown to retain normal levels and inducibility of
key enzyme related to heme metabolism. 169,299 300 651 652 An initial objective
was to use the chick embryo liver cell culture system to study the effects of
iron on the induction of heme oxygenase , ALA synthase, cytochrome
450' s and porphyrn accumulation, since iron was known to potentiate
heme synthesis under certain conditions.548 653-657
Additionally, the chick embryo liver cell culture system was to used
to test the porphyrnogenicity of different terpenes, in relation to the disease
sufered by Vincent van Gogh. The structures of the chemicals tested here
and elsewhere 183 183 306 352 518 651 658,659 are shown in Figue 2. 1. These
preliminary results were designed to demonstrate the utility of the chick
embryo liver culture model for studying hepatic heme metabolism, and to
test the ability of chemicals to potentiate , or cause porphyra.
ner ic ef cts of iron on induction of heme oxygenase b
lutethimide. ' Iron is known to potentiate the onset of PCT in humans and
animal models 304 453 660-662 and to potentiate the induction of ALA
Figure 2. 1: Structures of drugs tested in chick embryo liver cell
cultures. The drugs shown are either known as porphyrinogenic or were
tested for their ability to be porphyrinogenic. Glutethimide (31) was the
compound used throughout the research as a prototypical cytochrome P-450
lIB inducer, while camphor (32), thujone (33), and a-pinene (34) were
subsequently shown to induce cytochrome P-450 lIB and to be
porphyrinogenic (Chapter IV). The structure of 20-methylcholanthrene
(35), a cytochrome P-450 IA inducer, is shown to emphasize the structural
differences between the chemicals that induce the IA forms of P-450 and
those that induce the lIB forms of P-450 , although a clear picture of the
structural requirements for inducers of P-450 lIB have yet to emerge.
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synthase in culture 258 548 655-657 663 and intact rats.471 653 661-666 Iron was
also described to induce heme oxygenase in animal systems 548 667 668
although the activity of heme oxygenase in PCT is still not known. Small
amounts of iron (5~M) were known to increase uroporphyrn accumulation
in cultured chick embryo liver cells 669 and these experiments were to be
extended to describing the effects of iron on hepatic ALA synthase activity,
and mRNA levels, in the presence of different porphyrnogenic chemicals.
Research was undertaken to elucidate the mechanism whereby the
combination of glutethimide and FeNTA produced synergistic increases in
heme oxygenase activities in cultured chick embryo liver cells.
Mechanism of the ner stic induction of ALA s nthase b 
thimi iron. Regulation of hepatic heme metabolism is thought
to occur via a regulatory heme pool. This model was first proposed222 and
further developed168 181 by Granick who suggested that heme is first used
for formation of cellular hemoproteins; second, any "excess" heme is used
to regulate ALA synthase and effectively tur off heme biosynthesis; and
third, if the cell is presented with too much heme , heme oxygenase is
induced. The synergistic induction of both ALA synthase and heme
oxygenase in chick embryo liver cells upon treatment of the cells with
glutethimide and iron would not be predicted by the regulatory heme pool
model and seems at variance with the view that regulatory heme is solely
responsible for the regulation of heme metabolism. Two different
hypotheses could be proposed that would explain these inductions: First
glutethimide and iron could cause a rapid uncontrolled induction of ALA
synthase, exposing the cell to high levels of heme and producing a
secondary induction of heme oxygenase; or second , glutethimide and iron
could cause a rapid induction of heme oxygenase , depleting the cell of heme
and producing a synergistic induction of ALA synthase. Research was
undertaken to describe the interrelationship that exists between ALA
synthase and heme oxygenase and the role of the regulatory heme pool on
both enzymes.
Effects of metallo ns on ALA s nthase. The discovery that
after treatment of chick embryo liver cells with glutethimide and iron
heme oxygenase activity was synergistically induced before ALA synthase
activity,258 554 provided a rationale for the use of the metalloporphyrns to
modulate AL synthase activity. The use of a metalloporphyrn to decrease
activity of AL synthase was first described in 1984670 and proposed as a
therapeutic agent for inducible porphyra after studies in AlA-treated
rats.596 The first patient studies reporting the use of tin-protoporphyrn
appeared in 1991 and furher studies reported the use of the combination of
heme arginate and tin-protoporphyrin to lower the excretion of ALA and
PBG in patients with acute porphyra.626 The rationale for the use of tin-
protoporphyrn was to inhibit heme oxygenase and thereby prevent the
heme arginate from being degraded. The report by Dover et al. appeared
after the experiments describing the additive effect of tin-mesoporphyrn
and heme at rapidly lowering ALA synthase activity had been completed.258
The final stages of the research were to describe which combinations of
heme and a series of metalloporphyrins (Figure 2.2) were effective at
reducing ALA synthase activity in chick embryo liver cell cultures , and to
Figure 2: Structures of heme-analog metalloporphyrins tested in
chick embryo liver cell cultures. Chapter VII shows the screening of a
number of metalloporphyrns for inhibitory effects on heme oxygenase and
their ability to decrease AL synthase activity.
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provide evidence which provided some insight into the mechanism whereby
metalloporphyrns exerted their effects.
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CHATER III
TES AN METHODS
NY).
Materials. All tissue culture dishes were from Corning (Corning,
Chloroform, dimethylformamide, glacial acetic acid , isopropanol
methanol, perchloric acid were from Fisher (Pittsburgh, P A).
Dexamethasone was from Gensia Pharmaceuticals (Irvine, CA).
Methoxyresorufn , ethoxyresorufin, benzyloxyresoruf pentoxvresorufin
3-cyano-7-ethoxycoumarin, resorufin, and 3-cyano-
, -
hydr coumarin
were from Molecular Probes (Eugene, OR). pd(N)6 , Oligo dT(12- 18),
PhastSystem pre-cast 8-25% gels and buffer strips , Sephadex G- , and
Sephadex G-75 were from Pharmacia (Piscataway, NJ). Bicinchoninic acid
was from Pierce (Rockford, IL). o-Aminolevulinic acid, coproporphyrin I
hemin chloride HPLC fluorescence standards mesoporphyrin IX, N-
methylmesoporphyrn, protoporphyrn IX, Sn- diiododeuteroporphyrin
Sn-mesoporphyrn IX, Sn-protoporphyrin IX, uroporphyrin I, Zn-
deuteroporphyrin- bisglycol Zn-mesoporphyrin and Zn-
Cu-protoporphyrn IX were from Porphyrin Products (Logan, UT).
mesoporphyrin Cu-protoporphyrin Cu-hematoporphyrin Cu-
deuteroporphyrn were generous gifts from Dr. Dabney Dixon (Georgia
State University, Atlanta, GA). The plasmid pALX265 was a generous gift
from Dr. Doug Engel (Northwestern University, Evanston, IL). AMV-
Reverse Transcriptase, dTTP, dGTP, dATP, dCTP, Klenow DNA
polymerase, and RNAsin were from Promega (Madison, WI). Adenosine
triphosphate, actinomycin D , ammonium phosphate , ammonium chloride
-mercaptoethanol, bovine serum albumin coenzyme A, deferoxamine
dioxoheptanoic acid diethylpyrocarbonate, dimethylsulfoxide
dimethylaminobenzaldehyde, DNase, ficoll, Folin s phenol reagent
formaldehyde (37%), a- glucose (tissue culture grade), glutethimide
glycine hemin chloride, 4- (2-hydroxyethyl)- piperazineethanesulfonic
acid
, p-
hydroxymercuribenzoic acid, keyhole limpet hemocyanin
leupeptin , magnesium acetate , magnesium chloride , m-maleimidobenzoic
acid - N - hydroxysuccinimide ester, mercurc chloride , nicotinamide adenine
dinucleotide phosphate (reduced), nitrilotriacetic acid, poly (A),
polyvinylpyrrolidone , potassium carbonate , potassium flouride , potassium
phosphate (dibasic) , potassium phosphate (monobasic), pyridoxal
phosphate salmon sperm DNA sodium acetate sodium bicarbonate
sodium chloride , sodium citrate, sodium dodecyl sulfate, sodium
hydroxide , sodium phosphate (monobasic), sodium phosphate (dibasic)
sodium succinate, trichloroacetic acid, 3 3' triiodo- thyronine and
trizma base were from Sigma (St. Louis , MO). Fertilized chicken eggs were
either Barred Rock from Carrousel Farms (Hopkinton, MA), or White
Leghorn from Hyline Farms (Mansfield, GA) or Spafas (Norwich, CT).
William s E medium, trypsin, and penicillin/streptomycin and blocking
solution for immunoblotting were from Gibco (Grand Island, NY).
Formamide (spectral grade) and levulinic acid was from Aldrich
(Milwuakee, WI). 2 pentanedione was from E.M. Science (Cherry Hill
NJ).
IN).
Succinic thiokinase was from Boeringer Mannheim (Indianapolis
RNAzol was from Cinna/Biotexc (Friendswood, TX). The mini-
protean gel system, alkaline phosphatase conjugated goat anti-rabbit IgG
mini-protean gel system and alkaline phosphatase 5-bromo-4-chloro-
indoyl phosphate-Nitroblue tetrazolium color development reagents were
from Bio-Rad Laboratories (Richmond, CA). Nitrocellulose 0.45 ~m was
from Schleicher and Schuell (Keene , NH). All 32p and 35S radionuclides
were from New England Nuclear (Boston, MA).
ment. The SLM-Aminco DW-2000 was from SLM-Aminco
Instruments (Urbana, IL). Waters Baseline 810 HPLC System equipped
with a WISP 712 Autoinjector was from Waters Division of Millipore
(Milford, MA). The Shimadzu model RF-551 fluorescence detector was from
Shimadzu Instruments (Gaithersburg, MD). The LS-50B luminescence
fluorometer was from Perkin Elmer (Newton, MA). The flourometers were
equipped with red sensitive photomultiplier tubes (R944) to increase the
sensitivity to the fluorescent porphyrins. All centrifuges were from
Beckman (Fullerton, CA). The dot blot apparatus was from Schleicher and
Schuell (Keene, NH). The -counter was from Gen (Millvale , CA). The
Speed-Vac was from Savant (Farmingdale, NY). The computer equipment
was from Apple , Inc. (Cupertino , CA).
Chick embryo liver cell cutu
Introduction. Primary chick embryo liver cell cultures are a simple
reproducible system for exploring hepatic function.1 227 548 554 669 671 672
These have intercellularincludedinvestigations testing
communications 672 viral infections 671 porphyrin
metabolism 169 227 548 554 669 and other metabolic pathways.673-675 Other
culture systems , most notably primary rat hepatocyte cultures, do not
retain normal heme and cytochrome P-450 metabolism. 676 677 Since chick
embryo liver cultures are not pure hepatocytes, but contain approximately
10% fibroblasts , use is essential within 3-5 days since the fibroblasts divide
in culture , while the hepatocytes do not. Preparation of cells for culture is a
simple process in which the liver is minced into fine pieces , and treated
with a protease to digest the hepatocellular matrix. The red blood cells
must be removed , and finally the small groups of cells must be separated
from the larger fragments , and plated to form a monolayer culture.
Pre aration of liver cells. Chick embryos were dissected 16- 18 days
after fertilization. The livers were removed and washed three times 
Hanks physiologic buffer, minus calcium (136 mM NaCl, 5.S5 mM
glucose , 0.345 ro MgCI2, 0.338 ro Na2HP04, 0.441 mM KH2P04, 4.
ro NaHC03, pH 7.4). Ten milliliters of final innoculum can be obtained
from 1 chick embryo liver. Gall bladders were removed from the livers
before washing, to prevent contamination of the livers with bile , especially
bile salts. Ten to twelve livers were chopped for two minutes with razor
blades in Hanks buffer minus calcium with 4.5x10 5% trypsin (w/v) in 60
mm glass culture dishes. Contents of two or three chopping dishes 
were
combined and transferred to 125 ml sterile Erlenmeyer flasks , with an
enlarged bore pipette , mixed thoroughly with the pipette , and incubated for
a total of 20 minutes in a C water bath. Ten minutes after the start of
incubation DNase was added to a final concentration of 75~g/ml. Mter an
additional two minutes the mixture was again mixed thoroughly with the
large bore pipette and returned to the water bath for the remaining time.
The mixture from each Erlenmeyer flask was evenly distributed among 
fifteen ml conical tubes containing 10 mls of Hanks buffer minus calcium
at 4 C. The tubes were centrifuged at 500 x g for 90 seconds , and the Hanks
buffer was aspirated. The cellular pellets were resuspended in 10 ml of
room temperature ammonium bicarbonate buffer (129 mM NH4CI , 17 mM
Tris , 10 mM K2C03, pH 7.5)678 to lyse red blood cells , and mixed on a
rotating wheel for three minutes. The suspension was centrifuged at 500 x
g for 90 seconds and the buffer aspirated. This procedure was repeated
once, and after the second wash, the cellular pellet was resuspended in
William s E medium679 containing dexamethasone, insulin, and 3
triiodo-thyronine. The cells were spun at 80 x g momentarily to remove the
large debris , and the supernatant was removed , the volume corrected as
necessar, and the cells were plated onto tissue culture dishes. The volume
of innoculum added per size of plate was as follows: 25 mm plate (or 1 well
of a 6 well plate), 2 mI; 60 ro plate, 6 mI; 100 mm plate, 15 mI.
* The enlarged bore pipette was made by removing the tip on a glass 25 ml 
pipettE! so that the
remaining opening was approximately 4 mm I.D. The tip was flamed to remove any sharp
edges, and the pipette sterilized prior to use.
Maintenance and treatment of cultures. The insulin was removed
from the cells after 24 hours in culture by washing each dish with the
William s E medium containing only dexamethasone and T3. The dishes
were allowed to incubate for 1 hour after each wash in the presence of the
washing medium, the dishes were washed a total of two times , and the
induction volumes were dispensed into the dishes. The wash and induction
volumes for each of the dishes was as follows: 25 mm plate (or 1 well of a 6
well plate), 1 ml, 2 ml; 60 mm plate , 2 ml , 5 ml; 100 mm plate , 5 ml , 10 ml
respectively. The cells were not generally left exposed to the same medium
for more than 24 hours, although the volumes or times occasionally were
varied slightly if these changes expedited experimentation. Appropriate
controls were always done.
AL sythae assay
Theor Aminolevulinate (ALA) synthase (E.C. 2. 1.37) catalyzes
the condensation of 1 molecule of glycine and 1 molecule of succinyl-CoA to
form o-aminolevulinic acid (Figure 3. , reaction 1). The Km for glycine is
51 mM199 680 and the Km for succinyl-CoA is 10-55 ~M. 680 681 This
enzyme is only physiologically active in mitochondria because of the
subcellular distribution of succinyl-CoA. ALA synthase requires pyrdoxal
phosphate as a cofactor.1 198 Assays for this enzyme require a source of
succinyl-CoA, glycine, pyridoxal- phosphate and when crude tissue
extracts are used, an inhibitor of ALA-dehydratase to prevent further
metabolism of the product all within a suitable buffer system. ALA
generated in cellular supernatants is converted to a pyrrole (Figure 3.
reaction and reacted with Ehrlich' reagent
(p-
dimethylaminobenzaldehyde) to form a colored Ehrlich's pyrrole salt
(Figue 3. , reaction 3).682-684 The concentration of this resulting product is
determined spectrophotometrically.682-684
Descri tion. o-Amnolevuinic acid was produced from chick embryo
liver cell sonicates in 150 ~l of an appropriate assay buffer containing: 35
ro Tris, 30 ro sodium phosphate , 8 mM magnesium chloride , 5 mM
EDT A, 15 mM sodium succinate, 10 mM sodium levulinate , 500 
pyrdoxal 5' phosphate, and 66 ro glycine. The buffer system maintained
the pH at 7.4 for at least 30 minutes at 685 686 Magnesium-EDTA
inhibits ALA dehydratase and prevents formation of amino acetone
pyrole 682 and levuinate also inhbits ALA dehydratase.682 The reaction
Figure 1: Mechanisms of the reactions utilized in the assay for
ALA synthase. Reaction 1: The reaction carried out in vitro and catalyzed
by ALA synthase. This reaction requires glycine , pyrdoxal 5' -phosphate
and succinyl CoA. The intermediate a-amino- ketoadipic acid remains
enzyme bound (See figure 1.3 reaction 1). Reaction 2: The formation of
2-methyl-3-acetyl- propionic acid pyrrole (46). This reaction derivitizes the
AL formed by the enzyme into an Ehrlich' s reactive species. Reaction 3:
Derivatization of 2-methyl-3-acetyl- propionic acid pyrrole to a
chromophoric substance, the characteristic red Ehrlich's ALA salt (4 7J.
Solutions of this compound are quantified and the amount of ALA formed
in the original reaction is calculated.
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was started by adding glycine and incubating at 37 C for 30 minutes.
Succinyl-CoA formation was occasionally supplemented by the addition of a
succinyl-CoA generating system: 10 ro ATP , 100 ~M Coenzyme A, 5 mM
-mercaptoethanol , 100 mM potassium fluoride , and succinic thiokinase (5
nmoles succinyl-CoA generated/hour/ml total volume). Succinic
thiokinase condenses succinate and CoA to form succinyl-CoA, under the
proper reducing conditions and potassium fluoride was added to inhibit
ATPases that may have been released into solution after the disruption of
the mitochondria. 687 The succinyl Co-A generating system supplements
by about 20-30% , formation of ALA in some cell culture systems , while
having no additional effect in others (E. Cable, unpublished observations).
This was dependent on the source for the liver cells used and should be
determined empirically for each species. The reaction was allowed to
proceed for 30 minutes at which time TCA was added to a final
concentration of 4% to terminate the reaction. Spectrophotometric blanks
were obtained from identically treated aliquots of cellular sonicates except
that the blanks were not incubated. The assay samples and the
spectrophotometric blanks were treated identically from this point forward.
The TCA precipitates were removed after centrifugation for 10 minutes at
1000 x g, and a portion (150 ~l) of the supernatant containing the ALA was
removed. The ALA was then condensed with 4% 2 pentanedione in the
presence of 0.4 sodium acetate (pH 4.6) to form an ALA-pyrrole
(2-methyl-3-acetyl- propionic acid pyrole) in a Knorr-type condensation
reaction. This reaction was complete after incubation at 85 C for 
minutes. The ALA-pyrole was converted to a chromophore by the addition
equal vol ume modified Ehrlich' reagent (2%
dimethylaminobenzaldehyd (DMAB), 0. 375% mercuric chloride in 
32:168 (v/v) solution of 70% perchloric acid: glacial acetic acid). The colored
solution has a e555-650 = 68 mM- cm- 682 683 The mono-DMAB adduct, a
chromophoric Ehrlich' s salt, forms in solution with a maximum
absorbance obtained after 10 minutes. This timing was precise since longer
incubation ( 15 minutes) allowed a secondary reaction to form a colorless
dipyrolphenyl methane683 which led to a decrease in absorbance.
erimental results. ALA synthase is easily detectable in sonicates
of chick embryo liver cell cultures, even at basal levels (0.5 nmoles
ALAemg protein- lehour-l), especially after addition of chemicals which
induce ALA synthase to very high levels.548,688 689 Detection of reductions
of ALA synthase activity from basal levels , or detection in tissue samples
that contain very low levels (.:250 pmoles ALAemg protein- hour- l),
require other assay methods , such as radiochemical methods 690 or HPLC
separation and fluorometric detection of ALA derivatives.691
The spectrophotometric method employed throughout the duration of
this research was ideal since high levels of ALA synthase were present
(0. 25 nmoles ALAemg protein- hour-l). This assay was linear through
60 minutes , even at a high specific activity (Figure 3.2), although the 30
minute incubation time employed was sufcient to produce ALA quantities
that were easily detectable. The dependence of the assay on protein
concentration was linear throughout the range used in all the studies
(Figue 3.3).
Figue 2: Linearity of the assay for ALA synthase with respect to
incubation time. Chick embryo liver cell cultures were treated with 50 
glutethimide and 50 ~M FeNT A for 18 hours prior to harvest. The cells
were harvested and the assay completed as described in Methods , except
that the cell sonicates were pooled, and the time of incubation was as
indicated. The data are mean. SEM , n=3. Where no error bars are shown
the error falls within the size of the symbol.
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Formation of Ehrlich's salt pyrrole was rapid for the first minute and
continued with a rate that was first order with respect to ALA-pyrrole
concentration and zero order with respect to DMAB concentration with an
initial reaction rate of 15. 7 ~M eminute- l or a first order rate constant of
52 minute- l (Figure 3.4 , inset). The concentration of chromophore
stabilized after about 8 minutes and started to decay about 18 minutes after
initiation of the reaction (Figure 3.4). The decay occurred at a constant rate
of 18.5 nMeminute- l and was linear for at least two hours (Figure 3.4
inset). The disappearance of chromophore from solution was due to the
formation of the dipyrole adduct of DMA as opposed to the formation of a
di-DMAB adduct of the pyrrole (Figure 3. , reaction 3). The decrease in
absorbance did not significantly interfere since all the samples were
analyzed 10-15 miutes after the addition of modified Ehrlich's reagent.
, '
Figue 3: Linearity of the assay for ALA synthase with respect to
protein concentration. Chick embryo liver cell cultures were treated with
50 ~M glutethimide and 50 ~M FeNTA for 18 hours prior to harvest. The
cells were harvested and the assay completed as described in Methods
except that the cell sonicates were pooled, and the amount of sonicate added
to the 30 minute incubation was varied as indicated. Typical assays are
done with the protein concentration between 0. 1.0 mgeml- . The data are
single point determnations. Where no error bars are shown the error falls
within the size of the symbol.
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Figure 3.4: The formation of the chromophoric Ehrlich' s salt of 2-
methyl-3-acetyl- propionic acid pyrole. Chick embryo liver cell cultures
, \
were treated with 50 ~M glutethimide and 50 ~M FeNTA 18 hours prior to
harvest. The cell were harvested and assays done as described in Methods
expect that the time for the final formation of the chromophoric Ehrlich'
salt of 2-methyl-3-acetyl- propionic acid pyrrole was varied. The scans
were ru at the times indicated in the graph using the split beam mode on
the spectrophotometer run against the appropriate spectrophotometric
blank, as described in Methods. The inset shows the dual wavelength
kinetic formation of the chromophore and represent the change with time
in Mbs between 555nm and 650nm.
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Heme oxygena assays
Theo Heme oxygenase (E.C. 1.14.88.3) is the first and rate-limiting
step in heme catabolism 549 551 in chick liver cells.227 548 550 The
microsomal heme oxygenase system contains two different enzymes; heme
oxygenase which reduces the ferric iron of heme , binds molecular oxygen
and degrades the porphyrin macrocycle , and NADPH ferrhemoprotein
reductase (E.C. 1.6.2.4) which transfers six moles of reducing equivalents
obtained from the oxidation of NADPH.692 Three molecules of molecular
oxygen are required , of which two atoms of oxygen, obtained from different
oxygen molecules, remain as part of the biliverdin product (Figure 3. 5).
All mammals contain biliverdin reductase (BVR) (E.C. 1.3. 1.24) which
reduces biliverdin to bilirubin. Chickens can not reduce biliverdin to
bilirubin due to a lack of biliverdin reductase. Bilirubin has an extinction
coefficient more than 4-fold greater than that of biliverdin (bilirubin
.1E470-540 = 66 mM- cm- 230 biliverdin .1E680-750 = 15 mM- cm-
1).227 Thus, in
order to increase the sensitivity of the heme oxygenase assay, 1.5 units of
exogenous biliverdin reductase are added to convert the biliverdin to
bilirubin.
Kinetic assa . The original assay developed to detect heme oxygenase
activity was a dual wavelength spectrophotometric method that followed the
formation of bilirubin using the differences in absorbance at 470 nm, the
peak absorbance of bilirubin, and 540 nm, an isosbestic point for bilirubin in
the assay mixture (Figure 3.6).571 The assay mixture contained 70 mM
potassium phosphate , pH 7.40 , 5 mM deferoxamine , biliverdin reductase
Figure 5: Mechanisms of the reactions utilized in the assay for
heme oxygenase. The microsomal heme oxygenase system catalyzes the
degradation of heme (ferrc protoporphyrn IX) to biliverdin (49). The
reduction of the iron is the first reaction which leads to the binding of
molecular oxygen. The a-meso carbon of the tetrapyrole macrocycle 
specifically oxygenated leading to the formation of biliverdin IXa. This is
reduced to bilirubin IXa (48) in order to enhance sensitivity and to increase
the stability of the final product.
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Figure 6: Change in absorbance between 470 nm and 540 nm due to
the formation of bilirubin IXa catalyzed by the heme oxygenase assay
miture. Purfied chick liver heme oxygenase (5 ~l) was assayed and the
calculated activity of the undiluted protein was 66 pmolemin- . Assays
performed by John Healey.
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(BVR, capable of producing 1.5 nmole bilirubin/minute in a total volume of
one mI), 40 ~M heme , in bovine serum albumn at a heme/albumin molar
ratio of 5/3 554 571 in a final volume of 1 mI. Heme-albumin (ca 1.66 moles
heme/1 mole albumin) was prepared by adding 100 ~l of 10 mM heme (6.
mg/mI), dissolved in dimethyl sulfoxide (DMSO), to 3.9 ml of a solution of
BSA, 11.1 mg/ml , dissolved in 40 ro Tris.HCl (pH 7.4). The level of
endogenous NADPH ferrhemoprotein reductase was unknown, but was
also in excess since additional NADPH ferrhemoprotein reductase did not
increase heme oxygenase activity, even in fresh cell sonicates that
contained highly induced levels of heme oxygenase. The heme oxygenase
reaction in this system was started with the addition of NADPH, after
warming the entire mixture at C for 5 minutes. Formation of the
bilirubin product begins immediately and the activity was calculated from
the change in absorbance with respect to time with E470- 540nm=
66 mM- l.cm-
Batch ass Heme oxygenase activity was also measured by
scanning the final product after incubation of the assay mixture at 37 C for
fixed time. The reaction was stopped by adding mM p-
hydroxymercuribenzoic acid. The mercury ions do not affect the heme
oxygenase protein per se but inhibit NADPH ferrhemoprotein reductase
and prevent the transfer of reducing equivalents necessary to drive the
reaction. Typically this reaction was run for 10 minutes , twice as long as
the kinetic assay, to increase sensitivity. This assay was linear for at least
ten minutes and had a variability from the kinetic assay of 5%. The assay
miture "remained the same, but the reaction was started with the addition
,;.
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of the heme:BSA mixture , after a five minute pre-incubation at 37 C. This
pre-incubation warms the mixture from 4 , and at the same time reduces
any endogenous biliverdin in the samples. Spectrophotometric blanks were
aliquots of cell sonicates , treated identically, including all the additions
except that the hemin was added after the addition of the
p- 
hydroxymercuribenzoic acid. Heme oxygenase activity in cellular
sonicates were calculated from the difference in absorbance from 470 nm-
540 nm, scanned against appropriate spectrophotometric blanks
E470-540nm= 66 mM- lecm- l (Figure 3.7). Addition of the albumin to the
reaction not only helped to solubilize the heme , but stabilized the bilirubin
that was produced.
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Figure 3.7: Spectral scan of bilirubin IXa formed in the heme
oxygenase assay system. Purfied chick liver heme oxygenase (5 ~l) was
assayed and the calculated activity of the undiluted protein was 
pmol-min- . Assays performed by John Healey.
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Prtein asays
Protein concentrations from cell culture were quantitated utilizing
the reduction of copper sulfate as an estimate of the protein concentration.
The assay for the reduced monovalent copper was done either with the
classic Folin phenol reagent 693 or the more sensitive bicinchoninic acid.694
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Porphyr asays
Dierenti fluorometrc prour for estiti porpyr
Theor . Estimates of porphyrn concentrations in cultures were done
taking advantage of the differential fluorescence of uro- , copro- , and proto-
porphyrns.695 The wavelength pairs for this assay were Ex (nm)fEm (nm),
400/595 , 405/595 , 410/605. These wavelengths were chosen to give the
maximal difference in fluorescence between the corresponding porphyrns.
Through solving a series of three equations for three unknowns , by using
previously determined linear functions to describe the fluorescent
properties of each porphyrn at each wavelength pair (Figure 3.8), the
porphyrn concentrations were readily determned. The algebraic solution
to this problem can be described as follows:
A matrix describing the correlation coefficients of the linear
regression line describing the fluorescence of each porphyrin at each
wavelength pair can be written:
Ex (nrn)f UrofErn (nrn)
4OOA95
%95
%05
Copro Proto
Where , B, D, E, F G, , I, J were the respective coeffcients of each line
describing the fluorescent properties of the porphyrns (Figure 3.8).
107
Figure 8: Linearity of uroporphyrn (2), coproporphyrin (3), and
protoporphyrn (4) at each of the wavelength pairs utilized in the
spectrofluorometri detection of porphyrns. Solutions of each of the
individual porphyrns were made in PCA:methanol:H20 (5:45:50) and the
fluorescence of each porphyrn assayed at each of the wavelength pairs
utilized in the assay to characterize porphyrn mixtures in sonicates from
cell culture. The amounts of porphyrns utilized encompass the amounts
that can be produced by the cell culture system. The data represent
individual points, and three separate solutions were read at each
concentration and each wavelength pair. The lines were fit using a least
squares regression and the line was not forced through the origin.
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If:
(UroJ
(CoproJ
=Xu
(Proto J =Xp
and
Total fluorescence at
400/595 =F1
405/595 =F2
410/605 =F3
Then three equations can be written to describe the total fluorescence of the
miture as a sum of the fluorescence of the individual components (Figure
8):
+BX +DX
EXu +FXc +GX
HXu +IXc +Jp
Whch can then be rewritten as the matri equation:
A B 
E F
F3 H I 
This equation was easily solved within Excel (Microsoft) on a
Macintosh. The total porphyrn concentration within the medium is the
sumation of each of the individual porphyrn concentrations.
The utility of the assay was demonstrated by the use of mixtures of
the three porphyrns in known compositions (Figure 3.9A). The solutions
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were read in the same fashion as an unknown and the porphyrin
composition was calculated from the data presented in Figure 3.8. The
assay was precise to within 15% (Figure 3.9B). Mixtures of two and single
pure porphyrn solutions were read as well and the same precision was
obtained, but in the interest of clarity the data were not presented.
Descri tion. Total porphyrns were solubilized from cells and media
by takng the cells plus media miture from each 35 mm plate (or 1 well of a
6 well plate) by scraping with a spatula. The miture of media and cells
was sonicated for 5 seconds with a Branson microtip sonicator (25% of
maxmum setting). The sonicated solution (400 ~l) was mixed with 400 ~l
of 10% PCA/methanol (v/v) in a 6 x 50 mm borosilicate glass tube. The
PCA/methanol effectively solubilized porphyrins and oxidized
porphyrnogens to their corresponding porphyrns. The tubes were spun at
500 x g for 5 minutes to precipitate any cellular debris and the fluorescence
of the supernatant was quantitated within the same tube. The fluorescence
of the medium not exposed to cells was subtracted after the medium had
been treated in an identical maner.
."1
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Figure 9: Detection of porphyrins in known tertiary solutions
containing uroporphyrn, coproporphyrin, and protoporphyrn utilizing the
difference in fluorescence between three wavelength pairs. Solutions
containing known amounts of uroporphyrin, coproporphyrin and
protoporphyrin were made (A) and assayed (B). The solutions were mixed
with 2. , 10 and 50 ng of porphyrn and the concentration calculated as
described in Methods. The calculated results agree within 15% of the
known mixture composition. The data represent single determinations of
individual solutions. The individual porphyrins and the binary solutions
were assayed as well and similar correlation between the calculated and
known composition of the solution was obtained (data not shown).
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HPLC separtion of porphyr
Theor High-performance liquid chromatography (HPLC) of
porphyrn mixtures in solution is a highly quantitative method of detection.
Absorbance measurements can be used to detect porphyrins however
fluorescence is more sensitive , and is the method of choice , if available.696
Porphyrns isomers were originally separated after derivitization to
the methyl ester using adsorption chromatography697 or thin layer
chromatography. 698-700 Although porphyrn methyl esters can be formed
from the free acids , complete derivatization might not be possible , especially
for porphyrns with higher numbers of carboxyl groups. Reverse-phase
HPLC was first used to separate isohardero and hardero-porphyrn methyl
esters 701 but HPLC methods were developed that separated the porphyrn
free acids , and obviated the need for a derivitization reaction.696 702 Free
acids of porphyrns are easily obtained from almost any kind of sample
including cell culture 703 urine 703-706 blood703 and feces 703 706 707 by
extraction of the porphyrins directly into methanol, acetone/HCI , HCI
alone, or other acidified solvents. These solvent systems conveniently
extract the porphyrns and porphyrnogens , precipitate the proteins , and
oxidize the porphyrnogens to porphyrns. Extracts may be injected directly
onto the column without damage to the silica matrix. Reverse-phase HPLC
allows the separation of different isomers , and can greatly facilitate the
diagnosis of specific types of porphyria 704 705 and is now the method of
choi ce . 140 412 696 708- 714 Linear gradients were originally
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developed 702 705,715-717 however a convex gradient was used for porphyrn
separations in this work (Figure 3. 10). 708
Descri tion. Cell culture samples , normally a mixture of cells
scraped directly into the media, were extracted with O. lN HCI. The
mixture was centrifuged to precipitate the particulate matter, and the
supernatant was injected using a WISP auto injector. The porphyrins
heme and biliverdin, were separated on a C18 ~bondpak column the
mobile phase consisted of a gradient of two solvents: solvent A was a 1: 1
(v:v) miture of 0. 1 M ammonium phosphate , pH 4. , and methanol; solvent
B was 100% methanol. The gradient went from 70% solvent A and 30%
solvent B to 100% solvent B over 7 minutes at a flow rate of 1.5 ml/min
followed by 100% solvent B for an additional 11 minutes. (Figure 3. 10).
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Figure 3.10: Chromatographic separations of porphyrn free acids
over a C18 ~bondpak colum. The separation of octa-
, hepta- , hexa- , penta-
.,.
I '
tetra- , and di-carboxylic acid porphyrns, (I isomers) were accomplished
using a gradient separations of ammonium phosphate:methanol (solvent
A) and methanol (solvent B). The percentage of solvent B during the
chromatographic run is depicted along with the corresponding retention
times of the different porphyrns. The porphyrns eluted in the 
order of
2 carboxyl porphyrns.
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Cyme P-4 assays
ectro hotometric. The classical assay for the quantitation of total
cytochrome P-450 is based upon the binding of carbon monoxide as the 6
ligand to the reduced heme in the cytochrome P-450 protein. 718 , 719 Chick
embryo liver cell culture plates were harvested in 200 mM potassium
phosphate, pH 7.4 and briefly (c: 1 sec) sonicated. Cellular debris was
removed by centrifugation in a microfuge for 10 minutes at 4 C. The
supernatant (500 ~l) was added to 2X Emulgen 913 buffer (400 mM
potassium phosphate, pH 7.4 40% glycerol , 0.5% Emulgen 913). The
solution was gently mixed and split into two equal volumes and placed in a
microcuvette, with one cuvette placed in the sample position and the other
placed in the blan position. A few (3-5) grains of sodium hydro sulfite were
added to each cuvette and a split beam wavelength scan was done from
400nm-540nm. Ten bubbles of carbon monoxide were bubbled through the
sample cuvette and another wavelength scan was done. The spectra
obtained before and after the addition of carbon monoxide were subtracted
and the concentration of cytochrome P-450 was calculated from the
difference in absorbance between 450 nm and 520 nm E450- 520nm
91 mM- cm- 718
Cyt hrome P-450 de endent dealk lations. Cytochrome P-450
isozymes can be differentiated due to their activity on isozyme selective
substrates. The use of a homologous series of phenoxazones (Figure 3. 11)
has been used to differentiated induction of different cytocQrome P-450
isozymes in rats 720-723 and mice.720 Rat cytochrome P-450 IA typically
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Figure 3. 11: Structures of substrates for cytochrome P-450 dependent
mono-oxygenation reactions. The substrates of a homolgous series of
phenoxazone ethers , the resorufins , which are O-dealkylated by cytochrome
450 IA. 3-Cyano-7-ethoxycoumarn is also a substrate for this isozyme.
One of the best substrates for the lIB form of cytochrome P-450 is
benzphetamine which is N-demethylated, however the turnover number for
the reactions catalyzed by the lIB isozyme are much lower than the
turover numbers of the IA reactions.
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CH N-CH I 2
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catalyzes the de alkylation of longer chain phenoxazone ethers better than
the shortest chain phenoxazone ether; ethoxyresorufin (51) =
propoxyresorufin :;:; methoxyresorufin 721 724 whereas rat P-450 lIB
preferentially catalyzes the dealkylation of benzyloxyresorufn (53)724 and 7-
ethoxycoumarin 725 although at a rate much lower than that catalyzed by
the 1A forms of the enzyme. There are substrate differences between
different species , for example the Japanese quail P-450 1A dealkylate
ethoxy- :; methoxy- :; propoxy- :; benzyloxy- :;:; pentoxy- resorun while the
lIB forms show minimal catalytic activity toward all of these substrates. 724
These kinds of P-450 dependent oxidation reactions can be helpful in
characterizing the induction of different forms of P-450 , but only after the
catalytc activity of the species specifc P-450' s have been characterized.
Alkox resorufin dealk latin assa The alkoxyresorufin
dealkylating assays were done with 100 ~l of cell culture harvested from 60
mm dishes in 500 ~l Tris 20 mM, pH 7.8 and sonicated for 1 second. The
reaction was carred out in a final volume of 150 ~l containing 100 ~l of
sonicate, 1.7 mM NADPH, 20 mM dl-isocitrate , 0.03 U isocitrate
dehydrogenase, 13 mM nicotinamide, 12.5 mM MgCI2, 20 
alkoxyresorun (e.g. ethoxy- , pentoxy- (52), or benzyloxy- resorufn). The
mixture was incubated at C for 15 min, and the reaction stopped by
adding 1 ml cold methanol. The mixture was vortexed and centrifuged
1000xg for 10 minutes. The methanol supernatant was removed and the
fluorescence Ex 528 nm Em 590 nM was recorded. 720-724 726 727 The amount
of resorufin (50) formed in each assay was calculated from a standard
cure of identically treated resorun.
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Coumarin dealk latin assa s. The coumarin dealkylating assays
were done identically to the resorufin assays except that the substrate was
the 3-cyano-7-ethoxycoumarin (55), the product was 3-cyano-
hydroxycoumarin (54) and the excitation and emission wavelengths were
Ex 407nmm 450nm.728
Benz hetamine demeth latin assa s. Cell cultures samples were
harvested from 60 mm dishes in 450 ~l of 0. 1 M sodium phosphate pH 7.4
and sonicated for 1 second. The reaction was carred out in a final volume
of 140 ~l containing 100 ~l sonicate , 1.7 mM NADP , 20 mM dl-isocitrate
02U isocitrate dehydrogenase , 13 mM nicotinamide , 9 mM semicarbazide
12.5 mM MgCI2, and 3 mM benzphetamineeHCl (56). The reaction was
incubated at 37 C for 1 hour, and the reaction stopped by the addition of 50
~l 20% TCA. The miture was centrifuged at 1400 x g for 10 min at 4 C to
precipitate the protein, and 150 ~l of the supernatant was transferred to a
6x50 tube. Nash reagent (75 ~l of 4 ~l/ml 2 pentanedione in 30%
ammonium acetate) was added to each tube and incubated at 70 C for 15
minutes.245 729 The volume was adjusted with additional Nash reagent in
order to fill the tube and the fluorescence of the formaldehyde-
pentanedione adduct measure at Ex 420 nm Em 514 nm. The activity of the
enzyme was calculated from a standard curve of formaldehyde reacted with
the Nash reagent. The demethylation of 1 mole of benzphetamine (56) leads
to the production 1 mole of formaldehyde, and the formaldehyde was easier
to quantitate than the demethylated benzphetame. 300 , 730-737
. .
:,1.
Imunodetetion of AL sythae and heme oxygena
Anti en Pre aration. An attempt was made to raise antibodies
specific to the pre-mitochondrial and mitochondrial form of ALA synthase
using synthetic peptide sequences identical to those in the chick ALA
synthase protein. The cDNA sequence for chicken hepatic ALA synthase 738
was obtained from Genbank and the sequence translated using the
universal codon preferences. The two sequences chosen represented , as
much as possible , a hydrophilic a-helix, that had a high probability of
surface exposure. One sequence was chosen to be as near to the carboxyl
terminus as possible to be specific to both forms of ALA synthase, while the
amino terminal sequence was to represent the immature, pre-
mitochondral enzyme. The sequences were analyzed with Prosis for the
IBM using both the Robson and Chou Fasman secondary structure
prediction algorithms , the Jameson/olf antigenic index algorithm, and
the Pustell surface probability algorithm (Figure 3. 12).
The anti-chicken heme oxygenase antibody was raised against a
partially purfied chicken liver heme oxygenase protein. The details of the
purification of the protein are presented elsewhere.571
aration of oli peptides. The oligopeptides for the anti-ALA
synthase antibodies were synthesized using standard solid phase
fl uorenylmethoxycarbonyl (FMOC) chemistry
(2' dimethoxyphenyl-Fmoc-aminomethyl)phenoxy resin at the
micro sequence facility at Emory University. 739 The f1rst peptide
Figure 12: Protein analysis of the derived amino acid sequences
used as antigens for raising anti chicken ALA synthase antibodies. Figure
A shows the analysis of the amino terminal pepetide specific for the
precursor form of the enzyme and Figure B shows the analysis of the
carboxyl termnal peptide specific for both forms of the enzyme.
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representing mature ALA synthase was CRRPLHFEVMSERER and was
chosen as a hydrophilic, region that was probably exposed. Although the
antigenic index was not very high for this region , the other indexes made
this the choice for the oligopeptide. An additional consideration was that
the amino terminal cysteine in this sequence was used to generate a
specific bond from the cysteinyl sulfur through m-maleimidobenzoic acid-
hydroxysuccinimide ester (MBS) to free amino groups on the carrer
protein. The second peptide representing the immature , cytosolic form of
ALA synthase was LARVSQAFLQKAGPSC. The carboxyl terminal
cysteine was added to facilitate coupling with MBS in a fashion identical to
the fist peptide.
Cou lin to KLH and se aration. Each oligopeptide was coupled to
KLH using the bifunctional reagent, MBS. MBS couples the succinimide
ester to free amino groups on the carrer protein, KLH, and the N -alkyl
maleimide group to a free sulfhydryl group on the oligopepetide. KLH was
dissolved in 10 ro phosphate , pH 7.0 to a final concentration of 20 mg/mI
and a final volume of 2 mI. MBS was dissolved in DMF, final concentration
25 mg/mI. 100 ~l of the MBS solution was added to 2 mI of the KLH solution.
The solutions were mixed thoroughly and allowed to stand for 30 minutes at
room temperature , 25 C. The excess MBS was removed from the solution
by gel filtration through a 1 x 30 cm Sephadex G-25 column using 0. 1 M
phosphate pH 6.5 as an eluant. The fractions containing the protein peak
approximately 3.0 mg/ml protein concentration, were pooled. The
oligopepetide was dissolved in O. lM phosphate , pH 6. , 2 ro EDTA to a
final concentration of 10 mg/mI. 600 ~l of the oligopeptide solution was
added to 6 mls of the pooled carrer protein and allowed to sit at room
temperature for 4 hours. The uneacted oligopeptide was removed by gel
filtration through a 1 x 30 cm Sephadex G-75 column.
Raisin Antibodies. The ALA synthase carboxyl-terminal specific
anti-peptide antibody was raised in New Zealand Whte rabbits using a
regimen of Freund's complete and Freund's incomplete adjuvant. 740- 742
The ALA synthase amino-terminal specific anti-peptide antibody was
raised in New Zealand Whte rabbits using Hunter s Titer-Max
743
The anti-chicken heme oxygenase antibody was raised against
purfied heme oxygenase in New Zealand White rabbits using a regimen of
Freund' s complete and Freund's incomplete adjuvant. 740-742 The
polyclonal IgG was prepared from serum using octanoic acid 7 44 from
which was prepared IgG mono specific for heme oxygenase.745 This
antibody has previously been shown to be specific for chick heme oxygenase
from chick embryo liver cell cultures.740
Phast el blottin Cultured cells were homogenized in 0. 1 M
potassium phosphate buffer (pH 7.5), 20% glycerol (v/v), 1 mM EDTA
containing leupeptin (40 ~g/ml) as a protease inhibitor. Samples were
diluted 2:1 into a concentrated (3x) LaemmIi746 sample bufer. The samples
were separated by electrophoresis on a PhastSystem (Pharmacia) according
to manufacturer s instructions on 8-25% gradient gels. The samples were
transferred to nitrocellulose using the following procedure: Nitrocellulose
gels and 3 sheets of blotting paper were soaked in transfer buffer (25 mM
Tris-HCI 5% methanol, 192 mM glycine , pH 9.2) for 10 minutes then
assembled in a petri dish containing transfer buffer in the folldwng order
(from bottom to top): Phast gel (with plastic backing facing the bottom of the
petri dish), nitrocellulose, blotting paper, and a heavy (50g) weight. The
transfer was complete after incubation for 2 hours at 70 C. The blot was
blocked overnight with PBS containing 1% BSA and the incubated with
rabbit anti-chicken heme oxygenase 740 and the secondary antibody was
goat anti-rabbit IgG conjugated to alkaline phosphatase.
Mini-gel b ttin . Cultured cells were sonicated in 0. 1 M potassium
phosphate buffer (pH 7.5), 20% glycerol (v/v), 1 mM EDTA. Samples were
diluted in a concentrated (3x) Laemmli746 sample buffer. The samples (10
~g protein) were separated by electrophoresis on a mini-protean gel system
using 8. 5% acrylamide gels. The samples were transferred
electrophoretically to PVDF membranes using an electroblotting apparatus
from Idea Scientific. The blot was blocked for 2 hours with blocking
solution from Gibco , and the primary antibody (anti-chicken ALA synthase)
exposed to the blot overnight at room temperature. The second antibody,
goat-anti rabbit IgG conjugated to alkaline phosphatase , was exposed for 2
hours and the blot developed using the BCIP-NBT development system.
Results of ST search. The protein sequences were used to search the
Genbank database using a translation algorithm that allows "on the fly
translation of the co dons in all six reading frames.
747 748 The results of the
search were used to determne the probability of cross reactivity between
ALA synthase proteins from different species. The carboxyl terminal
peptide corresponded closely with the sequences from mouse (erythroid),
human (erythroid and hepatic), rat (hepatic) ALA synthase. These
sequences are the only animal ALA synthase sequences to' have been
published. 268, 738 749-753 The amino terminal peptide is only similar to
human (hepatic) and rat (hepatic) forms of the enzyme (Figue 3. 13).
1: .
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Figure 13: Sequence homology of closely related proteins to the
peptides used to raise anti chicken ALA synthase antibodies. The query
sequences were searched against the animal subset 
of the Genbank data
base and the results show all of the retrieved sequences. The scoring cut-off
for both searches was identical.
1arvs af 1
.. ..... . . . ... . ..  . ... . .
1arvsqaf 1qkagps117 147
 
lsrvpqaflqk113 143
. .. ..
1srvpqaf1qk58 
rrp1h fevmsere
. .   
crrp1hf evmserer1908 1938
 . .  
crrplhfevmserek1919 1949
  
crrp1hfevmser1873 1903
 .. 
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3511
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Query Sequence (Amno Termna Peptide)
Chick ALA Synthase (Hepatic)
Human ALA Synthase (Hepatic)
Rat ALA synthase (Hepatic)
Query Sequence (Carboxy Termna Peptide)
Chick ALA synthase (Hepatic)
Human ALA Synthase (Hepatic)
Rat ALA synthase (Hepatic)
Human ALA Synthase (Erythroid)
Mouse ALA synthase (Erythroid)
Human calcium-ATPase (HK2)
Mouse mRA for tenascin
Human Thy- 1 glycoprotei gene
Mouse V-H region of late (E3)
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RN Islation and Detetion
Introduction. Extraction of RNA from chick embryo liver cell
cultures can be carred out using guanidinium isothiocyanate and a phase
separation technque 754. This procedure utilizes the variable solubilities of
RNA, DNA and protein in solutions of guanidine and phenol. Using the
commercial preparation of RNAzoICI , the cells are lysed and chloroform
added to produce a biphasic miture. The RNA partitions into the upper
aqueous phase while the DNA parttions into the lower, organic phase. The
protein forms an interface between the phases. The RNA is precipitated out
of the aqueous phase by adding isopropanol to 50% (v/v). The RNA was
washed with ethanol and was suitable for northern analysis. This isolation
obviates the need for cesium chloride gradient centrifugation, or other
handling technques. 7 
Pro ocol. Total RNA was isolated from 100 mm plates with
RNAzoICI. The medium was aspirated from the plate and the cells were
washed twice with room temperature PBS. Excess PBS was carefully
aspirated and 500 ~l of RNAzol was added directly to the dish. The cellular
mixture was scraped off the plate with a spatula and transferred to a sterile
Eppendorf tube. Chloroform was added to the RNAzol cellular suspension
at a concentration of 1 ~l CHCl3 per 10 ~l of RNAzol solution. The miture
was vortexed for 10 seconds, or until homogeneously opaque. The miture
was allowed to incubate on ice for 15 minutes and a crude phase separation
had occured. The miture was centrifuged in a microfuge at 12 000 x g for
10 minutes at 4 C in a fixed angle rotor. The upper, aqueous phase was
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carefully removed, transferred to a fresh, sterile Eppendorf tube and an
equal volume of isopropanol was added to precipitate the RNA. The
solution was incubated at - C for at least 1 hour or overnght. Overnight
incubation decreased the yield of RNA and was not routinely used. The
RNA was pelleted by centrifugation for 15 minutes in a microfuge at 12 000
x g at 4 C with a horizontal rotor. The supernatant was removed and the
pellet was washed 2 times with 70% ethanol in DE PC treated water. Mter
each wash the pellet was centrifuged for 7 minutes at 12 000 x g at 4 C in a
horizontal rotor. Mter the final wash volume was removed, the RNA pellet
was dried in a Speed-Vac (Savant). The dred pellet was resuspended in
50- 100 ~l of 0.5% SDS in DEPC treated water. The solution was heated to
C to facilitate solubilization of the RNA. Typical RNA concentrations
were from 1-5 ~g/~l and yields were 100-300 ~g for a 100 mm dish. The
RNA concentration was estimated from the absorbance at 260 nm (1 AU260
= 40 ~g/ml) and quality, from absorbance ratios 260nm280nm, greater than
or equal to was 1.80 required.
hern Blo . Northern blots were done after separation of total
RNA on formaldehyde agarose gels.756 The RNA was transferred to
GenescreentI (NEN) membranes using capillary action.757 The blots were
hybridized at 65 overnight in a buffer containing an end-labeled
oligonucleotide probe complementary to a portion of the heme oxygenase
cDNA. 758 The blots were washed in O. lX SSC , without SDS , at room
temperature and exposed to X-ray film at -
ttin . The dot-blotting protocol used total RNA and a probe
that had previously been shown to react with the mRNA of interest. 40 ~g of
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RNA in a final volume of 40 ~l were treated with 24 ~l of 20X SSC and 16 ~l
of 37% formaldehyde and incubated at 65 C for 15 minutes. The samples
were diluted to 1200 ~l with lOX SSC and 10 ~g of RNA were loaded per dot
in duplicate, and duplicate nitrocellulose filters were prepared. The blots
were crosslinked by exposure to 2.4 ~joules of UV radiation using a UV-
Stratalinker and prehybridized at 42 C in 15 ml of a buffer containing 50%
formamde, 5X SSC , 100 ~g/ml salmon sperm DNA, 5X Denhardt's , and 
SDS. After 2 hours the solution was removed and replaced with a smaller
volume (5-7 mls) of the same buffer and a boiled radioactive probe was
added to 30 x 106 counts per blot. After hybridization for 18 hours at 42
the blots were washed with O. lX SSC at room temperature for 30 minutes
with 3 bufer changes and either exposed to X-ray film at - C or counted
on a -counter. If the background was too high, the blot was washed
further using the same conditions or the temperature was increased to
C for subsequent washes.
PCR am lific tion of ALX. The plasmid pALX, a subclone of a
Agt11 library isolated and characterized in the laboratory of Dr. Doug
Engel 265 was grown using a mini-prep procedure.757 The plasmid DNA
was then subjected to PCR amplification using 200 ~M each dATP, dCTP
dGTP, dTTP, IX PCR bufer (50 ro KCI, 10 ro Tris , 0.0001% gelatin), 200
~g each SP6 and T7 primers , 2 ~g of mini-prep pAL, 7.25 mM MgCI2, and
5 U of Taq polymerase. The reaction was ru for 30 cycles: with the initial
melt 94 , 2 minutes; denaturing 94 , 1 minute; annealing 40 , 2
minutes; and extending 75 , 2 minutes. This was essentially according to
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Perkin-EImer s instructions with the exception of the primers and template
DNA.
End labellin . The oligonucleotid specific for heme oxygenase was
prepared from the sequence of chick heme oxygenase previously described
(CGATAGAGCTGTTTGAACTTGGTGG).
758 The probe was end-labeled
using a-32P-ATP and T4 polynucleotide kinase.
253 The unicorporated 32p
was separated from the oligonucleotid using a NEN sorb 
column (NEN)
according to manufacturer s instructions.
Hexamer rimin method. The radioactive 
AL synthase probe was
generated using the method described by Feinberg
759 utilizing random
hexanucleotide primers to amplify a known 
cDNA template. Basically, 100- lili1'''
j..I
400 ng of DNA was boiled for 5 minutes
, and a buffered solution containing
250 ro Tris , 250 mM HEPES, 21 ro MgCI2, 12 ~M j3-mercaptoethanol
75 U of pd(N)6, 25 ~M each dATP , dTTP , dGTP
, 50 ~Ci of dCTP (3000
Ci/mmol) and 1 U of Klenow DNA polymerase. The mixture was incubated
for 2 hours at 37 C and the DNA was precipitated with 75 ~110 
ro Tris 0.
ro EDTA pH 8. 0, 4 l (0. g/~l) yeast tRNA, 100 
l 4M sterile ammonium
acetate, and 600 ~l 95% ethanol. The miture was 
incubated at - C for 20
minutes and the DNA precipitated by centrifugation in a 
microfuge at 4
for 5 minutes. The supernatant was removed from the pellet containing the
radiolabelled cDNA fragments , and the pellet resuspended in 
100 l 10 
Tris 0.1 mM EDTA pH 8.0. The probe was boiled for 5 minutes and
immediately placed on ice for another 5 
minutes. One microliter was
counted and an appropriate amount of radioactivity 
was loaded onto the
blot.
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Norma zation of mRNA content late robe.
Accuracy of the samples loading of dot-blots for RNA was checked by
probing for the amount of poly-A mRNA using a polythymidylate probe
(poly-T).760 This procedure normalizes the amount of poly-A mRNA within
a given sample and can be performed on previously probed blots or blots
loaded with samples from the same sample preparation.
761 This procedure
was used preferentially to probing for other control mRNAs since
transcription levels change under certain conditions.
762 763
Poly- T probe was synthesized using 140 ~g Poly- A (Sigma) 10~g/~I
, 2
mM DTT, 50 mM Tris (pH 8.3), 40 mM KCI 50 U AMV -reverse
transcriptase , 100 ro dTTP , 40 U RNAsin, 7 mM MgC12, 2 U Oligo dT( 12-
18) (Pharmacia), and 50 ~Ci p32 dTTP (NEN) in a final volume of 500 
~l.
The mixture was incubated for 2 hours at 37 C and the probe then
iL,
':r
l.I:'
hydrolyzed by the addition of 50 ~l 0. 1 N NaOH at 65 C for 30 minutes.
760
The probe was then used to probe the blots under the conditions 
previously
described for hybridizatio of dot-blots.
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Statitica ~etlod
Data collection and calculation. Routine assays (e.
g. ALA synthase
heme oxygenase , porphyrins) were designed to facilitate entry of data 
into
pre-programmed spreadsheets. Excel 3.0 or 4.
0 (Microsoft Corporatio
, )
was used to calculate means and standard error of the mean for 
most data
presented. When statistical analyses were done, the individual data were
used instead of the calculated means and standard 
errors. Exstatix
(Selected Micro Systems, Yorktown Heights , NY) or JMP 2.
0 (SAS Institute
Inc. , Cary, NC) were the statistical analysis packages routinely 
used.
,. ,
Exstatix was used to perform Students t-
test and ANOVA. JMP 2.0 was
used to perform ANOV A, Tukey-Kramer test for multiple 
compariso
linear least squares regression analysis.
considered significant for all tests.
p Values less than 0.05 were
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CHATER IV
PRIY CmCK EMRYO LIV CEL AS A ~ODEL FOR HEPATIC
HE MEABOLI~
lI~uction
The chick embryo liver cell culture system was used to characterize
the effects of iron on the induction of ALA synthase, porphyrns , and heme
oxygenase in the presence of phenobarbital-like drugs and iron. Primary
chick embryo liver cell cultures are a simple , reproducible system for
exploring hepatic porphyrn metabolism. 169 227 , 548 554 669 Other culture
systems , most notably primary rat hepatocyte cultures , do not retain
normal heme and cytochrome P-450 metabolism 676,677 and the conversion
of ALA to heme is more like humans in chicks than in rats.764 765 The
chick embryo liver cell culture 169,227,548 554 669 yields data similar to that
observed in whole animals such as chick embr os 215,253 mice 766
rats302 767,768 or man. 161 415 416
Most of the previous work in the field has focused on describing the
inductions of ALA synthase or porphyrins in the presence of various
drugs 298, 301 552 , most notably AIA 232- 234 DDC 235 236 or
hexachlorobenzene 306 352 with some research focusing on the function of
cytochrome P-450 IIB forms in chick.230,305 326,669 The research presented
within this chapter further explores the induction of ALA synthase
porphyrns , cytochrome P-450s, and heme oxygenase in the' presence of
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phenobarbital-lik drugs, terpenes and iron. These experiments further
demonstrate the usefulness of the chick 
embryo liver system for testing
chemicals for porphyrinogenic properties , and for characterizing the
cytochro 450 enzymes for catalytic activity. The final 
section will
demonstrate the utility of the culture system for testing the
porphyrnogenicity of terpenes and the posthumous diagnosis of Vincent
van Gogh's illness.
j,;
1 '
I",
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Reults
ALA s thase induction. The initial 
goal was to determine the
effects of iron on the induction of ALA synthase, and to 
determine a
mechanism by which both ALA synthase and heme 
oxygenase were highly
induced under these conditions. Many drugs were 
screened for their ability
to highly induce the synthse in the 
presence of iron. Previous data showed
that, in the presence of 5 ~M FeNT A, 
treatment of chick embryo liver cells
with phenobarbital-like drugs caused uroporphyri
accumulation and
AL synthase induction.230,669 The only inducers that had 
this effect were
those that are traditionally classified as phenobarbital-
type inducers (e.
:r'
..r
glutethimid (31), mephenytoi and phenobarbital). These chemicals were
known to preferentially induce cytochro
450 IIB 769-771 while others
j3-naphthoflavone and 20-methylcholanthr
ene (35), primarily induced
cychro 450 IA.77?-777 These chemicas were screened 
for their ability
to induce ALA synthase 5 hours after treatment 
(Figue 4.1). The typical
doses of the chemicals were chosen as the concentrations 
that produced the
highest amount of cytochrome P-450 
previously described.
230,669
Subsequent work was done with glutethimid
as a prototypical
phenobarbital-lik inducer, since it 
produced a measurable induction of
ALA synthase at a lower concentration than the other phenobarbital-
like
chemicals, possibly because it 
is more lipophilic than phenobarbital.
Glutethimide was also more consistent at inducing ALA 
synthase than any
of the other chemicals tested, and glutethimid
was readily available.
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Figure 4. 1: Effects of selected chemicals on activity of ALA synthase
in chick embryo liver cell cultures. Chick embryo liver cell cultures were
"" ",
treated as indicated for 5 hours prior to harest. The 
cell were harvested
and assay performed as described in methods.
SEM, n=3.
Data represent mean +
Control DMSO
Glut 50
FeNT A 50 
Naph 15
Meph 200
PB 400
20-MC 4
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The solvents (DMSO , NTA alone or the combination) were tested to
see if they had any inductive effects on ALA synthase. Treatment of the
cells with glutethimide , or the combination of glutethimide and FeNTA
increased ALA synthase activity, while treatment of the cells with the
solvents alone, or in combination produced no change in ALA synthase
activity (Figure 4.2), The controls for all subsequent ALA synthase assay
data presented were cells that had not been treated with solvents alone.
This was done because: first, the solvents alone had no effect on ALA
synthase activity; second, the requirements for doing all of the appropriate
solvent controls would double the size of the subsequent experiments due to
the number of different solvents used; and third, that the inclusion of both
the "no treatment" control and the "glutethimide and iron" treatment in all
subsequent experiments allows the direct comparison of data from week to
week.
OI:p cumulation. Porphyrn accumulation in chick embryo
liver cells treated with glutethimide was highly stimulated by the addition
of iron (Figue 4.3). The mechanisms for porphyrn accumulation may be
either due to the cytochrome P-450-dependent oxidation of the
porphyrinogen precursors246 301 306 307 669 or the inhibition of heme
biosynthetic enzymes 246 352 and the marked increase in the production of
porphyrns and porphyrn precursor by AL synthase. The mechanism by
which uroporphyrn accumulates in these chick embryo liver cell cultures
is through the oxidation of uroporphyrnogen and not the inhibition of
uroporphyrinogen decarboxylase (UROD).306 307 The accumulation of
uroporphyrn in these cells in the presence of iron mimics the effects of
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Figure 4.2: Synergistic induction of ALA synthase by glutethimide
and FeNTA and lack of effect of DMSO or NTA. Chick embryo liver cell
cultures were treated with 50 ~M glutethimide , 50 ~M FeNTA, or the
combination for 18 hours prior to harvest. Equal concentrations of the
solvents , DMSO and NTA, were added to other plates for an identical time.
NT A was added at 100~M since the iron:NTA ratio is 1:2 and DMSO was
not added at more than 1 ~l per ml medium. The cells were harested and
assays performed as described in Methods. Data represent mean + SEM
n=3. An asterisk (*) represents a significant difference from "none
students t-test, Pc:0.05.
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Figure 
Effects of glutethimide and FeNTA on porphyrin
accumulation in chick embryo liver cell cultures. 
Chick embryo liver cell
cultures were treated as indicated for 18 
hours prior to harvest. The cells l:r.
;,
and media were harvested together and the spectrofl 
uorometric porphyrn
assay was done as described in Methods. Data represent mean
, n=3. Error
bars were excluded for clarity, and were within 7.
5% of the mean (data not
shown). An asterisk (*) represents a significant increase in total porphyrn
from "none , students t-test, P.:0.05.
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excess hepatic iron in patients suffering from porphyria cutanea
tarda.477 778-780 The accumulation of small amounts of porphyrn in the
presence of glutethimide , and the relatively equal distributions of these
porphyrns (Figure 4.3), can be adequately explained by the increase of ALA
synthase (Figure 4.2). However, in the presence of iron , porphyrins
accumulated rapidly, with higher accumulations of uroporphyrin than any
of the other porphyrns. The lack of effect of DMSO or NT A showed that 
the
effect was dependent on the iron and glutethimide. Time course
experiments showed that the majority of the porphyrns accumulated after
an initial lag phase, and not immediately after the addition of the
chemicals (Figue 4.4). Other porphyrns, such as protoporphyrn, can be
accumulated in this system after treatment with deferoxamine or
N-methylprotoporphyrin both inhibitors of ferrochelatase
209 231 781-784 or
after treatment with ALA (data not shown).
ochrome P-450 induction. Induction of holo-cytochrome P-450 by
drugs and exogenous xenobiotics, requires production of nascent heme.
Holo-cytochrome P-450 is required for completion of phase 1 drug
metabolism (For reviews see 2 158 785- 788). A priori it would seem
logical that heme would act as a positive regulator of cytochrome P-450
expression. Padmanaban and co-workers have presented data that show
heme acts as a positive regulator of cytochrome P-450 gene expression in
rats. 789-794 Holo-cytochrome P-450 is more stable than apo-cytochrome
450,795 furher supporting the notion that heme should positively regulate
cytochrome P-450 expression. The earlier data presented by Padmanaban
used relatively toxic, somewhat non-specific heme biosynthesis
' "
inhbitors
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Figure 4.4: Time course of total porphyrn accumulation in chick
embryo liver cell cultures treated with glutethimide and FeNT A. Chick
embryo liver cell cultures were treated with 50 ~M glutethimide , 50 ~M
FeNT A, or the combination for the times indicated prior to harvest. The
cells and media were harvested and the spectrofluorometric porphyrin
assay completed as described in Methods. Data represent mean + SEM
n=3.
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notably cobalt and 3-amio- triazole. Cobalt does not specifically inhibit
heme biosynthesis, and it also induces heme oxygenase and other proteins
including metallothionein. 796 797 3-Amno- triazole inhibits catalase
along with having other effects on ethanol-inducible cytochrome
450.316 798-805 Later research used 4 dioxoheptanoic acid 790 a specific
inhibitor of ALA dehydratase, and produced similar results. However
others have presented data indicating that cytochrome P-450 gene
expression occurs in the presence or absence of heme 195 806-810 using both
the same experimental model810 and in cultured rat hepatocytes.807
Whether heme regulates the transcription of P-450 remains to 
definitively answered. However, inducibility of cytochromes P-450 is critical
for a good culture model of hepatic heme metabolism and occurs in the
chick embryo liver cell culture model (Table 4. 1).
Glutethimide , phenobarbital , mephenytoin, 20-methylcholanthrene
and -naphthoflavone , all caused significant elevations of cytochrome P-450
in chick embryo liver cell cultures (Table 4. 1). These inductions were
associated with increases of specific cytochrome P-450 related activities.
The MC-type drugs caused increases in ethoxyresorufin O-deethylase
(EROD) activities, and benzyloxyresorun O-dealkylase (BROD) (Figure
5). However, no induction of pentoxyresorufin O-dealkylase activity was
observed under any condition, unlike that seen in the rat. 721 , but similar to
that observed in quai1.811-814 This may be due to the species specific
differences in the catalytic properties of the P-450' s between the chick and
rat. 785 815 None of the phenobarbital-like chemicals caused inductions of
any of the alkoxyresorun O-dealkylase activities, similar t6 the lack of
152
Table 4. 1: Induction of total cytochrome P-450 in the presence of
different chemicals. Chick embryo liver cell cultures were treated 
with the
indicated chemicals for 18 hours. The cells were harvested and total
'''
cytochrome P-450 content was assayed as described in Methods. The values
represent mean 1: SEM, n=3.An asterisk (*) represents a significant
increase in total porphyrn from "Control" , students t-test , Pc:0.05.
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Trtmnt Cyme P-4 Concentrtion
(pmol p-450 mg protein-
Control
Glutethimide (50 ~M)
Phenobarbital (400 ~M)
20-Methylcholanthrene (4 ~M)
Naphthoflavone (15 ~M)
2::t 9
ff:t 7*
~~~
:h,
72:t 5*
58 :t 10
ff:t 6*
82:t 2*
Mephenytoin (200 11M)
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Figure 5: Fold induction in cytochrome P-450-dependent oxidase
activities in chick embryo liver cell cultures. Chick embryo liver cell
cultures were treated with 50 ~M glutethimide (Glut), 400 
phenobarbital (PB), 4 ~M 20-methylcholanthrene (20-MC), 15 ~M
-naphthoflavone NF) or 200 ~M mephenytoin (meph) as indicated 
hours prior to harvest. The cells were harvested and assays performed as
described in Methods. Data represent mean + SEM, n=3. An asterisk
represent a signficant difference from control (p c: 0.05), Student' s t-test.
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induction observed in rats. 721 Other similarities include induction of
ethoxycoumarin O-deethylase (ECOD) activity by the MC-type chemicals
(Figure 4.5) and induction of benzphetamine demethylase (Bphet DME)
activity by phenobarbital-like drugs , but not by MC-type drugs (Figure 4.5).
The small induction of cytochrome P-450 lIB dependent activity is due to the
lack of a specific substrate for this isoform with a high turnover
rate. 403 , 770 812 816-819
Heme oxye-enase induction. Heme oxygenase can be induced to high
levels by at least two disparate mechanisms. One mechanism is dependent
upon nascent heme synthesis , and one mechanism is independent of
nascent heme synthesis. The first mechanism requires the cell to produce
heme, which is the proximate inducer of heme oxygenase. This induction
is rapid, with maximum activity observed between 6 and 12 hours after
initial treatment (Figure 4.6). In the presence of a heme biosynthesis
inhibitor, the induction of heme oxygenase is blocked, demonstrating the
dependence on nascent heme synthesis.230 271 820 The second mechanism
utilized for the induction of heme oxygenase is observed in the presence 
metals, such as cadmium or cobalt with maximum activity observed after
18 hours (Figue 4.6). 553 556 557 This mechanism is fundamentally different
since addition of heme biosynthesis inhibitors does not block induction of
heme oxygenase.230 Induction of heme oxygenase by glutethimide and iron
was shown to be due to the chemicals added, not the solvent vehicles
(Figure 4.7), subsequently, unless otherwise specified, controls were
untreated cells. The mechanism whereby glutethimide and iron
synergistically induce heme oxygenase is the subject of chapter V.
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Figure 4.6: Time course of induction of heme oxygenase in the
presence of heme and cobalt. Chick embryo liver cell cultures were treated
with 10 ~M heme or 75 cobalt chloride for the times indicated prior to
harvest. The cells were harvested and the batch heme oxygenase assay
performed as described in Methods. Data represent mean:: SEM , n=3.
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Figure 7: Effects of glutethimide and FeNTA on activity of heme
oxygenase in chick embryo liver cell cultures. Chick embryo liver cell
cultures were treated as indicated 18 hours prior to harvest. The cells were
harvested and the batch heme oxygenase assay performed as described in
Methods. Data represent mean + SEM , n=3. An asterisk (*) denotes a
significant change from control, p",0. , Student' s t-test.
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. There have been some retrospective diagnoses of porphyria in
persons of historical interest who suffered from 
undiagnosed diseases
which had symptoms characteristic of porphyria.
One of the more
interesting historical figures is King George III
, England. 821-825 The
hypothesis is as follows: The ancestors of 
George III , in the Royal Houses
of Stuart and Hanover suffered from intermittent bouts of 
abdominal pain
and passed port wine colored urine. Sir 
Theodore Turquet de Mayerne
:::ii
"'I
;:':,.
physician to James VI described one of the attacks as follows:
On his return (from a hunting trip) he passed blood red urine.... He also
told me that he quite frequently passed water
, red like Alicante wine but
without attendant pain....
Intermittent bouts of abdominal pain were also sufered by James
' mother
Mary Queen of Scots. Similar accounts were recorded in the extensive
documentation associated with royalty for descendants of these houses
including- -Geor:g-e -HI- -Skeptics--of -the -porphyra- -
theory -have yet -to- -pr:opose
an acceptable alternative theory.1
It is interesting to note that King
George s illness may have caused excessive taxation for the colonies in the
America s in the 1770's, and may have had a part in 
the independence of
the American colonies, since it is proposed 
that part of the reason for King
George s temper and lack of rational thought 
was the neurologic
dysfunctio of porphyra. However
, these conclusions must remain only
tentative due to the lack of direct evidence
, and the equivocal diagnosis of
the attending physicians.
Vincent van Gogh, another historically interesting figure
. may have
sufered from acute intermttent porphyra.
826 His torrd and brief career
162
was interspersed with bouts of abdominal pain, hallucinations and
seizures , which occasionally required hospitaIization.826- 828 van Gogh
frequently exposed himself to terpenes , namely camphor (32), thujone (33),
and a-pinene (34), the major constituent of oil of turpentine. These terpenes
were tested for their ability to cause porphyrin accumulation in chick
embryo liver cells , alone and in the presence of deferoxamine , a chemical
that causes a block in heme biosynthesis similar to that observed in
porphyra. The porphyrns were separated by reverse phase HPLC and
show that all the chemicals tested caused a slight increase in porphyrn
accumulation. However in the presence of deferoxamine , a large amount
of porphyrn was accumulated (Figure 4.8), indicating that if van Gogh
suffered from AlP, ingestion of any, or all, of these chemicals could
certainly precipitate an acute attack. The accumulation of the porphyrns
were associated with increases in AL synthase activity, cytochrome P-450
and heme oxygenase.245 The data provided in this study support, but do not
prove , the hypothesis of Arnold826 that Vincent van Gogh suffered from
acute intermttent porphyra.
ii,
. .
. f
!\t
- "'.'" ;
163
Figure 8: HPLC separation of porphyrins accumulated by chick
embryo liver cell cultures treated with 50 ~M glutethimide, 100 
deferoxamine and selected terpenes (1 ro each). Chick embryo liver cell
cultures were treated as indicated 18 hours prior to harvest. The cells were
harvested and the porphyrns separated on HPLC as described in Methods
(Assay performed by Sue Donohue). Data show representative samples
from single 60 mm tissue culture dishes.
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Conclusion
The utility of the chick embryo liver cell culture system for the study
of porphyrn and heme metabolism, along with the study of phase 1 
drug
metabolism, has been demonstrated. The inductions of AL synthase and
heme oxygenase, the rate-limiting enzymes of heme anabolism and
catabolism, respectively, recommend this system for use in the study of the
regulatory features of heme metabolism. The regulation of chick P-
450'
'i:
recommend the use of this system for studying the biotransformation of
different chemicals by the cytochrome P-450 dependent reactions
, and the
accumulation of porphyrns in this system provides a simple , and rapid test
for porphyrnogeni chemicals. The consistency of data obtained among
humans , rats and the chick culture system demonstrates the applicability
of results obtained with it to humans. This includes humans suffering
from porphyra, or exposed to chemicals which perturb heme metabolism
and the testing of possible treatments for these patients.
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CHATE V
MECHA~ OF TH SYRGISTIC INUCTION OF 
OXYGENASE BY GLUTTHE AN mON
IItructon
Heme oxygenase can be induced by at least two different
mechanisms.230 One mechanism utilized by cadmium, cobalt and other
ili
metals increases heme oxygenase activity 5-15 fold, dependent on the metal
and experimental system
553 556,557 568,829-831 and is independent of
endogenous heme synthesis. The induction mediated by metal ions is not
diminished in the presence of heme biosynthesis inhibitors , such as 4
dioxoheptanoic acid (4 DHA). The time required for induction of heme
oxygenase by metal ions is longer than the time required to induce 
heme
oxygenase in the presence of heme (Figure 4.6). These observations apply
for activities 230 mRNA levels 568 and transcriptional activity.
761
A second mechanism utilized for induction of heme oxygenase is
mediated by its substrate , heme.230 The levels of induction are similar to
those seen in the presence of metals , however the induction is much more
rapid (Figure 4.6).230 568 761 One distinguishing characteristic of a heme-
mediated induction of heme oxygenase is the interdicting effects of
inhibitors of heme synthesis. For example, the induction of heme
oxygenase by chemicals such as phenobarbital or glutethimide is blocked in
the presence of 4 DHA.230 Induction of heme oxygenase in the presence of
DHA still occurs if the cells are treated with heme , providing evidence
167
that the induction produced by chemicals is mediated by the increase in
intracellular heme , and not by some "heme-analog-like" or toxic effect of
DHA.
Previous work230 has demonstrated that 5 ~M FeNT A was capable of
producing remarkable synergism of drug-mediated increases of heme
oxygenase , ALA synthase , and experimental uroporphyria.669 The effects
of iron on heme metabolism are of particular importance not only because
the role of iron as an essential element and component of heme , but also
because iron overload may be associated with exacerbations of acute832 and
chronic415,833 porphyras and with increases in activities of both heme
oxygenase and ALA synthase. The work described in this chapter was
undertaken to elucidate the mechanism whereby FeNTA produces
synergistic increases in heme oxygenase activities in cultured chick
embryo liver cells treated with glutethimide.
168
Reults
ner sm of iron and time course of induction. Induction of heme
oxygenase by iron alone was small 2 fold), if at all (Figure 5. 1). This
induction was probably due to the metal-mediated induction of heme
oxygenase. 279 548 553, 556 557 568,668 820 829-831 The induction of heme
oxygenase by glutethimide was slightly larger, 2-3 fold, and has been shown
to be dependent on nascent heme synthesis.230 When the combination of
glutethimide and iron were added to the cell cultures heme oxygenase was
induced synergistically (Figure 4. , Table 5. 1). Furthermore , the addition
of exogenous heme did not enhance the induction produced by glutethimide
and iron (Table 5. 1). A time course study demonstrated that a synergistic
increase in activity was not observed until after 6 hours, with the activity
remaining elevated through 24 hours. The increase over the expected
additive effects of glutethimide and iron individually was significant after
six hours (Figue 5. 1). The time course of the induction by glutethimide
and iron more closely resembled that produced by heme and was more
rapid than that observed with metal ions, although there was a lag time of
6 hours. These data provide evidence supporting the concept that
endogenously synthesized heme mediates the induction of heme oxygenase
produced by glutethimide and iron. One possible reason for increased
heme formation in the presence of added iron is that iron, combined with
increased protoporphyrn accumulation stimulated by glutethimide 230 669
increased heme formation.548
100
Figure 5. 1: Time course of induction of hepatic heme oxygenase by
glutethimide and ferrc nitrilotriacetate. Chick embryo liver cell cultures
were treated with 50 ~M glutethimide, 50 ~M FeNTA, or the combination of
50 ~M glutethimide and 50 ~M FeNT A as indicated. The expected additive
values were obtained by summing the inductive effects of glutethimide
alone and FeNT A alone. The inset shows a detailed time course for the
induction of heme oxygenase in the presence of both glutethimide and
FeNTA between 6 and 12 hours. The activities for the combination
treatment are signficantly greater (pc:0.02) than the additive values at 12
and 24 hours , Student's t- test. (The errors for the expected additive values
that were used to determne the p-values were the sums of the errors for the
glutethimide alone and FeNTA alone data points. Points represent the
means and standard deviations of three determnations. When no error
bars are shown the standard deviation falls within the size of the symbol.
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Table 5. Heme oxygenase activity in chick embryo liver cell
cultures after 18 hour treatments with 50 ~M glutethimide, 50 ~M FeNTA
and the combination of both chemicals in the presence or absence of 2 mM
DHA. The results are means:! standard error of the mean, number of
samples as indicated in parentheses. DHA, an inhibitor of heme
biosynthesis , abolished the synergistic induction of heme oxygenase by
glutethimide and FeNTA, indicating that ongoing heme synthesis is
important for heme oxygenase induction. The additive value was obtained
by snmming the inductive effects of glutethimide and FeNTA individually.
An asterisk (*) indicates a significant difference from control, a cross (t)
indicates a significant difference from Glutethimide + FeNTA, and a
British pound (;E) indicates a significant difference from Glutethimide +
FeNTA + 4 DHA. The statistical differences were detected using the
Tukey-Kramer test for multiple comparisons.
172
Treatment Activity of Heme Oxygenase
(pmol BR min
Control (n=l1) 91.1 :t 10.5tf:
Glutethimide (n=12) 173.3 :t 20.3*t
FeNTA (n=l1) 132. 1 :t 12.
Glutethimide + FeNTA (n=15) 484.9 :t 20. 7*f:
Additive effect of Glutethimide and FeNTA 214
Glutethimide + FeNTA + Heme (n=3) 448.0 :t 13.0*f:
Glutethimide + FeNTA + 4 DHA (n=14) 186.7 :t 14.0*t
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Dose res onse of iron. Dose response studies showed that as 
little as
5 ~M FeNTA synergistically enhanced the induction of heme 
oxygenase
in the presence of glutethimide, as seen with earlier experiments (Figure
2).230 The minimally effective concentration of FeNTA is unclear
, but the
data demonstrate that nanomolar amounts 
of iron can produce a
significant potentiation of heme oxygenase activity, while increasing
amounts will increase heme oxygenase activity in a dose dependent
manner.
ects of 4 dioxohe tanoic acid. When 4 DHA was added at the
same time as glutethimide and FeNTA, the activity of heme 
oxygenase only
increased to a level that was equal to that seen with either iron or
glutethimide alone. The effects of 4 DHA on the induction of heme
oxygenase provided strong evidence that nascent 
heme synthesis was
required to produce the synergistic increase in heme oxygenase activity in
the presence of glutethimide and iron (Table 5. 1). Glutethimide and FeNTA
in presence of 4 DHA produced heme oxygenase activities that 
were
significantly different from control, but not significantly different from
those observed in the presence of either glutethimide or iron 
individually
(Table 5. 1). When the increases in heme oxygenase activity for both
glutethimide and FeNTA individually were added to the control 
heme
oxygenase value, the expected increase in heme oxygenase activity in the
presence of both glutethimide and FeNTA was obtained. The 
difference
between the additive increase and the observed increase accentuates 
the
synergistic effect of the combination of glutethimide and iron
, over the
expected additive induction from both chemicals individually. 
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Figure 2: Dose response of 
the iron synergism for the induction of
hepatic heme oxygenase by glutethimide. Chick 
embryo liver cell cultures
::' ",+\:
:;:;i
 ,
;1)'
were treated with 50 ~M glutethimid and the indicated concentration of
FeNTA 18 hours prior to harvest. Heme oxygenase activity for untreated
cells was 91 pmol bilirubin formedemg protein-
leminute-l and the heme
oxygenase activity for glutethimide alone was 
173 pmol bilirubin
formedemg protein leminute- The points represent the 
means and
standard deviations of three determinations.
shown the error fell within the size of the 
symbol.
When no error bars are
Heme Oxygenase Activity
(pmol BR/mg protein/min)
,5"
, '; \, .
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uantitation of immunorea tive rotein and mRNA. Iron
synergism of heme oxygenase induction was accompanied by increased
levels of heme oxygenase protein and mRNA (Figure 5.3). The levels of
heme oxygenase immunoreactive protein and mRNA correlated with the
observed activities. In the presence of either glutethimide or FeNTA both
the mRNA and immunoreactive protein were slightly increased; however
when both chemicals were added together, larger amounts of both protein
and mRNA were observed. When 4 DHA was added concomitantly with
glutethimide and FeNTA the levels of protein and mRNA were
dramatically decreased (Figure 5.3). These results suggest that the
synergistic induction of heme oxygenase protein by glutethimide and
FeNT A depends upon an increase in the level of heme oxygenase mRNA
and thus the amount of heme oxygenase synthesized, rather than an
increase in the half-life of the heme oxygenase protein. The apparent
disparty between the increases in mRNA and protein may be due to several
factors: first, the samples were taken at a single time point and due to the
long half-life of the protein the mRNA levels were not maximal;
761 second
there may not be a one-to-one relationship between the amounts of mRNA
and protein; and third, the differences may be due to an, as yet, undefined
mechanism. Further research is needed to delineate between these
possibilities. These data are in agreement with other data demonstrating
increased heme oxygenase mRNA in the presence of heme due to an
increase in heme oxygenase gene transcription.228 229,834
835
. ,
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Figure 3: \Vestern blots and northern blots showing the relative
amounts of heme oxygenase protein and mRNA from chick embryo liver
cell cultures treated to induce heme oxygenase with and without an
inhibitor of heme synthesis. The northern blot (top) lanes are 1- l~g hepatic
mRNA from Cd+2 treated chicken, 2-6 25 ~g of total RNA from cultured
chick embryo liver cells 18 hours after treatment with (2 , control; 3 , 50 ~M
glutethimide; 4 , 50 ~M FeNTA; 5 , 50 ~M glutethimide and 50 ~M FeNTA; 6
50 ~M glutethimide and 50 ~M FeNTA and 2 mM 4 DHAJ. The total RNA
was resolved on formaldehyde/agarose gels and transferred to
GenescreenQD membranes and probed with an oligonucleotide identical to a
portion of the chicken heme oxygenase cDNA as described in the Methods.
The western blot (bottom) lanes are 1 ~g of the following: 1- purfied avian
hepatic heme oxygenase , 2-6 cultures chick embryo liver cells 18 hours after
treatment with (2 , control; 3 , 50 ~M glutethimide; 4 , 50 ~M FeNTA; 5 , 50
~M glutethimide and 50 ~M FeNTA; 6, 50 ~M glutethimide and 50 11M
FeNTA and mM 4 DHAJ. The proteins were separated by
electrophoresis on a PhastSystem and the material transferred to
nitrocellulose and probed with anti-chicken heme oxygenase as described
in the Methods. The figure shows the synergistic increase in the amount of
heme oxygenase protein and mRNA in the cells treated with glutethimide
and FeNT A and the marked decrease when heme biosynthesis was
inhbited by 4 DHA.
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Conclusion
In summary, these results indicate that the iron synergism of heme
oxygenase induction by glutethimide was associated with increased levels
of heme oxygenase mRNA and protein, in agreement with the
transcriptional mechanism described by others.228 229 834 835 That this
synergistic induction of heme oxygenase mRNA and protein was mediated
by heme is supported by several pieces of evidence: first, the induction was
rapid and analogous to the induction of heme oxygenase by heme alone;
second, addition of heme did not further induce heme oxygenase; and third
the synergistic induction of heme oxygenase was abolished with the
addition of 4 DHA, a potent inhbitor of heme biosynthesis. These results
provide a biochemical explanation for the previously described increased
rate of hepatic heme breakdown in rats treated with iron and AIA 836 and
may help to account for the known potentiation by iron of drug-mediated
induction of ALA synthase832 837 and for the propensity of iron to exacerbate
or precipitate porphyrias.415,832 833 To my knowledge , these studies were
the first to characterize changes in levels of heme oxygenase mRNA and
protein produced by chemicals or iron in a primary cell culture model that
retains the same expression and inducibility of heme metabolic enzymes
and hemoproteins as the intact animal. 838 839
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CHATER VI
INUCTION OF AL SYNE: RELATIONSHIP TO INUCTION OF
HE OXYGENASE
IItructon
Regulation of hepatic heme metabolism is thought to occur via a
reguatory heme pool. In this model heme oxygenase was assigned the role
of primarily degrading excess amounts of heme presented to , or produced
de novo within the cell.168 In contrast, others proposed that changes in
activity of heme oxygenase , presumably acting by reciprocal alterations in
the size of the regulatory heme pool, were capable of exerting major effects
on activity of AL synthase251 and on levels of cytochrome P-450.226 840 841
Indeed an inverse relationship between activity of heme oxygenase and
levels of cytochrome P-450 is frequently observed 226,549 842 although no
known obligatory inverse relationship exists between these
enzymes.230,829,843 The synergistic induction of both ALA synthase (Figue
2) and heme oxygenase (Figure 4.6) in chick embryo liver cells upon
treatment of the cells with glutethimide and iron would not be predicted by
the regulatory heme pool model and seems at variance with the view that
regulatory heme is solely responsible for the regulation of heme
metabolism. Two different hypotheses could be proposed that would explain
these inductions: First, glutethimide and iron could cause a rapid
uncontrolled induction of AL synthase , exposing the cell to t ansient high
* '
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levels of heme and producing a secondary induction of heme oxygenase; or
second, glutethimide and iron could cause a rapid induction of heme
oxygenase , depleting the cell of heme and producing a synergistic induction
of ALA synthase. The following results support the latter view.
182
Reults
Effects of tin-meso n on induction of ALA s nthase and heme
enase activit
y p
roduced b lutethimide and iron. In agreement with
results of previous experiments in chick embryo liver cell cultures (Figure
, Figure 4. , Table 5. 1),230,554 treatment of the cultures with 50 
glutethimide and 50 ~M FeNTA led to synergistic induction of ALA
synthase and heme oxygenase (Figure 6. 1). To modulate heme oxygenase
induction, 50 nM tin-mesoporphyrin (41J, a potent inhibitor of heme
oxygenase571 611 844 was used to inhibit heme oxygenase activity. Tin-
mesoporphyrn, when added with glutethimide and iron 18 hours prior to
harvest, inhibited heme oxygenase activity and suppressed the synergistic
induction of ALA synthase (Figure 6. 1). Tin-mesoporphyrn inhibited
heme oxygenase activity under all conditions, but only suppressed ALA
synthase induction in the group treated with glutethimide and iron. ALA
synthase induction by glutethimide alone was not affected by tin-
mesoporphyrin nor did tin-mesoporphyrin significantly reduce ALA
synthase activity in the presence of FeNTA alone.
Time course of induction of ALA thase and hem enase.
Further understanding of the synergistic inductions of heme oxygenase
and ALA synthase by glutethimide and iron was gained from detailed time
course experiments (Figure 6.2). The results show a small increase in
ALA synthase as soon as 3 hours and that both ALA synthase and heme
oxygenase are highly (::2 fold) induced after 6 hours and before twelve
183
Figure 6.1: Effects of 50 nM Tin-mesoporphyrin on ALA synthase
and heme oxygenase induction by 50 ~M glutethimide and 50 ~M FeNT 
Tin-mesoporphyrn (Sn-meso) was added to chick embryo liver cell cultures
together with glutethimide and FeNTA. After 18 hours the cells were
harvested and assays were performed as described in Methods. The results
demonstrate the effectiveness of 50 nM tin-mesoporphyrn at inhibiting
heme oxygenase activity, while only exerting an effect on ALA synthase
activity in the presence of both glutethimide and FeNTA but not in the
presence of either one individually. Results are mean + SEM , n=3.
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Figure 6.2: Time course of induction of ALA synthase and heme
oxygenase by glutethimide and FeNTA. Chick embryo liver cell cultures
were treated with 50 ~M glutethimide and 50 ~M FeNTA and harvested at
the times indicated. Assays were performed as described in Methods. The
inset shows a more detailed time course during the critical time from six to
twelve hours after the start of treatment. Heme oxygenase reached
maximum activity by nine hours while ALA synthase started to increase
dramatically after 10 hours and continued to rise through 24 hours.
Results are mean :t SEM, n=3. When no error bars are present the
standard error of the mean falls within the size of the symbol.
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hours. An hourly time course of the critical period between 6 and 12 hours
indicated that the synergistic induction of heme oxygenase activity preceded
the synergistic induction of ALA synthase activity (Figure 6. , inset).
Specifically, heme oxygenase reached maximum activity by nine hours
while the increase in AL synthase activity above that observed at six hours
first became signficant at 11- 12 hours and continued to increase through 24
hours. Since heme oxygenase was synergistically induced first, these
results suggest that synergistic induction of 
heme oxygenase activity may
produce the synergistic induction of ALA synthase by glutethimide and
Iron.
ression of A s ase activit tin-meso n and heme.
The next experiment tested whether tin-mesoporphyrn could terminate or
blunt the synergistic induction of ALA synthase that had already
commenced upon prior treatment with glutethimide and iron. This 
was
done to test the hypothesis that early inductions of heme oxygenase would
deplete a regulatory heme pool allowing uncontrolled induction of ALA
synthase. When tin-mesoporphyrn was added 14 hours after the treatment
of the cultures with glutethimide and iron, heme oxygenase activity was
decreased within two hours and no further increases in ALA synthase
activity were observed (Figure 6.3). Since tin-mesoporphyrn probably
affects induction of ALA synthase by virtue of its ability to increase a
reguatory heme pool, heme (10 ~M) was added to the cultures to determne
if it would have an effect similar to that of tin-mesoporphyrin. This
concentration of heme was used since it gave maximal induction of heme
oxygenase.227,230 Heme not only prevented further increases in ALA
;\\
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Figure 6.3: Effects of 10 ~M heme and 100 nM Sn-mesoporphyrin
added to chick embryo liver cell cultures treated with 50 ~M glutethimide
and 50 ~M FeNTA. Heme , Sn-mesoporphyrn, or a combination of both
were added after cultures had been treated for 14 hours with glutethimide
and FeNTA. The cells were harvested at the indicated times and assays
were performed as described in Methods. The results show the dramatic
decrease in ALA synthase activity in the presence of the combination of
heme and tin-mesoporphyrin, while either metalloporphyrn produced
significant, but less rapid decreases in ALA synthase activity. The
inhibitory effects of 100 nM tin-mesoporphyrin are potent even in the
presence of 10 ~M heme. Results are mean:t SEM, n=3. When no error bar
is present the standard error of the mean falls within the size of the symbol.
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synthase activity, but caused a reduction in ALA synthase activity within 4
hours after heme addition (Figure 6.3A). The combination of tin-
mesoporphyrn and heme , when added at 14 hours after treatment with
glutethimide and iron, reduced ALA synthase activity by 70% within two
hours after treatment, more rapidly than addition of heme alone. These
data further support the concept that heme oxygenase activity can infuence
activity of AL synthase by modulating levels of a reguatory heme pool.
Effects of heme synthesis inhibitors on induction of ALA synthase
In an effort to deplete the regulatory heme pool by a different means
inhibitors of heme synthesis, either 4 DHA, an inhibitor of ALA
dehydratase 239 678 845 or N-methylmesoporphyrin, an inhibitor of
ferrochelatase 244 were added to the cultures. Addition of either inhbitor in
combination with both glutethimide and iron suppressed the synergistic
induction of heme oxygenase (Table 6. 1), indicating that this induction
requires intracellular heme synthesis, in accordance with previous
findings (Table 5. 1).244 When 10 ~M exogenous heme was added along with
6 DHA, glutethimide and iron, heme oxygenase activity was induced to a
level coinciding with heme oxygenase activities following treatment with
glutethimide and iron alone. When 10 ~M heme was added with
N -methylmesoporphyrin, glutethimide and iron, heme oxygenase activity
increased but did not retur to fully induced levels. AL synthase activity
was further increased when either 4 DHA or N-methylmesoporphyrn
was added to the culture along with glutethimide and iron (Table 6. 1),
indicating that if a reguatory heme pool is depleted, very marked induction
of ALA synthase can occur. As expected, 10 ~M exogenous heme
191
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Table 6. 1: Effects of inhbitors of heme biosynthesis on activities of
AL synthase and heme oxygenase. Chick embryo liver cell cultures were
. I
treated for 18 hours with 50 ~M glutethimide and 50 ~M Fe NT A and with
2mM 4 dioxoheptanoic acid (4 DHA), 100 nM N-methylmesoporphyrn
or 10 ~M heme as indicated for 18 hours prior to harest. Cells were
harvested and assays performed as described in Methods. Results are
mean 1: SEM , n=3. An asterisk (*) represents values that are significantly
different than "Glutethimide + FeNTA" , pc:0. , Student' s t-test.
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diminished the induction of ALA synthase by glutethimide , iron and
DHA or N-methylmesoporphyri
194
Conclusion
The ability of iron in combination with phenobarbital-like drugs to
produce synergistic induction of hepatic ALA synthase has been known for
many years, although the precise mechanisms underlying this synergism
have remained obscure.415 548 653 669 838 The observation that the
combination of iron and glutethimide produced synergistic induction of
heme oxygenase (Figue 5. , 6. 1),669 to a level that is produced by the most
potent inducers , prompted us to investigate the hypothesis that induction of
heme oxygenase could sufficiently deplete the regulatory heme pool
permtting a synergistic induction of ALA synthase. The detailed time
course experiment (Figure 6. , inset) shows that marked synergistic
induction of heme oxygenase activity by glutethimide and iron did, in fact
precede by 4-8 hours the synergistic induction of ALA synthase. A small
(c:3 fold) increase in ALA synthase activity was observed within 6 hours 
treatment, in agreement with previous results (Figure 4. 1 and 253).
Addition of tin-mesoporphyrn, a potent inhibitor of heme oxygenase
prevented (Figure 6. 1) or promptly blunted (Figure 6.3) the synergistic
induction of ALA synthase by glutethimide and iron. When heme was
added during the period that ALA synthase activity was increasing, not
only were further increases prevented, but reduction of ALA synthase
activity occurred within 4 hours. When tin-mesoporphyrn and heme were
added concUrently, ALA synthase activity was reduced within two hours
even more rapidly than the reduction that occurred with , heme alone
(Figure 6. 3). This suppressive effect of tin-mesoporphyrin on the
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synergistic induction of AL synthase activity, by glutethimide and iron , is
unikely to be due to a direct or "heme-like" effect on ALA synthase by tin-
mesoporphyrin because: 1) low concentrations of tin-mesoporphyrn (50 or
100 nM) were used, 2) tin-mesoporphyrin had no effect on the induction of
ALA synthase by glutethimide alone , and 3) 5 ~M tin-mesoporphyrin had
no effect on ALA synthase activity in vitro (data not shown).
Attempts to deplete the regulatory heme pool by impeding heme
synthesis within the cell using 4 DHA or N-methylmesoporphyrin also
suggested that heme oxygenase induction by glutethimide and iron was
dependent upon heme formation (Table 6. 1). Thus , inhibitors of heme
synthesis suppressed induction of heme oxygenase. They also led to even
greater inductions of ALA synthase, demonstrating that when heme
synthesis was blocked in the presence of glutethimide , marked induction of
ALA synthase occurs. These data are in agreement with previous
reports. 239 678 When the deficiency of reguatory heme , produced by the
inhbition of heme synthesis , was corrected by the addition of exogenous
heme, the effects on induction of ALA synthase were blunted or abolished
(Table 6. 1). As shown in Figue 6. , effects of heme to reduce AL synthase
were rapid and impressive. The lesser effects observed in Table 6. 1 are due
to the long incubation time (18 hours). N-methylmesoporphyrn is not a
direct inhbitor of heme oxygenase in vitro; 571 thus , the reason that heme in
the presence of N-methylmesoporphyrn failed to restore heme oxygenase
activity to levels comparable to those obtained with the glutethimide and
iron treatment is not clearly understood. These results support the
hypothesis that alterations in activity of heme oxygenase can modulate the
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size of a regulatory heme pool and thereby affect the activity of ALA
synthase.
, "
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CHATER VI
RERESSION OF AL SYE BY METALOPORPHYS
lI~ucton
ALA synthase is the first and rate-controlling enzyme of heme
biosynthesis in liver and can be induced to high levels by a variety of
compounds. 169 232 239 247 253 258 653 Activity of this enzyme is elevated in
humans with acute porphyras 161 415 416 in whom occurrence of clinical
illness is associated with increased excretions of porphyrns and porphyrn
precursors, the biochemical hallmarks of the acute porphyrias. The
treatment of choice, for all but mild attacks of acute porphyra, is
intravenous heme 513,521 536,537 846 first described twenty-two years ago.513
Heme reduces hepatic AL synthase levels in various experimental models
of acute porphyra159,670 847,848 and undoubtedly has the same effect in
patients suffering from acute porphyra.513 521 536 537 846 High doses of
heme , 10~M in culture models and 3-4 mg/kg/day in patients, are required
to decrease ALA synthase activities.
Reasons for the high required doses of heme include its ability to
induce heme oxygenase , the first and rate-controlling enzyme in heme
degradation. 1 Certain non-heme metalloporphyrns , notably cobalt- , tin-
and zinc-porphyrins, inhibit heme oxygenase in a competitive
manner.571 576 579 584 585,628 849 850 Tin-protoporphyrn (42), tested for its
effect in hyperbilirubinemic patients 577 has also been shown to modestly
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decrease urinary excretion of ALA and porphobilinogen in patients
suffering from acute porphyria.595 Recently a combination of tin-
protoporphyrn and heme has been considered effective in treating a patient
with severe, recurrent attacks of acute porphyria.
626 Nevertheless
concerns about the therapeutic use of tin-protoporphyrn, or other tin-
porphyrins persist because their photosensi tizing
propertes 597 607 609 610 613,634 639 851 852 long biological half-lie 626 inbition
of steroidogenesis 628 850 and the ability of tin-porphyrns to cross the blood-
brain barrier.853 The use of tin-diiododeuteroporphyrn (40J, in place of tin-
proto- or tin-meso-porphyrn, may allay some of the concerns, since the
iodinated porphyrn has been suggested to be less photoactive.
851
Theoretically, a combination of relatively low concentrations of heme
and another metalloporphyrn, inhibitory for heme oxygenase activity,
should markedly repress hepatic ALA synthase activity. Accordingly, the
potencies and efficacies of several non-heme metalloporphyrns (with and
without heme) were compared with respect to inhbition of heme oxygenase
and reduction of ALA synthase activity. The results showed that there was
a direct relationship between inhibition of heme oxygenase activity and
repression of AL synthase activity, in chick embryo cultures induced with
glutethimide and iron, and that zinc- mesoporphyrin or -protoporphyrin
was as potent and efficacious as the corresponding tin-porphyrins in
exerting these effects. In contrast, zinc-deuteroporphyrn- bisglycol or
copper-porphyrins were ineffective at the concentrations tested.
Furthermore, the combination of tin- or zinc- porphyrn plus heme
additionally reduced ALA synthase activity, with maximal feduction of
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activity obtained at concentrations of metalloporphyrins orders of
magnitude lower than those previously used.
Reults
Correlation of reduction of ALA nthase activit with heme
vg-enase inhibition. Previously, ALA synthase activity was markedly
increased after treatment of chick embryo liver cell cultures with 50 
glutethimide and 50 ~M iron.258 This increase in activity followed, by
several hours, a synergistic induction of heme oxygenase, and could be
halted, or reversed using either tin-mesoporphyrin (100 nM) or heme
00 ~M) alone , or a combination of tin-mesoporphyrin (100 nM) and heme
(10 ~M).258 554 Tin-mesoporphyrn was previously shown to be more potent
than tin-protoporphyrin for inhibiting heme oxygenase. 5 71 611
Consequently, in the present work tin-mesoporphyrin was used as a
benchmark for comparison of the effectiveness of low concentrations
(50 nM) of selected metalloporphyrns , alone or in the presence of heme , in
decreasing ALA synthase activity (Table 7. 1). The ability to decrease ALA
synthase activity was determined after induction of ALA synthase with
50 ~M glutethimide and 50 ~M iron.258 Tin-diiododeuteroporphyrin and
zinc-mesoporphyrn (44) were the most effective metalloporphyrins at
reducing ALA synthase activity. Similarly, in the presence of 200 nM
heme , zinc-mesoporphyrn and tin-diiododeuteroporphyrn again caused
the greatest reduction of ALA synthase activity. The results also showed
that heme enhanced the effectiveness of metalloporphyrns in reducing
ALA synthase activities with only nanomolar concentrations of each
required to obtain a signficant reduction. The metalloporphyrns that were
not effective at reducing ALA synthase activity of intact cellEf were zinc-
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Table 7.1: Effects of selected metalloporphyrins to inhibit heme
oxygenase and decrease induction of ALA synthase in chick embryo liver
cells. Chick embryo liver cell cultures were treated with 50 ~M
glutethimide and 50 ~M FeNT A 18 hours prior to harvest , except for the
uninduced which received treatment. Non-
hemegroup
metalloporphyrns were added at a concentration of 50 nM with 
heme
added at the indicated concentrations 4 hours prior to harvest. 
Cultures
,.,.'''
were harvested , sonicated and enzymatic activities measured as 
described
in Methods. The unchelated porphyrns or the ionic metals alone (all added
at 50nM concentration), had no significant effects (results not shown). An
asterisk (*) denotes signficant reduction of activity versus glutethimide and
FeNTA, and a cross (t) denotes signficant reduction of activity versus zinc-
mesoporphyrn alone (pc: 0.05), Student' s t-test. Data are mean:t SEM with
the numbers of samples (n) in parentheses.
Activity of Activity of HemeSynth Oxgenase
(nmole ALA .mg (pmole bilrubin. 
Treatment protein -1. hour protein
1.minute
Uninduced 9:t 0.2 (17)*
136:t 7 (19)*
Induced (Glutethimide + FeNTA) 12.8 :t 0. 7 (23) 44 :t 12 (22)
Induced cells trted with Heme
+ 200 nM Heme 9:t 0.7 (14)*
488:t 9 (23)
+ l Heme 3:t 1.1 (5)*
428:t 10 (3)
Induced cell trted with Tin porphyrns
Sn-Mesoporphyrin (41) 3 :t 0.8 (3) 237 :t 2 (3)*
Sn-Mesoporphyrin + 1 JlM Heme 9 :t 0.7 (8)*
155:t 31 (8)*
Sn-Diiododeuteroporphyrin (40) 3 :t 0.4 (3)* 190:t 19 (3)*
Sn-Diiododeuteroporphyrin + 200 nM Heme 8 :t 0.2 (3)*
216:t 7 (3)*
Induced cell trted with Zinc porphyr
Zn-Mesoporphyrin (44) 7 :t 0.4 (26)* 191:t 14 (14)*
Zn-Mesoporphyrin + 200 nM Heme 7:t 0.5 (14)*t
181:t 15 (14)*
Zn-Mesoporphyrin + 1 Heme 3 :t 0.5 (3)* 260 :t 0 (3)*
Zn - Protoporphyrn (42) 6 :t 0.4 (3)
326 :t 19 (3)
Zn-Protoporphyrn + 1 Heme 3 :t 0.6 (3)*
379 :t 12 (3)
Zn-Deuteroporphyrin- bisglycol (43) 11.6:t 1.4 (3)
544:t 21 (3)
Zn-Deuteroporphyrin- bisglycol + 1 Heme 31: 0.3 (3)
542:t 57 (3)
Induc cell trte with Coppe porphyr
Cu-Mesoporphyri (38) 15. 1:t 1.9 (5)
441:t 35 (5)
Cu-Mesoporphyrin + 200 nM Heme 13.6:t 1.3 (5)
433 :t 46 (5)
Cu-Protoporphyr (39) 14.2:t 1.5 (5)
455:t 31 (5)
Cu-Protoporphyrn + 200 nM Heme 13. 1:t 1.5 (5)
404:t 40 (5)
Cu-Deuteroporphyrn (36) 14. 5:t 1.3 (5)
416:t 27 (5)
Cu-Deuteroporphyrn + 200 nM Heme 13.0:t 1.0 (5)
412:t 46 (5)
Cu- Hematoporphyrin (37) 13.3 :t 1.2 (5) 401:t 36 (5)
Cu-Hematoporphyrn + 200 nM Heme 13.4 :t 1.4 (5)
4181: 27 (5)
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Figure 7. 1: Correlation of effects of selected metalloporphyrns on
activities of heme oxygenase and ALA synthase. Chick embryo liver cell
cultures were treated with 50 ~M glutethimide and 50 ~M FeNTA for 
hours prior to harvest. Selected metalloporphyrns were added 4 hours
prior to harvest at the concentrations described in Table 7. 1. The cultures
were then harvested and the assays done as described in Methods. In all
cases the greater the inhbition of heme oxygenase , the larger the reduction
of ALA synthase activity. As shown in the legend, the metal ions are
denoted by the large open symbols , the different porphyrin macrocycles
denoted as the smaller cross-like inset symbols , and the additions of heme
as the smallest round (white or black) symbols. The error bars represent
the standard errors for either ALA synthase (vertical) or heme oxygenase
(horizontal) (Table 7. 1). Where no error bars are shown, the error falls
wi thin the size of the symbol. The correlation is highly significant
(pc:0.00002), linear regression analysis.
16, ,
IS No A
dditions
14t ""p-
,/ 1 0 Tin Porphyrins
.
.
 
A
. 
Zinc Porphryins
Q) .. 12 
en
 
E :
Copper porphyrins
c: 2 10 .
?i 
Q$ 
M
esoporphynns
c: a. 
;; E 
j + 
Protoporphyrins
.
.
 
e;; 6. 
1000 nM
 H
em
e
"*
 
/' 
1 . 
200 nM
 H
em
e
c: E 
Y
= 1. 1 +O
. 024x R=
J-J.
100
200 300 400
H
em
e O
xygenase Activity
(pmol bilirubinemg protein
m
in
500
600
FC;
deuteroporphyrn- bisglycol (43) and all the copper metalloporphyrins
tested (36-39J.
In vitro effects of meta rins on ALA nthase and heme
enase activities. To characterize the effects of metalloporphyrins
further, they were added in vitro to cell homogenates (Table 7.
2).
concentrations of 50 nM, all the tin- and the zinc- metalloporphyrins
(including zinc-deuteroporphyrin- bisglycol) were effective heme
oxygenase inhibitors but had no effect on ALA synthase activity.
The
copper porphyrns were ineffective at inhbiting heme oxygenase and had
no effect on ALA synthase. In intact cells , the ability of 
metalloporphyrins
to decrease ALA synthase activity was directly correlated to their 
ability to
inhbit heme oxygenase (Table 7. , Figue 7. 1). The metalloporphyrns that
..,.
strongly inhibited heme oxygenase, e. , zinc- and tin- porphyrins
, also
produced the large reduction of ALA synthase activity. In contrast
, the
metalloporphyrns that produced little or no heme oxygenase inhibition
, copper-porphyrns and zinc-deuteroporphyrn- bisglycol
, had little
or no effect on ALA synthase activities.
nt re uction oLALA s nthase activit zinc-
mesoporp n and heme. The effects of increased concentrations of zinc-
mesoporphyrn, in the presence of different concentrations of heme
, were
studied further (Figure 7.2). As shown, there was a dose-dependent
decrease in ALA synthase activity with increasing concentrations of 
zinc-
mesoporphyrn, and addition of heme (200 nM or 1 ~M) enhanced this
effect.
Table 7.2: Effects of selected metalloporphyrns on activities of 
synthase and heme oxygenase in vitro. Cells were treated for 18 hours with
50 ~M glutethimide and 50 ~M FeNTA, after which they were harvested
sonicated and pooled. Metalloporphyrns (50 nM) were added to portions of
the sonicates and enzyme activities assayed as described in Methods.
Results shown are the means :t SEM , n=3 , expressed as a percent of the
control to which the carrer (BSA) had been added. The absolute activity of
the control ALA synthase was 20. 1:t 0.2 nmole ALAemg protein
and the control heme oxygenase value was 357 :t 5 pmole bilirubin emg
protein minute Asterisks (*) denote a significant different from
glutethimide and ferrc nitrilotriacetate alone (pc:0.05), Dunet'
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Figure 7.2: Effects of zinc-mesoporphyrn and heme on activity of
ALA synthase. Chick embryo liver cell cultures were treated with 50 ~M
glutethimide and 50 ~M FeNTA for 18 hours prior to harvest. The indicated
concentrations of heme and zinc mesoporphyrn were added 4 hours prior
to harvest. Cells were harvested, sonicated, and the activity of ALA
synthase measured as described in Methods. The data represent means +
SEM, n=3. Where no error bars are shown, the error falls within the size of
the symbol.
CD CI .
CO '7
c: 
:: -
en 
:5 
c( E
'0 S
- 
u 0
c( E
14 T
12 
: 1\
r\ 6 T \
. ' . - - - - - - -\  / .._. . . . . -. . . . . . . - - - -...
100
Concentration of Zinc-mesoporphyrin (nM)
-
0 nM heme
 ..
. 200 nM heme
-.  , 
M heme
1000
210
Effects of zinc-meso n and heme on ALA s thase induced b
iffer nt chemical . In addition to the combination of glutethimide and
iron marked induction of hepatic ALA synthase can be produced by
treatment with glutethimide, or other phenobarbital-like drugs, and
inhibitors of heme biosynthesis such as 4 DHA258 554 or deferoxamine
(Des).245 The induction is thought to be due to a direct effect of the drug on
the apparatus for enzyme synthesis, amplified by marked depletion of the
regulatory heme pool due to inhbition of heme synthesis. If the effect of
zinc- or tin- porphyrns to decrease the activity of ALA synthase is indeed
due to the ability of these compounds to inhbit heme oxygenase , they should
have little , if any, effect when heme synthesis has been blocked by prior
treatment within the time frame studied (4 hours). The results shown in
Figure 7. confirm this prediction. Unlike the ability of zinc-
mesoporphyrin to significantly reduce ALA synthase induced by
glutethimide and iron (Figure 7. , Table 7.3), zinc-mesoporphyrin had no
significant effect on ALA synthase activity induced by either glutethimide
and 4 dioxoheptanoic acid or glutethimide and deferoxamne (Table 7.3).
In contrast, 200 nM heme had a large effect on ALA synthase activity,
probably because heme oxygenase activities found under these conditions
are not significantly different from basal heme oxygenase activity (data not
shown). Since heme oxygenase activity was low under these conditions , a
relatively low concentration of heme (200 nM) significantly reduced the
activity of ALA synthase (Figure 7. , Table 7.3). At the time chosen for
study, the combination of heme and zinc-mesoporphyrn was signficantly
211
Figu 3: Effects of zinc-mesoporphyrin and heme on ALA
synthase activity induced by glutethimide and inhibitors of heme synthesis.
Chick embryo liver cell cultures were exposed to 50 ~M glutethimide and 50
~M FeNTA or an inhibitor of heme biosynthesis , either 250 ~M 4
dioxoheptanoic acid (4 DHA) or 1 ro deferoxamine (Des), 18 hours prior
to harvest. Zinc-mesoporphyrn (50 nM) and/or heme (200 nM) was added
as indicated 4 hours prior to harvest. Cells were harvested, sonicated, and
the activity of ALA synthase measured as described in Methods. The
results are mean + SEM
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Table 3: Tukey-Kramer statistics of the data presented in Figue 6.3 using
JMP software. The positive (bold) values show pairs of treatments that are
significantly different. As shown, the results for cells pre-treated with
glutethimide and iron and then with heme , zinc-mesoporphyrin, or the
combination were all signficantly different from one another (ac:0.05). For
the other pre-treatment regimens , zinc-mesoporphyrn alone had no effect
whereas addition of heme led to signficant decreases in activity, compared
with no heme addition. For simplicity, the value for each comparison is
listed once , the duplicate values being replaced by . . For each condition
n;;8.
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Glut + Irn None + Heme +ZnM + ZnM + Heme
None
+ Heme
. 0
.i.
+ZnM 2.4
+ ZnM + Heme 
2.4
Glut + Des None +ZnM + Heme + ZnM + Heme
None 3.4
+ZnM 3.4
+ Heme 3.4
+ ZnM + Heme 
3.4
Glut + 4,6-DHA +ZnM None + Heme + ZnM + Heme
+ZnM 2.4 1.0
None
+ Heme
+ ZnM + Heme 
. I
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more effective than the individual treatments only in the model where both
ALA synthase and heme oxygenase had been induced (Table 7.3),
Effects of zinc-meso rin and heme on the half-life of ALA
thase activit . There was no change in the half-life of ALA synthase
activity, after treatment with glutethimide and iron, in the presence of
10 ~M heme, or 200 nM heme and 50 nM Zn-mesoporphyrn (Figure 7.4
apparent half-life =1.9- 1 hours).
earance of recursor ALA s nthase rotein. The appearance of
the precursor, cytosolic form of ALA synthase was observed in western
blots using the antibodies raised against the carboxyl terminal peptide.
These antipeptide antibodies should detect both the mature and immature
forms of the enzyme. An early time course (0-2 hours after addition of both
zinc-mesoporphyrn and heme) showed the rapid appearance of a higher
molecular weight immunoreactive protein with the maximum observed
1 hour after metalloporphyrn treatment (Figure 7.5). The premature form
of the enzyme was no longer observed 2.5 hours after metalloporphyrn
treatment. These data are consistent with the concept that both heme and
the combination treatment of zinc-mesoporphyrin and heme decreases
mitochondrial uptake of the precursor ALA synthase protein via the same
mechanism, involving the heme reguatory motif. The data correlate with
the recent identification of this motif as a regulatory element for ALA
synthase211 and other data describing an inhbitory effect of heme on the
mitochondrial translocation of AL synthase.205-208 210,215 216
Effects of Zinc-meso n and heme on the half-life of ALA
tha mRNA. The combination of zinc-mesoporphyrn and heme
216
Figue 7.4: Effects of zinc-mesoporphyrn and heme on the half-life
of ALA synthase activity. Chick embryo liver cell cultures were treated
with 50~M glutethimide and 50 ~M FeNTA for 14 hours. Cultures were
also exposed to a combination of 50 nM zinc-mesoporphyrn (ZnM) and 200
nM heme or 10 ~M heme as indicated after 14 hours and 4 ~M
cycloheximide was added 15 hours after the original treatment. Cells were
harvested at the indicated times, sonicated, and the activity of ALA
synthase measured as described in Methods. The results are mean :t SEM
n=3.
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Figure 7.5: Appearance of the cytosolic ALA synthase protein after
treatment with heme or the combination of zinc-mesoporphyrn and heme.
Chick embryo liver cell cultures were treated with 50 ~M glutethimide and
50 ~M FeNTA 14 hours prior to addition of the metalloporphyrins. Then
either 10 ~M heme or 50 nM zinc-mesoporphyrn and 200 nM heme were
added and the cells harvested at the times indicated after the addition of the
metalloporphyrns. The cell culture samples were harvested in a buffer
containing potassium phosphate , 20% glycerol , and EDTA. The samples
were sonicated and immediately placed into SDS-PAGE sample buffer as
described in Methods. The samples were separated by PAGE and
electrophoretically blotted onto PVDF, exposed to rabbit anti-chick ALA
synthase IgG as described in Methods. The image was digitized at 300 dpi
on a Hewlett Packard ScanJet Plus, and transfered into Image 1.41
(available from NIH). The image was digitally enhanced to highlight the
appearance of precursor ALA synthase , and the densitometric analysis
completed as described in the Image manual.
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decreased the half-life of ALA synthase mRNA in a manner similar to that
observed with heme (Figure 7.6). This is in agreement with previously
published data describing heme decreasing the half-life of ALA synthase
mRNA. 189 190 These data suggest that the combination of zinc-
mesoporphyrn and heme in sub-micromolar concentrations regulate ALA
synthase using the same cellular mecha isms that lead to the decrease in
ALA synthase activity in the presence of 10 ~M heme.
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Figure 7.6: Effect of heme and zinc-mesoporphyrn on the half-life of
hepatic ALA synthase mRNA after pretreatment with glutethimide and
FeNT A. Chick embryo liver cell cultures were treated with 50 
glutethimide and 50 ~M FeNTA 14 hours prior to addition of the
metalloporphyrns. Then either 10 ~M heme or 50 nM zinc-meso porphyrn
and 200 nM heme were added and the cells harested at the times indicated
after the addition of the metalloporphyrins. A) Time course of the
disappearance of ALA synthase mRNA with the time on the abscissa
shown after the addition of glutethimide and FeNTA. B) Apparent half-
lives after treatment with 10 ~M heme or 50 nM zinc-mesoporphyrn and
200 nM heme. Actinomycin D (0.4 ~M) was added 15 hours after original
treatment. The values on the abscissa represent the time after the addition
of the metalloporphyrns.
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Conclusion
In other systems576 582-584 854 855 zinc-porphyrns have been effective
inhibitors of heme oxygenase. In chick embryo liver cell cultures , low
concentrations (50 nM) tin-zinc-mesoporphyrin and
diiododeuteroporphyrn were the only metalloporphyrns that significantly
reduced ALA synthase, while tin-mesoporphyrn did not (Table 7. 1). Heme
oxygenase inhibition and reduction of ALA synthase activity were closely
correlated, supporting the notion that heme is the proxim te mediator of
ALA synthase reduction (Figure 7. 1). As shown in this chapter, chapter
VI and elsewhere 3 215 258 856 857 heme decreases ALA thase activit
and metalloporphyrins inhibit heme oxygenase (Tables 7. 1 and
2).576 579-585 600 611 849 855 858-860 Therefore, it is reasonable to conclude
that a reduction of heme oxygenase will lead to an increase in heme within
the cell, which in tur, will repress ALA synthase. The marked induction
of ALA synthase by glutethimide and iron is related to synergistic induction
of heme oxygenase after 6-12 hours of treatment (Figue 6.2).
The ability of metalloporphyrns to inhibit heme oxygenase in vivo
parallels the ability of these compounds to inhbit heme oxygenase in vitro
(Table 7. , 7.2), except that zinc-deuteroporphyrn- bisglycol had a higher
inhbitory effect in vitro than in vivo. This is probably due to the higher
hydrophilicity of this compound, which reduces its ability to cross biological
membranes. The lack of inhibitory effects of the copper-chelated
porphyrns on heme oxygenase may be due to the low formation constants
of axially  ligated copper metalloporphyrins. 861 The lower formation
constants , as much as 2-3 orders of magnitude when compared to zinc-
metalloporphyrins 861 would lead to much lower levels of copper-
metalloporphyrin:heme oxygenase complexes and therefore , at these low
concentrations , to virtually no heme oxygenase inhibition.
The significant differences in ALA synthase activity produced by
heme , zinc-mesoporphyrn, or the combination of zinc-mesoporphyrn and
heme , in the cultures treated with glutethimide and iron unequivocally
demonstrate the effectiveness of the combination of heme and
metalloporphyrin. Reduction of ALA synthase by a relatively high
concentration of heme (10 ~M) and tin-mesoporphyrin (100 nM) had
previously been shown to occur (Figure 6. 3), although, at these
concentrations, no further reduction of ALA synthase activity was
produced by 100 nM tin-mesoporphyrin, compared to those produced by 
~M heme alone. These preliminary studies provided the framework for the
present study, which establishes that, individually, relatively low
concentrations of heme (200 nM) and zinc-mesoporphyrn (50 nM), not only
significantly reduced ALA synthase activity, induced by glutethimide and
iron, but produced a further, significant and additive reduction when used
together.
In contrast, at the times and concentrations studied thus far
additive effects are not observed in cultures treated with glutethimide and
either 4 DHA or deferoxamine, although all of the induction regimens
produced a marked induction of ALA synthase (Figure 7.3). The most
likely explanation for the different effects of zinc-mesoporphyrn (:t heme)
on ALA synthase activity following glutethimide and iron, glutethimide
-' .
and 4 DHA, or glutethimide and deferoxamine treatment, lies in the fact
that glutethimide and iron produce a synergistic induction of 
heme
oxygenase while glutethimide and either of the heme biosynthesis
inhibitors do not.
258 554 Thus , following treatment with glutethimide and
iron, zinc-meso porphyrn, a potent inhibitor of heme oxygenase
, is able to
increase cellular heme, which represses ALA synthase. In contrast
following treatment with glutethimide and either 4 DHA or
deferoxamine , the models where heme oxygenase activity remains low,
zinc-mesoporphyrn (50 nM) had no effect on ALA synthase, at the times
studied. This supports the conclusion that 
the effect of zinc-mesoporphyrn
on ALA synthase (Figures 7. 2) is secondary to inhibition of heme
oxygenase , rather than a direct "heme-like" effect on ALA synthase.
Probably even lower concentrations of zinc-mesoporphyrin
, or other
metalloporphyrin , would be required to prevent heme breakdown when
heme oxygenase activities are at a basal level, like those observed in the
presence of 4 DHA or deferoxamne.258,
554 However addition of exogenous
heme will induce heme oxygenase after 4-8 hours
230 even in the presence
of heme biosynthesis inhbitors. Thus , in the presence of heme biosynthesis
inhbitors , addition of zinc-mesoporphyrin would most likely prolong 
the
heme suppression of ALA synthase, similar to that recently described
clinically for tin-protoporphyrn.626,862
In the acute hepatic porphyras in relapse , there is marked induction
of hepatic ALA synthase, often related to patients' ingestion of
porphyrnogenic chemicals (Table 1.1). 161 415,416 Activities of hepatic heme
oxygenase activity have not been reported for patients with acute
porphyras. Thus , the experimental model of ALA synthase induction that
most closely recapitulates acute porphyra remains uncertain. Probably,
the most comprehensive understanding will be gained by further study of
several such models. Regardless of the method used to achieve induction of
ALA synthase, low (nanomolar) concentrations of a combination of zinc-
mesoporphyrn and heme were highly effective in reducing ALA synthase
activity.
The short half-life of ALA synthase activity facilitates rapid
regulation of this activity in response to heme and other chemicals (Table
, Figures 7. , 7.2 and 7.4).258 The lack of a change in the half-life of the
activity following exposure of cells to heme or heme and zinc-
mesoporphyrn (Figure 7.4) demonstrates that regulation of this activity by
heme occurs by a mechanism other than a change in half-life of the
protein. The transient appearance . of the premature ALA synthase
provides evidence consistent with the concept that in vivo the heme
regulatory motif211 plays a role in controlling ALA synthase activity by
inhibi ting the mi tochondrial processing pre-ALA
synthase.205-208 210 215 216 The decrease in the half-life of AL synthase
mRNA after treatment with 10 ~M heme or the combination of much lower
concentrations of zinc-mesoporphyrn and heme supports the observation
that heme decreases the half-life of the mRNA.1 190 The mechanisms
whereby heme decreases the half-life of ALA synthase mRNA remain to 
elucidated. The principal focus of the work presented was to demonstrate
that a combination of metalloporphyrns , inhibitory for heme oxygenase
activity, and heme, both at nanomolar concentrations , is just As effective as
:i .
each individual treatment at micromolar concentrations and to present
evidence that supports the regulatory mechanisms recently reported for
high concentrations of heme alone.1 190,211
1'"
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CHATER VIII
CONCLUSION
IItruction
The primary chick embryo liver cell culture system was used for
exploring the regulation hepa tic porphyrin and heme
metabolism. 227 ,230,245 258 258,548,550
554 669 Results shown here (Chapter IV)
show that the cultures retain normal inducibility of ALA synthase
cytochrome P-450' , heme oxygenase , and overproduction of porphyrns.
Other culture systems , most notably primary rat hepatocyte cultures
, do not
retain normal heme and cytochrome P-450 metabolism.
676,677 The rate of
conversion of ALA to heme in chicks liver homogenates is similar to 
that
observed in human liver homogenates, although lower than that observed
in rat liver homogenates.764 765 In the absence of additional iron human
and chick liver homogenates accumulate similar amounts 
protoporphyrn and heme, while the addition of iron dramatically reduces
the amount of protoporphyrn and increases the accumulation of heme in
human liver homogenates.764
The primary chick embryo liver cell culture system has yielded data
similar to that observed in whole animals such as chick embryos
215,
mice 766 rats302 767,768 or man. 161 415,416 The ability of iron to increase 
synthase, porphyrns and heme oxygenase were described in chick liver
cell cultures. The results served to initiate further research mvestigating
the reason for the induction of both the rate controlling enzymes for heme
synthesis and degradation in the presence of iron. The utility of the system
was further demonstrated as a tool for testing the porphyrinogenicity of
terpenes , with a focus on supporting the posthumous diagnosis of Vincent
van Gogh as sufering from AlP. 826
The synergistic increase in heme oxygenase activity, in the presence
of glutethimide and iron, confirmed earlier observations that iron
increased heme degradation by phenobarbital-like drugs.548 Subsequent
research showed that the mechanism of the effect of iron was dependent
upon nascent heme synthesis (Chapter V),554 and was not related to the
metal-dependent induction previously described.230 The increases of heme
oxygenase activity were correlated with increased immunoreactive protein
and mRNA (Figure 5. 3). These results were the first to provide a
biochemical explanation for the effects of iron on hepatic heme degradation
and posed the possibility that the increased heme degradation could deplete
regulatory heme pooI1 161 415 causing increases in ALA
synthase.415,548 653 669 838
The hypothesis that induction of heme oxygenase could deplete the
reguatory heme pool suffciently to contribute to synergistic induction of
ALA synthase was investigated (Chapter VI). This hypothesis would be
considered unlikely using the model proposed by Granick168 181 222 for
control of ALA synthase , because the concentrations of heme needed to
saturate or induce heme oxygenase ( 2 ~M) are orders of magnitude
greater than those thought to be required to repress ALA synthase
(- 0. 1 ~M). 168 181 However, data to support the hypothesis that induction of
231
heme oxygenase can lead to induction of ALA synthase were later
presented by others.251 The time course experiments (Figure 6.2) and the
additions of tin-mesoporphyrin or heme (Figure 6.3) supported the
hypothesis that depletion of the regulatory heme pool played a role in
causing the induction of ALA synthase. When tin-mesoporphyrin and
heme were added concurrently, ALA synthase was repressed within two
hours, even more rapidly than the repression that occurred with heme
alone (Figure 6.3). These data thus provide further evidence that ALA
synthase activity is modulated via a regulatory heme pool and that a
sufcient amount of heme in the regulatory pool can repress ALA synthase
activity. They strongly suggest that, under at least some conditions
increases in- heme oxygenase activity can lead to increases in activity of
ALA synthase (Figue 8. 1).
Heme oxygenase inhibition and reduction of ALA synthase activity
were closely correlated, supporting the notion that heme is the proximate
metabolite reducing ALA synthase activity (Figure 7. 1). Heme decreases
ALA synthase activity, 215 258 856 857 and metalloporphyrns inhbit heme
oxygenase (Tables 7. 1 and 7.2).576 580,858 Therefore , it is reasonable to
conclude that a reduction of heme oxygenase will lead to an increase in
heme within the cell, which in turn, will repress ALA synthase. The
significant differences in ALA synthase activity produced by heme, zinc-
mesoporphyrn, or the combination of zinc-mesoporphyrn and heme, in
the cultures treated with glutethimide and iron unequivocally demonstrate
the effectiveness of this combination treatment. Reduction of AL synthase
by relatively high concentrations of heme (10 ~M) and tin-mesoporphyrn
Figure 8.1: Model for the synergistic induction of heme oxygenase
and ALA synthase in the presence of glutethimide and iron.
Glutethimide immediately caused a small induction of ALA synthase by a
direct interaction with the gene , and the added iron permitted greater
amounts of protoporphyrn to be converted to heme. B) After 6 hours the
regulatory heme pool was large enough to exert an inductive effect on the
heme oxygenase gene thereby increasing heme oxygenase activities to
maxmal levels. C) After 14- 18 hours the heme originally produced de novo
was degraded by heme oxygenase and there was no longer any regulatory
effect on ALA synthase, thereby allowing ALA synthase activities to
increase dramatically. The numbers in parentheses after the enzyme
names represent enzyme activities typically found within the specified time
frame. Units of measurement for ALA synthase activity are nanomoles
ALA formed mg protein- hour- l and for heme oxygenase are picomoles
bilirubin formed 8mg protein- minute-
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(100 nM) had previously been shown to occur (Figure 6.3), although, at
these concentrations , no further reduction of ALA synthase activity was
produced by 100 nM tin-mesoporphyrin, compared to those produced by 
~M heme alone. These results provided the framework for the present
study, which establishes that, individually, relatively low concentrations of
heme (200 nM) and zinc-mesoporphyrin (50 nM), not only significantly
reduced ALA synthase activity, induced by glutethimide and iron, but
produced a further, significant and additive reduction when used together.
Tin-chelated porphyrins cu taneouscan ca use
photosensitivity,597 609 610 639 863 864 and are not readily catabolized in vivo
595,602 605 865 raising concerns about possible long-term adverse effects of
these compounds.597,609,620,628 639 864 Previous results show that tin-
mesoporphyrin is a potent inhibitor of heme oxygenase 578,611 that
iodination of the tetrapyrole can reduce the photosensitizing properties of
tin-protoporphyrin612 and that zinc-protoporphyrn is also effective at
inhbiting heme oxygenase.582 583 627 628 634 866 Most of these studies were
carried out in rats. Zinc, unlike tin, is an essential trace metal , and
increased amounts of zinc-protoporphyrn occur naturally in red blood cells
and perhaps other tissues under some conditions. 138 140 141 867-871 Thus, if
zinc-mesoporphyrn or another zinc-porphyrn can be shown to be effective
in animals with little toxicity, its use would seem preferable to that of tin-
porphyrns. Other zinc porphyrns , with less catalytic activity for triplet
state reactions 872 and other non-photoactive inhbitors of heme oxygenase
require further development and study. The results obtained here with
zinc-mesoporphyrin recommend its further investigation For possible
clinical use , in conjunction with low doses of heme. A recent brief report of
one patient with acute intermttent porphyra suggested 
that a combination
of intravenous heme arginate and tin-protoporphyrin led to a more
prolonged repression of hepatic ALA synthase than intravenous heme
alone.626 This report and the data presented in this thesis suggest that the
combination of low doses of heme and a metalloporphyrin that is a potent
inhbitor of heme oxygenase may prove to be the most effective treatment for
the acute or inducible porphyras in relapse.
In sumary, the data presented provide a biochemical explanation
for the increases in heme oxygenase activity in the presence of a
phenobarbital-lik drug and iron, and establishes that increases in heme
oxygenase activity can deplete the regulatory heme pool and lead to
increases in ALA synthase activity. The model of chick embryo liver cell
cultures treated with glutethimide and iron, was used to characterize a
series of metalloporphyrins with respect to their ability to inhibit heme
oxygenase and decrease ALA synthase , alone and in the presence of heme.
These studies provide a rationale for the future clinical testing of the
combination of a metalloporphyrn and heme for patients suffering from
acute inducible porphyras, or for other patients in whom heme may be a
therapeutic agent.873 874
Note added in roof. Further studies carried out in the laboratory
under the direct supervision of Dr. Shirley Russo, using the theories
developed here , recently demonstrated that the combined effect of zinc-
mesoporphyrin and heme on ALA synthase in cultures treated with
glutethimide and 4 dioxoheptanoic acid, were greater than either alone
and that the combination produced a longer effect than heme alone
(Figure 8.2).
Figure Effects of zinc-mesoporphyrin and heme on ALA
synthase activity after with glutethimide andpretreatment
dioxoheptanoic acid. Chick embryo livers cell cultures were treated
with 50 ~M glutethimide and 250 ~M 4 dioxoheptanoic acid for 12 hours
prior to treatment with metalloporphyrins. Then 200 nM zinc-
mesoporphyrin and/or 1 ~M heme were added and the cells harvested at
the indicated times. The assays were performed as described in Methods.
Data represent means:! SEM , n 6. The assays were performed by Dr.
Shirley Russo.
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APPENDIX A: ENZ COMMSION NUERS
Aconitase
Aminolevulinate dehydratase
1.2.
1.24
1.37
1.3. 1.24
1.3.
99. 1.1
1.14. 88.
1.43
1.44
1.6. 2.4
1.8
1.3. 3.4
2.4. 1.17
1.1.37
1.75
Aminolevulinate synthase
Bilverdin reductase
Coproporphyrinogen oxidase
Ferrochelatase
Heme oxygenase
L-alanine:4 dioxovaleric acid aminotransferase
L-alanine:glyoxylate aminotransferase
NADPH ferrihemoprotein reductase
Porphobilinogen deaminase (hydroxymethylbilane synthase)
Protoporphyrinogen oxidase
Uridine diphosphoglucuronate glucuronosyltransferase
Uroporphyrinogen III decarboxylase
Uroporphyrinogen III synthase
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APPENDIX B: CONCISE LAORATORY PROTOCOLS
Chick Embryo Liver Cell Cultu
I. Theorv:
A. Remove hvers , placE: in physiological buffer.
B. Chop liver in presence of trypsin to degrade extracellular matrix and release cells.
C. Lyse red cells and wash debris from cell suspension.
D. Suspend cells in media a.'1d plate onto culture dishes.
E. Treat cells with substances and measure response (enzY::le levels , etc.
II. Materials:
A. Plastic bags (double layer) in ice buckets for carcasses (30 eggslbag).
B. Sterile instruments: scissors; small, fine- toothed curved forceps; toothed , straight end
forceps; surgical, narrow end forceps for transfers , mosquito clamp and single edged
razor blade (for chopping).
C. Sterile, 5 cm glass petri dishes for chopping (need one dish per ten eggs).
D. Stopwatch.
E. Sterile 25 mI glass pipette with large-bore end.
F. Sterile 125 ml flasks (need one flask per two chopping dishes).
G. Disposable glass 10 ml and 25 ml serological pipettes.
H. New, sterile , 15 ml plastic culture tubes (8 tubes/125 ml flask).
I. New, sterile culture dishes (labeled top and bottom).
III. Solutions:
A. Hank' s minus Ca-sterile filtered same day.
B. Sassa s Ammonium bicarbonate Tris buffer-sterile fitered same day.
C. Wiliam s E Medium without glutamine (one packet/liter, additions detailed below).
D. 5% trypsin , stored in 0.6 ml aliqouts.
E. DNase
F. Penicilin (10 000 U/mD/Streptomycin (10 000 U/mn-commercial stock.
G. Insulin
H. Dexamethasone phosphate
I. T3 (Triiodo-thyronine;
IV. rocedu
Start with 16-17 day embryo , assume 8- 10 ml innoculum/egg.
Cut blunt end of egg off with scissors , and remove embryo by holding neck between
scissors blades.
Hold neck with forceps , cutting off head with scissors.
Holding skin of abdomen with forceps , cut up the middle; avoid cutting liver.
Dissect out liver , taking care not to rupture gall bladder.
Place livers in 10 em dish containing 20 ml Hanks.
U sing surgical forceps , transfer livers to new 10 em culture dish containing 20 ml
Hank' s. Repeat transfers to fresh dish of Hank's two times. 
Add 90 III 5% trypsin to each glass petri dish containing 10 ml Hank' s. (trypsin must
be vortexed to resuspend any particulate matter).
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9. Evenly distribute the livers among the glass dishes , using surgical forceps, 10-
livers per dish.
10. Using sterilzed razor blade in clamp, chop livers in dish for two minutes , timed with
stopwatch.
11. Transfer livers to 125 ml sterile flask. (put 2-3 chopping dishes per flask)
12. Pipette liver up and down 2X using 25 ml wide bore pipette.
13. Place flask in 37 C water bath for a total of 20 min.
14. Afer 10 min in bath , add to flask 75 Ill1mg/ l DNase per chopping dish.
15. Afer 12 min in bath , remove flask and pipette up and down 4X using 25 ml wide bore
pipette.
16. Afr 20 min in bath, remove flask and pipette up and down 2X using same pipette.
17. Evenly distribute liver suspension into 15 ml conical tubes containing 10 ml 
cold
Hank' s (refrigerated prior to dissection) Note: Use one rack of 12 tubes for 2-
chopping dishes.
18. Centrifuge tubes 90 sec at 1200 rpm (-50Oxg) in tabletop centrifuge.
19. Aspirate supernatant and resuspend pellet in 10 ml Sassa s buffer
, inverting and
flcking to suspend pellet.
20. Place tubes on rotating wheel (wheel of fortune) for three min.
21. Centrifuge as in 18.
22. Repeat steps 19- , then aspirate supernatant taking care to remove as much as
possible
23. Suspend pellet in 10 ml WEIH , inverting and flicking tube.
24. Centrifuge tubes to 200 rpm, turning off centrifuge as soon as speed is reached (no need
to balance tubes).
25. Remove supernatant with 10 ml pipette, and place in innoculum bottle
, DO NOT
ASPIRATE SUPERNATANT INTO VACUUM FLASK
26. If desired, resuspend cells in more media and repeat 23-
25.
27. Plate cells as follows:
Plate size
5 cm
0 cm
10.0 cm
Innoculum vol.
2 ml
6 ml
15ml
1 ml
2ml
5 ml
Treatment vol.
2ml
5 ml
10ml
28. Shake tray at right angles to distribute innoculum evenly.
29. Next day, wash cells with WEH 2X at 37 C (add Dex and T3).
30. Remove all media with a vacuum system and add appropriate rinse 
volume of WEH
warmed to 37 C in water bath.
31. Allow incubation for 45-60 min , and repeat steps 30-31.
32. Remove second rinse and add appropriate volume of treatment.
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SOLUTONS
I. Willam s E without e:lutamine
1 envelope prepackaged powder
2 g sodium bicarbonate (NaH2C03
1 liter Milli Q water
0 g glucose
10 ml glutamine (200mM)
10 ml Pen/Strep (commercial stock)
10 mg/liter phenol red
Filter sterilize.
Filter Dex, T3, and insulin into sterile media.
use. Add insulin for WEIH first day only!)
(Add Dex and T3 for WEH on the day of
Dexamethasone: stock is 10 mg/ml , stored at room temp. Make up dilution 30 111/10 ml
water; use 10 ml/iter media. Make fresh daily!
;.:
T3 (Tri-iodo- thyronine): make up 1 mg/ml stock in .05 N NaOH; Dilute 1:10 in water
and use 10 ml/iter media. Can be stored in refrgerator for use on day 2 only!
Insulin: make up 10 mglml in .05 N NaOH. Dilute 1:10 in water. Use 1 mll liter media.
U sed only on day 1!
DNase: 1 mg/ml in water.
II. Hank' s minus Ca (1 liter) 
Add ingredients to water , otherwise precipitates occur.
:.;\,
0 g NaCl
1.0 g Dextrose (glucose)
345 ml 1M Magnesium chloride (20.3g MgC12 * 6 H 0/100 ml)
676 ml.5M Sodium phosphate dibasic (7. 1 gl100 ml)
441 ml1M Potassium phosphate monobasic (13.6 g/100 ml)
17 ml1M Sodium bicarbonate (8.4 gl100 ml)
il.
Adjust pH to 7.4 with 1 N HCl , make up to 1 liter , and store in non-sterile bottle at 4
Sterilize through Milipore filter the day of use. *Stable for 2 weeks.
III. Sassa s Ammonium b carbonate Tris buffer (1 
91 g Ammonium chloride
06 g Trs base
1.38 g Potassium carbonate
Add about 800 ml water, pH to 7.5 using (-10 ml) 6 Nand 1 N HCl, make up to 1 liter and
store in non-sterile bottle at 4 C. Filter sterilize the day of use. *Stable for 2 weeks. 
- ..
V. TrvDs
Gibco (lyophilized): add 10 ml sterile water to achieve 5% (w/v).
Store at -20 C in 0.6 ml aliquots. Discard after thawing.
CATALOG NUERS
Gibco: tel # 899-828-6686
Wiliams ' Medium E without L-glutamine, without NaHC03: formula 
#785133
Trypsin, 25 mg lyophilized. Cat. #610-5095
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AL Sytha AssayPu:
Measure the AL-S (aminolevuinic acid synthase) activity in CELC (chick
embryo liver culture) sonicates.
Bufers and Solutions:
Homogenization/Assay Buffer (pH 7.4 with HCI)
35 mM Tris
30 mM NaP
8 mM MgCl2
5 mM EDTA
15 mM succinate (disodium salt, 6H20)
10 mM Na levulinate
5 mM pyridoxal- phosphate
for 250 mls
75 mls of 1M Trs
15 mls 0.5 M Na2P04
4 mls 0.5 M MgCl2
5 mls of 0.5 M EDT A
75 ml of 1 M solution
5 ml of 1 M solution
03089g (Note: add at adjusting the
pH ofthe buffer)
This buffer made be made as a stock solution and kept at 4 C for at least one month.
1M Glycine , pH 7.
Note: freeze in 1 ml aliquots at -
(7.5g/100mls pH with NaOH)
10% TCA
1:10 dilution of 100 % TCA (Trchloroacetic Acid) stock solution in H20
...
100% TCA Stock Solution
Add 500 mls H20 to a 500 g bottle of TCA; let dissolve
1M Sodium Acetate (13.61 g/100 mls)
10% 2 4 pentaedione in 1M sodium acetate (lml added to 9 mls NaAC)
a) warm quickly in 85 C bath to get pentanedione into solution
b) Also the source of this is importat - use from E.M. Science only) Another name for this
chemical is acetyl acetone
) The solution should be pale yellow; if it is dark yellow it is no good!
Modified Erlich . ,ution
glacial acetic acid
70% Perchloric acid
Mercuric chloride
200 mls
168 mls
32 mls
75g
NOTE: a) the day to be used add 200 mg DMA (p-dimethylamino- benzaldehyde) per 10
mls of the above solution
b) This solution wil turn a yellow color.
1x PBS Dilute from lOx PBS stock
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Prur:
1. Wash the cells on a 6 cm plate 2 times with PBS at room temperature.
2. Add 700 III of complete homogenization buffer to the cells & scrape cells into buffer.
Transfer suspension to a 12 x 75 cm glass culture tube. Place on ice.
3. Sonicate for 2 seconds at output setting 1.5 , constant output.
4. Split each sonicate into 2 tubes (150 III per tube), one labeled reference & the other labeled
sample.
(Note: there is enough sonicate to do 2 sample tubes & this may be necessary
sometimes).
5. To the tubes labeled reference , add 101111 M glycine & 10011110% TCA. Place on ice.
6. To the tubes marked sample, add 10111 1M glycine. Incubate at 37 C for 30 minutes.
6a. Optional Also set up a blank and two standard tubes for each assay. This wil
show that the AL, 2 4 pentanedione and the Erhlich' s reagent really worked. The
blank should consist of 150 III homogenization buffer + 10 III of 1 M glycine. The
standard should consist of 140 III homogenization buffer, 10 III of 2j. AL, & 10
III 1M glycine. Incubate at 37 C for 30 minutes. Stop reaction with 100 III 10% TeA.
Continue processing tubes just like the reference tubes in the assay
8. Add 100 11110% TCA to the sample tubes.
9. Spin all tubes at 3 600 rpms (3,000 x g) in the Beckman Tabletop centrifuge at 4 , for 10
minutes.
10. Remove 150 III of supernatant from each tube, being careful not to disturb the pellet, and
place in a fresh tube.
11. Add 100 III of 10% 2 4 pentanedione in 1M sodium acetate to each tube.
12. Incubate tubes at 85 C for 15 minutes.
13. Remove and chil on ice, for -5 minutes , Remove and let come to room temperature.
14. Add 250 III of complete modified Ehrlich' s reagent to each tube. Let sit at room
temperature for 15 minutes for color development.
15. Read on the Amico with the following setup:
-split beam
lower wavelength = 530 nm
-upper wavelengt = 650 nm
do wavelengt acquisition
-set x axs as the wavelength & y axs as absorbance (0 to 0.
-use short skinny slits and rubber stoppers to raise cuvette up in order to read these small
samples-put reference tube into the R cuvette position & the sample tube into the S position
Note: use plastic mini cuvettes (1 ml capacity) to read the sample.
16. Calculate the nmole ALNmg protein/r for each sample using the ALA-S program in
Excel. The information necessary to do this includes:
Absorbance at both a. =555 & a. = 650
the results of the protein determination on standards & samples or the protein
concentrations of each sample
Note: the program is designed to calculate the average & standard error for a set of
triplicates for each treatment or assay group; be careful of where you enter the data.
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17. How the calculations are actually done by hand:
OD(550-650)*177. 78/mg protein/ml = nmoles ALAmg protein/r or
nmole ALA
mg protein. hr
OD555- 650. 1 em 5 mIs Ehlich' s salt 25 mIs ALA Pyn-oe 26 mls final assay 6O min / hour l ml
065/ll les / ml / em 0. 25 mls ALA Pyrole 0. 15 mls ALA TCA Sup 0. 15 mls homog 30 min prot cone
18. Typical Results:
Untreated CELC: 0.2 - 0.8 nmoles ALmg protein/r
Glut + Fe treated CELC: 6. 5 - 8.5 nmoles ALmg protein/r.
..-
Reference: This protocol is based on the method of L.F. Lein & D. Beatty, Enzyme 28: 120-
132 (1982).683
;
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Heme Oxgen Assay (Batc)55
10.
11.
12.
Wash plates twice with 1.5ml room temperature PBS (pipetting the PBS down side of
plate to prevent disturbing the cells)
Harvest cells from 6cm cell culture plates in . 1.0 ml Harvest Buffer with a
rubber policemen or spatula.
Transfer each into a labeled 12 x 75mm culture tube in a rack on ice.
Sonicate each for 3 seconds using a microtip sonicator.
Remove aliquot for protein assay. (- 50 
Label 16 x 100mm culture tubes 1 2A.....
Put tubes in rack on ice. To each tube add
KPi O. pH 7.40
*Desferal
BVR (rat liver 105 000g sup.
Sonicate
*NADPH (Sigma N6505)**
530 Ji
50 l (65mglml water)
200 l (0. 8 mg protein)
50 l (4mM - 96 mg/ml in . 1M KPi)
13.
14.
15.
16.
Run one control and one test per sample.
Place rack of tubes in 37 C shaking water bath for 5 min.
Add 150 1 *Methemealbumin to sample (" ) tubes.
Afer 10 min. , place tubes in ice bath.
Add 20 l p-hydroxymercuribenzoic acid (50mM stock stored in dark bottle at room
temperature) to each tube to completely stop the reaction.
Shake well.
Add Methemealbumin to Blank tubes (150 l).
Scan 450-550 nm. (Sample v. Blank-Split beam)
Use EmM=66 for 470-540 to calculate nmole bilrubin/ml.
40) X 1. ml fin volume X 1 000 pmol
066 O.DJnmol bilirubin/ml X 0.2m1 initial vol X 10 min X mg prot/ml X 1nmol
= pmol bilrubin/min X mg prot
*Make fresh before use; keep on ice except for hemin/MSO prior to adding to albumin.
Reagents:
10 mM KPi
15 M KCI
pH to 7.4
Harvest Buffer
lM KPi
20% Glycerol
1.0mM EDTA
pH to 7.4
Methemea bumi
Hemin 6.5 mg/ml in DMSO
BSA 1.1 mg/ml in 40mM Tris 7.
Add 100 l heme stock to 3.9 ml BSA
Chemicals Used:
Desferal (deferoxamine mesylate)
NADPH
Hemin
BSA (Bovine serum albumin)
hydroxymercuribenzoic acid
Sigma D-9533
Sigma N-6505
Sigma H-2375
Sigma A-7906
Sigma H-0642
**12/7/92 Chanlle:
To save cost of NADPH , we decided to use .2 Ilmoles per reaction rather than the lllmole per
reaction that we had been using. Testing shows no more than a 5% decrease in Heme
Oxygenase activity.
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Heme Oxgena Assay (Ketic)571
Wash plates twice with 1.5ml room temperature PBS (pipetting the PBS down side of
plate to prevent disturbing the cells)
Harvest cells from 6cm cell culture plates in . 1.0 ml Harvest Buffer with a
rubber policemen or spatula.
Transfer each into a labeled 12 x 75mm culture tube in a rack on ice.
Sonicate each for 3 seconds using a microtip sonicator.
Remove aliquot for protein assay. (-50 Ill)
Mix in a cuvette:
KPi O. pH 7.40
*Desferal
BVR (rat liver 105 000g sup.
Sonicate
Methemealbumin
530 Jl
50 III (65mglml water)
20 III
200 III (0. 8 mg protein)
150 Jl
10.
11.
Let cuvette come to 37 C in heated cuvette holder.
Add 50lll *NADPH (Sigma N6505)**
Shake well
Record dAdT one the Aminco , Dual wavelength assay, Mono 1 = 470, Mono 2
for 5 minutes.
Use Ero=66 for 470-540 to calculate nmole bilirubin/ml.
AO.D. (t ) X 1.000 ml final volume X 1000 pmole
066 O.D.lnmol bilrubin/ml X 0.2ml initial vol X 10 min X mg protlml X 1nmol X (
= 540
12.
= pmol bilirubin/min X mg prot
*Make fresh before use; keep on ice except for hemin/MSO prior to adding to albumin.
Reagents:
10 ro KPi
15 M KCl
pH to 7.4
Harvest Buffe
lM KPi
20% Glycerol
1.0mM EDTA
pH to 7.4
Methe
Hemin 6.5 mg/ml in DMSO
BSA 1.1 mg/ml in 40ro Tris 7.
Add 100 Jl heme stock to 3.9 ml BSA
HPLC Porphyr708
University of Massachusetts Protocol Developed by Sue Donohue
Reents
Concentrte Phoshoric Acd
10% Phosphoric acid: measure 10 ml of phosphoric acid and dilute to 100 ml with Mili-
water. Store at room temperature. Stable indefinitely.
Methanol: HPLC grade fisher. The solvent is degassed by fitration using a 0.45 micron
filter. On each day of use stir under vacuum for 5 minutes. Stable indefinitely at room
temperature.
1M ammonium phosphate: measure 11.5 grams of ammonium phosphate (Fisher
Scientific A-685) and dissolve in 950 ml of Mili-Q water.
Solvent A: Mix O. lM ammonium phosphate with an equal volume of HPLC grade
methanol. The pH of the final mixture is adjusted to 3.5 with concentrated phosphoric
acid. The solvent is then degassed by filtration using a 0.45 micron fiter. On each day of
use, stir under vacuum for 5 minutes. Stable indefinitely at room temperature.
Porphyrin acid chromatographic marker kit (Porphyrin Products , Logan Utah): Dissolve
contents of one tube in 2 ml 1M HCl. Final concentration of each porphyrin is 5nM.
Protect from light. Immediately before injection , dilute 100 III of porphyrin standard with
0 ml of O. lM HCl and inject 50 Ill. Each peak will contain 12.5 pmole of porphyrin.
Otr Equipment and Supplies
Waters Baseline 810 HPLC System
Shimadzu RF-551 Fluorometer with a R-928 (red-sensitive) PM tube
C18 Reverse Phase Radialpak #85721
Calbration an Quty Contrl
calibration standard curve was developed using the Porphyrin Acid
Chromatographic marker kit which contains 5 nmole/ml of porphyrns of the Type 1
series: Uroporphyrn I , 7-COOH, 6-COOH, 5-COOH, Coproporphyrin I , and Mesoporphyrin
IX.
Two point calibration curves are calculated by the Baseline System and printed as
needed. The calibration standard is ru with each ru and at repeated intervals during
the run. Using a 50 III injection, the concentration is 12.5 pmoles. The 810 Baseline
System will calculate concentrations and print the result on the custom report.
The porphyrin mixture used, dissolved in 0. 1 m HCl had a optimum peak
fluorescence excitation wavelength of 398 nm and peak emission wavelength of 612nm.
The excitation was scanned from 398-408nm and the emission scanned from 608-624nm .
Ce Cutu Saple Prpartion
Cell culture samples are obtained by scraping the cells into the media with a rubber
policeman or spatula and sonicating the cell:medium mixture for 5 seconds , sonicator
setting 2.5. Remove 400 III and add an equal volume of 0.2 M HCl and centrifuge at 12 000 x
g for 10 minutes to precipitate cellular debris. The supernatant is removed and 500 III
placed in a WISP micro sample tube and 200 III of each sample is injected. Place the
samples in the WISP starting at position 3.
A calibration standard is prepared each day of use: measure 2.0 ml O. lM HCI into a
WISP sample vial and add 100 III of the porphyrin acid chromatographic marker. Cap the
vial using the screw top cap with the septum and place in position 1 on the sample wheel.
Place 2.0 ml of 0. 1 m HCI in a vial and load into sample position 2.
Prur for tu on Baslie 810 Sym
Turn on the HPLC and all peripherals. Follow the prompts which appear on the screen:
Baseline, enter , n, enter until the Baseline 810 logo appears on the screen. Click on
mouse.
Move the mouse to Run and Monitor Control Events. The screen wil show the pumps
percentage of solvents and the flow per minute. Set the B pump to 30% and the flow to 1.5 ml
per minute. Move the cursor to GO and click the left mouse button , the screen should
display Active. The system wil take at least 15 minutes to equilbrate.
Set the detectors:
Waters 484:
Shimadzu RF-551:
405nm wavelength
Sensitivity: 0.
Data Display:
Auto Zero
AUFS: 0.
Excitation: 398nm:
Emission: 620nm
Range: x 16
Response: 1.5
The absorbance detector only needs to by used for bilirubin , heme or biliverdin analysis.
Next click the cursor on the Sample Queue. Click on Edit and clear the queue. Next
fill the sample queue with the appropriate information for the day ru including: a HCL
blank as the first sample, three calibration standards at the beginning and one set the end
of the ru and one after every five samples.
Check under the queue wide parameters and make sure the queue processing
options and report options are selected. If you want to process and print automatically, then
the "review chromatogram" option should be de-selected; if you want to process and delete
extraneous peaks from the integration , then the "review chromatogram" option should be
selected.
When the WISP sample wheel has been loaded , click on RUN , Execute Methods
move the cursor to the M column, and click on the first sample and type F. Next go to the
last sample to be ru and click on this sample and type L. All the samples in between wil
fill with X. Any you don t want to run , click on the sample and hit the space bar to de-select.
Click on START and F5 to display acquisition.
Return to the execute methods screen(F3) and click on resume to resume processing and
printing of reports.
To manipulate the chromatograms edit the queue wide parameters selecting
Review chromatogram . Now each chromatogram wil be displayed and many
parameters can be set, changed , verified and printed.
RNAzI
TOTAL RNA ISOLATION FROM CELL CULTURES
Eppendorf Tube Protocol
HarvestinQ" and Lvsis of Cuhures
Rinse the cells twice with room temperature PBS. (Aspirate well to remove any
excess PBS as this wil add enough volume so that the preparation wil not fit in a bullet
tube.) Cells grown in monolayer are lysed directly in the culture dish by the addition of 500
III RNAzol to one 10 cm plate. Scrape the cells with a rubber policeman or spatula , and
transfer the solution to the other plate. Scrape again and remove the suspension and place
in a sterile Eppendorf tube.
RNA Extraction
Add 100 III chloroform to the lysate in RNAzol. Cover the samples tightly; vortex
vigorously for 5 seconds and let them stay on ice for 15 min. Centrifuge the suspension at
high speed (- 000g, 4 C) for 15 min. Afer addition of chloroform and centrifugation , the
mixture forms two phases: the lower phenol-chloroform phase and the upper aqueous phase.
RNA remains exclusively in the aqueous phase, whereas DNA and proteins are in the
interphase and organic phase. The volume of the aqueous phase is about 50% of the initial
volume of RNAzol plus the volume of cells used.
RNA PreciDitation
Transfer the aqueous phase to a fresh Eppendorf tube, add an equal volume of
isopropanol and store the sample for at least lh (or overnight if this fits the time schedule) at
C to precipitate RNA. Centrifuge the samples for 15 min. at high speed. The RNA
precipitate forms a white pellet at the bottom of the tube.
RNA Wash
Remove the supernatant and wash the RNA pellet twice with 1 ml of 75% ETOH by
vortexing and subsequent centrifugation for 8 min at high speed. Briefly dry (1-2 min) the
pellet under vacuum, using a Speed-Vac. It is important not to let the RNA pellet dry
completely, as it will greatly decrease its solubilty.
Dissolution of RNA
Dissolve the RNA pellet in 50 III of 0.5% (w/v) SDS solution by vortexing or by
passing a few times through a pipette tip. Heating for 15-20 min to 65 C may be required to
dissolve a large scale preparation of RNA
6. Check of Purit;v and Quantitv of RNA
Dilute the above prep 1/200 (e. g. 5 Jl + 995111) with DEPC treated water, add to a semi-
micro quartz cuvette and read absorbance at 260 and 280 nm. If the ratio A260/A280 is 1.8 or
above, the nucleic acid is pure. To calculate the concentration of RNA, use the formula:
cone. RNA (llg/m1) = A260 x 40 Ilg/ml per 1 Abs unit x Dilution factor
!! 
RNDot Blot
Protocol for 10 Ilg RNNdot and 4 dots total
In a sterile bullet tube place 40 Ilg RNA.
Add DEPC H20 to 50 Ill.
Add 50 Jl20X SSC.
Add 40 III 37% formaldehyde.
Incubate at 65 C for 15 minutes.
Remove and add 1100 III of lOX SSC and mix thoroughly.
Add 300 III of RNA solution per well to previously prepared nitrocellulose (NC).
Wash each well with 400 III lOX SSC.
When wells are dry, remove the NC from the apparatus and immobilze the RNA by
UV irradiation 2400 Jloules exposure.
10. Prehybridize blot for 2-4 hours in 20 mls of Hybridization bufer 42
11. Remove 13 mls of the hybridization bufer and add boiled probe.
12. Hybridize blot overnight (::12 hours) at 42 C in blotting oven.
13. Wash blot 2X, in bottle, with 0. 1X SSC at 25 C for 15 minutes.
14. Allow to air dry and quantitate radioactivity of the gen counter or expose to X-ray
film at -
NOTE: If more samples are to be prepared, increase the H20 , SSC and formaldehyde
proportionally. These samples can also be prepared in sterile cryovials or snap
cap tubes.
Hybridition Bufer (50 ml)
25 ml Formamide
12.5 m120X SSC
5 m150X Denhardt's
2 ml DE PC H20
500 III Boiled salmon sperm DNA (10 mg/ml)
5OXDenhdt's
1 % Ficoll
1 % Polyvinylpyrolidone (PVP)
1 % BSA
Filter sterilize, store aliquotted at -
20SS
0 M NaCl
3 M Sodium citrate
pH 7.0 with 10 N NaOH
Autoclave 45 minutes liquid cycle.
Nitrllulos Prpartion (Schleicher and Schuell, BA 0.45 Jl)
1. Wet the NC in DEPC H20 for 5 minutes (If there are stil white spots on the NC , heat the
water to facilitate wetting. This wil occur with older NC.
Rinse the NC in lOX SSC
Assembly the Dot/Slot Apparatus with 2 sheets of 3MM paper underneath the NC.
Rinse wells with 400 III of lOX SSC.
Load samples as described above.
Hexaer Prer Lallg759
1. Boil 3 111 (100-400 ng) DNA in 10. 5 111 H20 for 5 minutes.2. Incubate on ice for 5 minutes.
3. Add 11.4111 LS + 511132p dCTP (3000 Ci/mmol , or 50 I1Ci final).
4. Add 1111 of Klenow DNA polymerase.
5 . Vortex briefly and microfuge.6. Incubate 1-2 hours 37
7. Add the following in order:
75111 TIEo.
4 111 CO. I1g/11l) yeast tRNA
100 1114M Ammonium Acetate (Sterile)
60011195% ETOH8. Incubate - C for 30 minutes.9. Microfuge 10 minutes to precipitate DNA, and aspirate the supernatant (Supernatant
MUST be discarded in the liquid radioactive waste).
10. Add 100111 ofTIEo.
11. Boil probe for 5 minutes.
12. Place on ice immediately for another 5 minutes.
13. Count a 1111 aliquot.
14. Add 5x106 cpm per blot to either fresh hydridization solution , or to the prehybridization
solution, depending on whether the solution is changed or not.
37. 1111 total
15.6 111 1M HEPES (pH 6.
0 Jll 0.2 mM dATP, dGTP , dTTP
0 111 2X 
5111 pd(N)6 Pharmacia 27-2166-01 (90 U in 1 mM Trs pH 7. , 1 mM EDTA)
2XTM
100 ml total
50 ml1M Tris pH 8.
5 ml 1M MgC12
620 111 -mecaptoethanol
45 ml H20
Poly Thymdylate Prbe'i
Aim: To find out relative level of RNA in the samples
Synthesis: Add following in the order
STOCK
POL Y- A (sigma) 10llg/1l1
DTT 1M
Trs pH 8.3 1M
KC11M
AM-RT (promega) 8 UI III
dTTP ( promega) 100mM
RNAsin (promega) 40 UI III
MgCl2 1M
Oligo dT(12- 18)(pharmacia)0025u/lll
32 dTTP (NEN) 51lCi/Ill
Mix gently by vortexing very slowly
Incubate 2 hrs at 37 C shakng
Hydrolyse the probe adding 50 III 1 N NaOH (0. 1 N) 65 c , 30 min.
FINAL
140 J.
2mM
50mM
40mM
50 units
1mM
40 units
7mM
2 units
50 IlCi
Boil the probe before probing membrane
FOR 500 JJ
14 III
1 III
25 III
20 III
6 III
5 III
1 III
5 III
8 III
10 III
406.5 III
Strip previously probed nitrocellulose blots by boiling in DEPC treated water for 5 minutes.
Prehyb. NC blots at 42 C for 1-3 hrs
Hybo blots for 30 hrs at 42
Wash blots at room temperature two times 0. 1% SSC
Prhybridition & Hybridization Bufer
50% Formamide
5X SSC
5X Denhardt'
1 % SDS
10 mg/ml Salmon sperm DNA
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g/m
l gluethim
ide (shelt) in DMSO
100 III of6.5 m
g/m
l hem
in (frig) in DMSO
dilute into 3. 9 m
ls 1.1%
 BSA in
40 m
M
Tris pH
 7.
43. 65 m
g/m
l M
eph in DM
SO
100 III of a 10 m
M
 stock in DM
SO
dilute into 3. 9 m
ls 1.1%
 BSA in
40 m
M
Tris pH
 7.4
07 m
g/m
l 20-M
C (Shelt) in DMSO
92.8 m
g/m
l PB (shelt) in DMSO
5M
 Stock (DM
SO)
100 III of7. 5 m
g/m
l Sn-m
eso in DM
SO
dilute into 3. 9 m
ls 1.1%
 BSA in
40 m
M
 Tris pH
 7.
5M
 Stock (DM
SO)
APPENDIX D: FORlTION OF WIIAS E MEDIU
Component mg/Z
Inorganic Salts
CaCl2 (anhydrous) 200.
CuS04 5H20 001
Fe(NOg)g 89H20 0001
KCI 400.
MgS04 97.
MnCl2 4H20 001
NaCI 800.
NaHCOg '" 200.
NaH2P04 H20 140.
ZnS04 7H20 0002
Other Components
Glucose * 00.
Glutathione
Methyl linoleate
Phenol Red 10.
Sodium Pyruvate 25.
Amino Acids
Alanine 90.
Arginine 50.
Asparagine 8 H20 20.
Aspartic acid 30.
Cysteine 40.
Cystine 82HCI 26.
Glutamic acid 50.
Glutamine 292.
Glycine 50.
Histidine 15.
Isoleucine 50.
Leucine 75.
Lysine HCI 87.46
Methionine 15.
Pheny lalanine 25.
Proline 30.
Serine 10.
* These chemicals were added the day the medium was reconstituted.
I Component
Amino acids cont.
mg/l
Threonine 40.
L- Tryptophan 10.
Tyrosine.2Na .2H20 50.
L- Valine 50.
Vitamins
Ascorbic Acid
Biotin
Ca Pantothenate 1.0
Choline Chloride
Ergocalciferol
Folic acid
Inositol
Menadione sodium bisulfate
Niacinamide 1.0
Pyridoxal. HCI 1.0
Riboflavin
Tocopherol phosphate , sodium salt
Thiamine HCI 1.0
Vitamin A acetate
Vitamin B12
